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Abstract 
Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular 
disease and end stage renal failure. Accurate identification of those with a reduced 
glomerular filtration rate and significant proteinuria facilitates early diagnosis and risk 
stratification. 
 
This thesis explores the optimal measure of proteinuria, to accurately quantify proteinuria 
and as a predictor of renal and patient outcomes. We examine the prevalence of CKD in a 
general population cohort and assess the impact of different estimated glomerular filtration 
rate (eGFR) formulae. We explore the prognostic role of reduced eGFR and proteinuria in 
patients with hypertension and present the baseline characteristics of a community cohort 
study of patients with predominantly early CKD.  They will be followed for ten years to 
identify predictors of cardiovascular and renal outcome. 
 
Urine total protein:creatinine ratio (TPCR) and albumin:creatinine ratio (ACR) have 
largely replaced 24-hour urine collections for proteinuria quantification. The performance 
of these spot measures to identify significant proteinuria is compared in a cohort of 6842 
patients attending a general nephrology clinic. Both tests perform well overall but TPCR is 
statistically significantly superior as a predictor of 24-hour total proteinuria than ACR (as 
measured by the area under the receiver operator characteristic (ROC) curve to predict 
1g/day total proteinuria). On sub-group analysis the performance of the spot samples is 
poorer in women and the elderly, likely as a result of low muscle mass and low urine 
creatinine (the denominator in TPCR/ACR).  
 
The performance of TPCR and ACR were then compared as predictors of outcome in a 
similar cohort of 5586 CKD patients using a hierarchical Cox survival model. TPCR and 
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ACR both performed well as independent predictors of death, commencement of renal 
replacement therapy (RRT) and doubling of serum creatinine. Notably TPCR performed 
well at low levels where albuminuria has been considered superior. These findings are 
novel. The spot samples performed as well as 24-hour collections in the sub-group with 
timed urine collections.  
 
The National Institute for Health and Clinical Excellence in England recommend ACR to 
monitor all patients with CKD; the Scottish Intercollegiate Guidelines Network 
recommend TPCR for non-diabetic renal disease. Therefore, we investigated the 
implications of these recommendations using survival modelling. The same cohort was 
divided into 5 groups: no proteinuria, low proteinuria (using TPCR and ACR), high 
proteinuria (TPCR and ACR) and two groups where TPCR and ACR were discordant (i.e. 
TPCR above the diagnostic threshold but ACR below it and vice versa) using the 
recommended thresholds (ACR 30mg/mmol/TPCR 50mg/mmol to predict 0.5g/day total 
proteinuria and ACR 70mg/mmol/TPCR 100mg/mmol to predict 1g/day total proteinuria). 
Using univariate survival analysis the discordant group had significantly poorer outcomes 
(using the same outcomes as previously) than those with significant proteinuria as 
measured by both tests. The discordant group was older with poorer renal function and 
some of the excess risk was abolished on multivariate analysis, however the risk did not 
return to the level of those without detectable proteinuria. TPCR, but not ACR, measures 
non-albumin proteins and these may have pathophysiological roles in progression. This 
requires further study. However this analysis confirmed that TPCR identifies patients at 
high risk of adverse outcomes.  
 
TPCR and ACR may vary as a result of muscle mass. We adjusted TPCR and ACR for 
estimated creatinine excretion (ECE) (calculated using the Cockcroft and Gault formula) 
and performed cross-sectional and longitudinal analyses. Adjusting TPCR and ACR for 
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ECE improves prediction of significant proteinuria in sub-groups with poor baseline test 
performance (such as women and the elderly) using ROC curve analysis. However when 
adjusted and unadjusted values were compared as predictors of outcome (using a net 
reclassification index analysis) adjusted values were significantly inferior. Urine creatinine 
is an independent predictor of mortality and hence may be directly contributing to the 
predictive value of TPCR and ACR rather than simply correcting for urine flow rate. As 
such, adjusting for ECE may act to remove the effect of a second independent predictor, 
leading to inferior test performance. Therefore the decision to adjust TPCR and ACR for 
ECE depends on the test application: to predict significant proteinuria adjustment of TPCR 
and ACR is of benefit, but adjustment leads to inferior performance as a prognostic test. 
 
The prevalence of CKD stages 3-5 was assessed using a general population laboratory 
database. Overall population prevalence was 5.63% using the modification of diet in renal 
disease (MDRD) formula and fell to 4.94% when the CKD-Epidemiology group (CKD-
EPI) formulae were applied. Those reclassified to an earlier stage of CKD were 
predominantly middle aged women. Prevalence over a five year period was found to be 
stable using the CKD-EPI formulae but rose slightly according to MDRD.  
 
Proteinuria and eGFR were assessed as predictors of outcome in a large specialist 
hypertension clinic cohort. On multivariate survival analysis both baseline dipstick 
proteinuria and an eGFR<60ml/min/1.73m
2
 remained strong independent predictors of 
cardiovascular and all-cause mortality, despite intensive specialist intervention to control 
blood pressure. These simple tests should be advocated for risk stratification in these 
patients. 
 
Lastly the baseline characteristics of a community CKD cohort are presented. We recruited 
411 participants from seven general practices around Ayrshire and a detailed baseline 
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clinical and biochemical assessment was performed. Patients were invited to participate if 
they were included in the primary care register of CKD stages 3-5. Over a quarter had an 
eGFR>60ml/min/1.73m
2
 on the meat-fasted study sample. Proteinuria was of notably low 
prevalence and the cohort had a large burden of cardiovascular disease. Complications of 
renal disease were uncommon. The characteristics of the cohort differ from those under 
hospital follow-up.  Their long term outcomes should contribute to refining risk 
stratification in this population.  
 
Proteinuria and eGFR are key aspects of diagnosis and monitoring in CKD. Identification 
of the optimal measures of both is essential and findings presented here contribute to that. 
There is a need to refine risk stratification in CKD, to identify those who require intensive 
intervention, and to reassure the rest. The findings of this thesis also contribute to that. 
Further study is required to refine the core aspects of diagnosis and investigation of CKD.
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1 Chapter 1: Introduction 
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1.1 Background 
The importance of renal disease has been recognised since Hippocrates made the 
association between bubbles in the urine and disease of the kidneys in 400 BC (1). In 
comparison, the epidemiological study of early kidney disease is a recent area of interest.  
Initially a lack of a consensus definition hindered research and clinical practice in this 
field. However, over the past 15 years, recognition of early renal disease has been 
improved by the advent of formulae derived from demographic studies to calculate the 
estimated glomerular filtration rate (eGFR) (1999), the publication of an international 
classification of chronic kidney disease (CKD) based on eGFR (2002), the introduction of 
widespread eGFR reporting and the implementation of primary care CKD registers in the 
UK (both 2006).  
 
The management of patients with end stage renal disease (ESRD) has been improved over 
the past 50 years with increased availability of renal replacement therapy (RRT), and 
technological and immunological advances in dialysis and transplantation respectively. 
However quality of life for patients receiving dialysis is significantly inferior to that of the 
general population (2), and the burden of premature cardiovascular disease and excess 
infections and cancers results in shortened life expectancy, with the greatest impact 
amongst the youngest patients (3). Therefore, improved diagnosis and risk stratification in 
early CKD remains essential, in order to allow early intervention and hopefully prevent, or 
reduce the rate, of progression to ESRD. 
 
This is a rapidly evolving field, and the developments to date will be reviewed in detail in 
this introduction (chapter 1). In subsequent chapters, key aspects of CKD diagnosis are 
considered. In chapter 2, the relationship between total proteinuria and albuminuria is 
explored and their roles in prognostication are examined in chapters 3 and 4. Chapter 5 
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considers whether modification of the total protein: creatinine ratio (TPCR) and albumin: 
creatinine ratio (ACR) would improve their prognostic ability. Chapter 6 compares eGFR 
prediction formulae and the impact of their use on a general population cohort and chapter 
7 presents the baseline findings from a primary care longitudinal cohort study of early 
CKD. Chapter 8 assesses the role of eGFR and proteinuria measurement in risk 
stratification in hypertension and the implications of these findings are explored in the 
discussion (chapter 9).  
 
1.2 Epidemiology of CKD 
1.2.1 Classification of Chronic Kidney Disease 
Proteinuria and reduced excretory capacity are cardinal features of kidney disease. Chronic 
kidney disease is defined as a persistent reduction in GFR with the presence of kidney 
damage, or kidney damage alone. The abnormality must be present for ≥90 days to be 
defined as persistent. The criteria used to define kidney damage are outlined in Table 1-1 
(4). Proteinuria is the most common marker of kidney damage (5). 
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Table 1-1 - Criteria for the definition of chronic kidney disease 
 
Structural or functional abnormalities of the kidneys for 
at least 90 days, as manifested by either: 
(1) Kidney damage, with or without decreased 
glomerular filtration rate (GFR), as defined by: 
• pathologic abnormalities 
• markers of kidney damage 
           – urinary abnormalities  
              (proteinuria and/ or haematuria) 
          – blood abnormalities (renal tubular syndromes) 
                 – imaging abnormalities 
                 – kidney transplantation 
• kidney transplant recipients 
 
(2) GFR <60 mL/min/1.73 m
2
, with or without kidney 
damage 
 
If any of the above criteria are fulfilled, CKD is then classified according to the staging 
system proposed by the National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative (NKF-KDOQI) in 2002, and endorsed by Kidney Disease: Improving Global 
Outcomes (KDIGO) in 2004 (5, 6). In the United Kingdom, the classification system has 
been endorsed in modified form by the Scottish Intercollegiate Guidelines Network 
(SIGN), National Institute for Health and Clinical Excellence (NICE) and Joint Specialty 
Committee on Renal Disease (7-9). The stages are described in Table 1-2 (5).  
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Table 1-2 – International Staging System of Chronic Kidney Disease 
Stage Definition eGFR 
(mL/min/1.73m
2
) 
1 Presence of kidney damage,  
with normal or raised GFR 
≥90 
2 Presence of kidney damage,  
with mildly reduced GFR 
60-89 
3 Moderately reduced GFR 30-59 
 
4 Severely reduced GFR 15-29 
 
5 End-stage kidney disease <15 
 
 
Since the introduction of the classification system in 2002, there have been proposals to 
modify it, as more prognostic evidence became available (10). An international 
controversies conference was held, which proposed three modifications. Firstly, to add the 
cause of kidney disease (if known) to the stage of CKD. Secondly, to subdivide  Stage 3 
(30 < eGFR  < 59),  into 2 levels, 3A and 3B, based on eGFR; 3A when 45 < eGFR < 59, 
and 3B when 30 < eGFR < 44). Thirdly, to add the stage of albuminuria to the stage of 
CKD, according to eGFR.  These changes seek to improve the assessment of overall 
prognosis by including these accepted prognostic indicators in the classification (11). New 
international CKD guidelines are currently under development by KDIGO, and are 
expected to incorporate these modifications in the form of the CGA classification (cause, 
eGFR and albuminuria). 
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1.2.2 Heterogeneity of Chronic Kidney Disease 
Chronic kidney disease is an “umbrella term” which includes numerous specific renal 
diseases, some of which are more well-defined than others. The term was introduced to 
facilitate recognition and classification of kidney disease as described above, but could 
obscure the importance of distinct renal pathologies with differing natural history and 
prognosis. For instance, compare two glomerular diseases; minimal change nephropathy 
characterized by nephrotic syndrome but no progressive loss of excretory renal function 
and idiopathic membranous nephropathy with variable levels of proteinuria and where 
around a third will develop progressive renal disease. Furthermore interstitial diseases have 
a different natural history such as patients with adult polycystic kidney disease who often 
suffer a linear decline in GFR without proteinuria. Subsequently the therapeutic 
approaches to these distinct conditions differ in some important aspects. The expected 
recommendation of the upcoming KDIGO guidelines to add cause to the classification is in 
recognition of this important feature of renal disease. 
 
1.2.3 Incidence and Prevalence of Chronic Kidney Disease 
The true incidence and prevalence of CKD, according to the definition outlined above, is 
difficult to ascertain. Prior to the CKD classification being introduced, studies used varying 
definitions of kidney disease and its severity which made comparisons of prevalence 
difficult. The incidence and prevalence of patients receiving dialysis treatment for 
established renal failure is well documented in the UK and around the world by a number 
of organisations: Scottish Renal Registry; UK Renal Registry; European Renal Registry; 
Australia and New Zealand Dialysis and Transplant Registry; and the United States Renal 
Data System (12-16). The incidence of new patients starting RRT in Scotland in 2006 – 
2010 was 10.7/100,000 population (12). However this reflects prevalence of treatment as 
opposed to prevalence of the disease. The prevalence and incidence of CKD itself is more 
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poorly documented. The majority of studies have relied on single measurements of serum 
creatinine and proteinuria in general population cohorts which may over-estimate the 
prevalence, compared to using a reduced eGFR on two occasions >90 days apart to define 
CKD (as recommended by the CKD classification). Laboratory studies of populations 
gathered during routine clinical care assume absence of disease in the unsampled 
population, which will underestimate prevalence. However there is also likely to be 
oversampling of patients being tested during an acute illness, when kidney function may 
have deteriorated acutely. This will overestimate prevalence (especially if a single measure 
is used). The relative contribution of these conflicting factors to the overall prevalence 
estimate is unknown but these studies still provide valuable information.  
 
In the past, studies often focussed on advanced kidney disease, in order to predict need for 
renal replacement therapy (17-19). More recently there has been a paradigm shift in 
nephrologists’ approach to kidney disease, exemplified by an increased recognition of the 
importance of early kidney disease as a potential time for intervention in order to prevent 
progression, late presentation and the recognition of the excess burden of cardiovascular 
disease in this group (20). Recent studies of incidence and prevalence reflect this, with 
more attention being paid to earlier disease. The identification of this patient group has 
also been improved greatly by routine eGFR reporting (21). 
 
The Health Survey of Nord-Trondelag County (HUNT II) in Norway found an overall 
prevalence of Stages 1 – 5 CKD of 10.2% (4.3% Stages 3 – 5)  in a representative sample 
of 15,625 adults (22). The Ausdiab study found a prevalence of Stage 3 – 5 CKD of 11.2% 
in a sample of 11,247 non-institutionalised adults ≥ 25years of age in Australia (23).  In the 
USA, prevalence estimates of CKD are derived from the National Health and Nutrition 
Examination Survey (NHANES). The most recent survey contains data from 13,233 non-
institutionalised adults ≥20 years during 1999 – 2004. The prevalence of Stages 1 -4 CKD 
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was 13.1%. This was compared to the same survey from 1988 – 1994 where the prevalence 
was 10%, with the largest increment being in Stage 3 CKD which rose from 5.4% to 7.7%. 
This is one of the few publications to have assessed secular trends, and showed an overall 
relative increase of 1.3 (24). The authors suggest that this may be partly accounted for by 
the increasing prevalence of diabetes and obesity. Proteinuria was also common in this 
cohort, with frank proteinuria in 1.3%, and microalbuminuria in 8.2% of subjects. 
 
There is increasing evidence from the UK in recent years. The Health Survey in England 
(HSE) is a regular survey of a selection of the population. It assessed kidney disease for the 
first time in 2009. Combining 2009 and 2010 data it now includes over 6000 participants 
aged ≥16 years and is a nationally representative sample in England. A single measurement 
of blood and urine was taken and 6% of men and 7% of women were found to have Stage 
3 – 5 CKD, according to eGFR measurement, with marked differences according to age. 
Less than 1% of men and women aged 16-24 had stage 3-5, rising to 29% of men and 35% 
of women aged 75 and over.  Albuminuria was found in 9% of men and 8% of women. In 
the majority, this was microalbuminuria (8% in men and women) and only 1% (or less) 
had macroalbuminuria. Again, there was marked variation according to age: around 5%-
6% in the younger age groups, rising to 26% of men and 19% of women aged 75 and over. 
Taking these parameters together, overall estimates for Stages 1-5 CKD were produced – 
13% in men and women (25). However these estimates will be subject to change 
depending on the age distribution in a given population because of the strong relationship 
between age and prevalence of CKD described above.  A slightly older study from 
England, the NEOERICA project, utilised primary care computer records in three regions 
of England to identify those with CKD. A valid creatinine was available in 30% of the total 
adult cohort (aged ≥18 years), and the study reported an age-standardised prevalence of 
stage 3 – 5 CKD of 10.6% for females and 5.8% for males (26). This study suffers from 
selection bias, as the 30% of the cohort with available results had serum creatinine 
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measured for a clinical indication and were not selected randomly. A summary of the 
findings of these prevalence studies is shown in table 1-3.  
 
Table 1-3 - Summary of studies of prevalence of CKD 
Study Year Country Number Stage of 
CKD 
Prevalence 
(%) 
HUNT-II 2006 Norway 15,625 3 – 5 4.3 
AusDiab 2003 Australia 11,247 3 – 5 11.2 
NHANES 1999-2004 USA 13,233 1 – 4 13.1 
HSE 2009-10 England >6000 1 – 5 13.0 
NEOERICA 1998-2003 England  
(laboratory 
database) 
130,226 3 – 5 Males 5.8 
Females 10.6 
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A reduced eGFR and proteinuria do not necessarily co-exist, and this was demonstrated in 
the Prevention or Renal and Vascular End Stage Disease (PREVEND) general population 
cohort study from the Netherlands (27). Both these measures identify at risk populations 
and the overlap is a relatively small proportion of the total, as shown in Figure 1-1. This 
was one of the few studies that assessed the presence of non-visible haematuria and none 
of the studies above took account of the other criteria for CKD such as structural or 
histological abnormalities. 
Figure 1-1 - Venn diagram indicating the prevalence of macroalbuminuria, erythrocyturia, and 
impaired renal function in a population of 8592 participants of general population screening (27) 
 
 
 
Figure reproduced with permission from the American Society of Nephrology. 
 
In summary, the estimated prevalence of CKD is 4.3 – 13.1% with significant 
international differences. The prevalence may be rising, at least in the USA. True 
estimates have been hampered by methodological problems. Given the marked 
differences in prevalence between age-groups and gender, the actual prevalence in any 
defined geographical area will be dependant upon its demographic composition.  
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1.3 Assessment of Kidney Function 
In order to define the severity of kidney disease according to the international classification 
we must be able to estimate GFR and quantify proteinuria accurately. Section 1.3 
summarises the key issues surrounding the measurement of these variables.  
 
1.3.1 Measurement of glomerular filtration rate 
One of the key measures of kidney function in current use is the glomerular filtration rate 
(GFR) (the sum of the filtration by all of the glomeruli). GFR is approximately 
proportional to the total number of nephrons and to the size of the glomeruli.  Therefore it 
is lower in children and small adults. GFR typically declines from the fourth decade 
onwards, at around 1 mL/min per year (28). In clinical practice, GFR is normalized to body 
surface area to take account of size differences.  Usually body surface area (BSA) is 
calculated from an equation proposed by Dubois and Dubois (1916) that depends on height 
and weight, but not age or gender (29). When GFR is normalized to BSA, GFR/1.73 m
2
 in 
young adult men and women is similar and is in the range of 100-120 mL/min.   
 
1.3.2 Use of serum creatinine as an endogenous marker of GFR 
GFR cannot be measured directly. It can be measured indirectly using the clearance of an 
exogenous marker substance such as inulin which is the recognised gold standard but is not 
widely used because of cost and inconvenience. Other exogenous markers are used 
occasionally in clinical practice but are limited by cost, inconvenience and exposure to 
radioactivity or iodinated contrast.  
 
Serum creatinine (SCr) is the most widely used endogenous marker of GFR. It is a low 
molecular weight organic cation (113 Daltons) which is produced at a relatively constant 
rate in each individual by the non-enzymatic degradation of creatine in muscle. Creatinine 
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is also derived from dietary intake of meat (either in the form of creatine, or creatinine 
itself) (30). The plasma level of creatinine is dictated by intake, generation, metabolism 
and excretion. Creatinine generation varies markedly between individuals mostly 
depending on their muscle mass (31). Muscle mass depends on body weight, and for any 
given weight, is higher in men than in women, and African Americans then Caucasians 
(32).  Muscle mass decreases markedly as we age (33): creatinine excretion rate in an 80-
year old is approximately half that in a 20-year-old of the same body weight, as shown in 
figure 1-2.  Patients with cachexia, such as those with cirrhosis, will also have a very low 
creatinine excretion rate (34). 
Figure 1-2 – Creatinine excretion according to age, sex and weight 
 
Creatinine is distributed throughout total body water, and is freely filtered by the 
glomerulus and actively secreted by the tubular cells. For this reason, total creatinine 
clearance is the sum of GFR and tubular secretion, and so overestimates the GFR. The 
percentage of creatinine removal by tubular secretion varies with kidney function. When 
GFR is high, this percentage is relatively small (10 – 40%), but when GFR is low, the 
contribution of tubular secretion to creatinine clearance becomes more important (50-60%) 
(35). Tubular secretion of creatinine can be competitively inhibited by the administration 
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of drugs such as trimethoprim and cimetidine allowing a more accurate estimation of true 
GFR (36). Extra-renal elimination of creatinine is negligible in individuals with normal 
renal function, but when GFR is significantly reduced, there is appreciable creatinine 
removal by other routes such as degradation by intestinal flora (37). 
 
Various equations have been developed over the past 35 years to predict creatinine 
excretion (as opposed to GFR) based on sex, age and weight, and more recent 
equations have added race, as follows: 
 
1. Cockcroft and Gault formula (1976) (32): 
• 24-hr creatinine excretion (g) = (140-age) x weight (kg) x 0.0002 [x 0.85 if female] 
 
     2. Walser formula (1987) (38): 
• Male: (28.2-0.172 x age) x weight (kg)   
• Female: (21.9-0.115 x age) x weight (kg) 
 
    3. Goldwasser formula (1997) (39): 
• [23.6-(age/8.3)(+1.9 if black)] x weight (kg) 
 
   4. Rule (Mayo Quadratic) Formula (2004) (40) 
• {exp[7.26-0.26(if female) – (0.011 x (age – 55) if age>55)]} xBSA/1.73 
 
  5. Ix (equation D) (2011) (41): 
• 879.89+12.51 x weight (kg) – 6.19 x age + (34.51 if black) – (379.42 if female) 
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1.3.3 Serum creatinine assays 
Most serum creatinine assays are based on the Jaffe colorimetric reaction with alkaline 
picrate. Various endogenous and exogenous substances (e.g. ketones, glucose, bilirubin) 
interfere with these colorimetric reactions, giving a falsely high, or less commonly, low 
serum creatinine. The degree of interference relates to the assay used and cannot be easily 
corrected for. The non-creatinine chromagens affect the assay most at lower levels of 
creatinine, when they contribute up to 20% (30). Serum creatinine can be measured using 
enzymatic methods which have fewer problems with interference, but are more expensive 
(42). Efforts are being made to adjust all creatinine assays to give results closer to the true 
serum creatinine concentration by using reference creatinine preparations and reference 
methods of measurement (isotope dilution mass spectroscopy – IDMS) (43). IDMS-
calibrated serum creatinine values tend to be lower (by about 6%) than serum creatinine 
measured using many of the older methods. 
 
1.3.4 GFR prediction equations 
GFR can be estimated from creatinine by a number of methods. Creatinine clearance can 
be calculated from the creatinine content of a 24-hour urine specimen and a serum 
creatinine level (measured during the collection period), but this is cumbersome.  
Therefore various authors have developed equations that, using surrogates for lean body 
mass (body size, gender, and age, and sometimes race) attempt to predict the GFR from 
serum creatinine measurement only (as opposed to the estimated creatinine excretion). The 
ones in common clinical use are shown in Table 1-4. The Cockcroft and Gault (C&G) 
formula estimates creatinine clearance (32). As creatinine clearance overestimates GFR 
because of tubular secretion of creatinine, some multiply the estimated creatinine clearance 
by 0.8 to remove the contribution of tubular secretion and obtain a value closer to the true 
GFR. It also requires a body weight measurement as it is not normalized to BSA. 
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The Modification of Diet in Renal Disease (MDRD) formula was derived during the 
clinical study of the same name, which studied patients primarily with a GFR less than 60 
mL/min (per 1.73 m
2
) (44). GFR was measured using isotopically tagged iothalamate; 
iothalamate is a substance that is filtered by the glomerulus but is not secreted by the 
tubules.  For a given value of SCr, the GFR was found to be about 26% lower in women 
than in men, and about 18% lower in Caucasians (men or women) than in African 
Americans.  The race effect is thought to be due to the fact that muscle mass in African 
Americans tends to be higher and so their creatinine excretion rate is also increased, but 
altered tubular handling of creatinine may also play a role (45). There are several forms of 
the MDRD equation as shown below. Few patients with GFR values higher than 
60mL/min/1.73m
2
 were included in the study cohort, and the MDRD equation is 
increasingly unreliable if GFR ≥60mL/min/1.73m
2
. Above 60mL/min/1.73m
2 
the MDRD 
equation underestimates GFR and has decreased precision. For this reason, some 
recommend that eGFR values greater than 60mL/min/1.73m
2 
estimated using the MDRD 
equation be reported simply as being >60ml/min/1.73m
2
 (46). The MDRD equation is 
normalized to 1.73 m
2
 of body surface area, unlike the Cockcroft and Gault equation, and 
this must be borne in mind when comparing values obtained using the two methods.   
 
The most recent equation to estimate GFR from serum creatinine was developed by the 
CKD-Epidemiology Group and was based on a large patient sample that included many 
patients with GFR >60mL/min/1.73m
2
 (47).  This CKD-EPI estimate of eGFR is actually a 
set of 8 equations; the choice of which equation to use depends on whether the patient is 
male or female, African American or Caucasian, and whether the SCr is in a lower or 
higher range (see Table 1-4).  When eGFR is below 50mL/min/1.73m
2
, the MDRD and 
CKD-EPI equations give very similar results. Above this level, CKD-EPI may be more 
reliable.
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Table 1-4 – Formulae to predict creatinine clearance and estimated GFR 
 Year IDMS Traceable Equation 
Cockcroft and Gault 
(Cr Cl) 
1976 No (140-age) × (Wt in kg) × (0.85 if female) / (72  × SCr in mg/dL) 
 
MDRD4 
(eGFR) 
1999 Yes eGFR=175 x (0.011312 x sCr)
-1.154
 x age
-0.203
 x 0.742 (if female) x 1.212 (if black) 
 
MDRD4 
(eGFR) 
1999 No eGFR=186 x (0.011312 x sCr)
-1.154
 x age
-0.203
 x 0.742 (if female) x 1.212 (if black) 
 
CKD-EPI 
(eGFR) 
2009 Yes  
White/ 
Other 
Female   If sCr ≤ 62µmol/L eGFR = 144 x (Scr/0.7)
-0.329  
x (0.993)
age
 
If sCr > 62µmol/L eGFR = 144 x (Scr/0.7)
-1.209  
x (0.993)
age
 
White/ 
Other 
Male   If sCr ≤80µmol/L eGFR = 141 x (Scr/0.9)
-0.411  
x (0.993)
age 
If sCr > 80µmol/L eGFR = 141 x (Scr/0.9)
-1.209  
x (0.993)
age
 
Black Female   If sCr ≤ 62µmol/L eGFR = 166 x (Scr/0.7)
-0.329  
x (0.993)
age 
If sCr > 62µmol/L eGFR = 166 x (Scr/0.7)
-1.209  
x (0.993)
age
 
Black Male   If sCr ≤80µmol/L eGFR = 163 x (Scr/0.9)
-0.411  
x (0.993)
age 
If sCr > 80µmol/L eGFR = 163 x (Scr/0.9)
-1.209  
x (0.993)
age
 
Cockcroft and Gault (32), MDRD formula: IDMS-traceable (48), not IDMS-traceable (44), CKD-EPI Equation (47): 
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Cystatin C is an alternative endogenous marker of GFR. It is a 13 kDalton protein which is 
produced at a constant rate by all nucleated cells, freely filtered at the glomerulus, and is 
not secreted, but is reabsorbed within the tubules where it is completely metabolized (49). 
It does not vary with muscle mass, gender or age so may be a superior marker of GFR in 
select groups (50). However it is more costly, assays have not been standardized and is not 
yet in widespread clinical use.  
 
1.3.5 Limitations of GFR prediction equations 
All the prediction equations rely on the assumption that muscle mass can be predicted from 
demographics such as age, sex and race. They cannot take inter-individual differences in 
muscle mass into consideration and as such will always remain more-or-less precise 
estimates of the true GFR. Whether based on serum creatinine or cystatin C, the eGFR 
prediction equations assume that kidney function is stable at the time it is measured and are 
unsuitable for use during periods of acute kidney injury. Also, in very lean or cachectic 
patients with body mass index < 18.5 kg/m
2
, both MDRD and C&G tend to overestimate 
eGFR and creatinine clearance, respectively (51). Obese patients present a particular 
problem for creatinine-based estimates of GFR. The muscle mass is a lower percentage of 
total weight than in normal individuals, but is greater than would be predicted by height. If 
actual body weight is used in the C&G formula, GFR is markedly overestimated, whereas 
if ideal body weight is used (as recommended by C&G), GFR will be underestimated. 
Lean body weight gives the closest estimate and can be calculated from height and weight. 
Cockcroft and Gault, but not MDRD, tends to overestimate clearances in obese patients 
with BMI > 30 kg/m
2
 (52). In the United Kingdom, laboratories currently measure serum 
creatinine, using either a colorimetric or enzymatic assay, calculate an IDMS traceable 
value and subsequently an eGFR, using the MDRD formula (21, 43). The significant issues 
with this technique should be borne in mind when interpreting the results.  
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1.3.6 Measurement of proteinuria 
In health, the glomerulus has a negatively charged, selective filtration barrier, composed of 
the glomerular capillary endothelium and glycocalyx, the glomerular basement membrane  
(GBM) and podocytes which prevent most proteins entering the urine (as shown in figure 
1-3) (53). Small proteins (typically molecules <4nm diameter) are freely filtered, large 
proteins are not, and in between the proportion filtered is determined by molecular size, 
conformation and charge. Large, negatively charged molecules such as albumin (molecular 
weight 67,000 Daltons) only penetrate the filtration barrier in very small amounts. 
Subsequently, filtered protein is then almost completely reabsorbed in the proximal tubule, 
via megalin and cubulin mediated endocytosis (54). A small quantity of protein is actively 
secreted by the tubular cells. Some proteins, such as uromodulin have physiological roles 
in urine, including urothelial defence against infection and a potential protective role in 
interstitial inflammation (55, 56). Normally the total daily urine protein excretion is up to 
150-200 mg, and for albumin 30 mg, but most healthy adults excrete substantially less. 
 
Some glomerular diseases affect the function of components of the filtration barrier (such 
as the podocyte). As this barrier is compromised, increasing amounts of protein appear in 
the filtrate, overwhelming the tubular reabsorption capacity, thus producing proteinuria. 
Figure 1-3 - – Schematic diagram of the glomerular filtration barrier 
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In disease, the amount of proteinuria may increase dramatically. This may be described as 
glomerular, tubular or overflow proteinuria.  The generally accepted paradigm is that once 
proteinuria reaches >1 g/day it is the result of glomerular damage with subsequent leakage 
through the glomerular barrier, and is predominantly albumin. Lower levels of proteinuria 
may also be albuminuria of glomerular origin but can also be caused by tubular damage, 
with resultant failure of re-absorption of filtered small physiological proteins (“tubular 
proteinuria”). Excess circulating protein can overwhelm tubular reabsorptive capabilities 
(e.g. free light chains in myeloma), and this is termed overflow proteinuria. However there 
is some emerging evidence of a tubular origin for albuminuria. An American research 
group studied rats with diabetic nephropathy and controls, using a relatively new technique 
called 2-photon microscopy. They found the glomerular sieving co-efficient of albumin to 
be 50 times higher than previously recorded, with no difference between the rats with 
nephropathy and controls. However, only the diabetic rats had albuminuria, supporting the 
hypothesis of a tubular source (57). This finding has been fiercely contested by other 
research groups (58). The terminology to describe the degree of proteinuria, and the 
equivalent values for albumin and total protein are shown in Table 1-5. 
 
Table 1-5 - Measures of albumin and protein excretion in the urine. The albumin and total protein 
columns are only approximate equivalents as there is a non-linear relationship between albuminuria 
and total proteinuria. 
 Albumin: 
creatinine ratio 
(mg/mmol) 
Albumin 
Excretion Rate  
(mg/day) 
Protein: 
creatinine 
ratio 
(mg/mmol) 
 
Protein 
Excretion 
Rate  
(mg/day) 
Normal <2.5 men * 
<3.5 women 
 
<30 <15 <150 
Microalbuminuria 2.5-30 men 
3.5-30 women 
 
30–300 - - 
Proteinuria 
 
>30 >300 50-300 
 
500-3500 
Nephrotic range - - >300 
 
>3500 
* some recommend a single threshold for males and females of 3mg/mmol 
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1.3.7 Quantification of urine protein 
Urine protein can be quantified by a variety of techniques, including urine dipsticks, 
laboratory quantification of timed urine collections (typically 24-hour collections or 
fractions of this) and spot urine samples (which may be first morning void or a random 
sample).  Laboratory quantification may be of total protein or albumin, and there are a 
number of assays in use worldwide. There are a number of aspects to be considered when 
evaluating these different techniques. 
 
Firstly, urine dipstick tests for total protein or albumin are cheap and easy to use. They 
utilize chemical or immune reactions to generate color changes in reagent pads. The colour 
is assessed by the operator, which has been shown to be operator dependant, or read by a 
machine (which improves reliability but raises cost) (59, 60). Dipsticks have four main 
disadvantages. Firstly, they measure concentration rather than quantity. Urine volume 
varies widely according to hydration status and osmotic load. Therefore, if the urine flow 
rate is high, significant proteinuria may be missed or, conversely, over-diagnosed at low 
urine flow rates. In order to improve this intra-individual variation, a creatinine test pad has 
been added to some dipsticks to give a measure of urine concentration. This appears 
promising, but requires further study (61). The second shortcoming is that total protein 
dipsticks typically detect a protein concentration of >0.15 g/L, but are less sensitive to 
some non-albumin proteins such as immunoglobulin light chains (Bence-Jones protein) 
(62, 63). The major manufacturers of these urine dipsticks (Roche and Siemens) use 
different cut-offs and a different number of concentration categories, which further 
confuses interpretation of the results. Thirdly the recording of dipstick urinalysis findings 
is less formal than a laboratory based record and may not be available for subsequent 
comparison. And lastly the use of dipstick quantification of urine protein is not subject to 
the same rigorous quality control as laboratory methods. Currently, they are not 
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recommended for routine screening for proteinuria in clinical practice because of a 
significant high false negative rate (7, 8, 64).  
 
They do have two main advantages. They do not require laboratory equipment or 
electricity so can be used in remote or resource-poor settings. Also, they provide an 
assessment of non-visible haematuria which can be an important additional diagnostic 
feature of glomerular disease.  
 
In the laboratory, total proteinuria is generally measured by a colorimetric or turbidimetric 
method, because of the variety of proteins being measured. Each assay has differing 
sensitivities for different proteins, making comparison between assays difficult.  Total 
protein assays have a lower precision than albumin assays and are difficult to standardize. 
Urinary albumin is usually measured by immunoassays which measure albumin 
specifically. Urine is a hostile and highly variable biochemical environment with a wide 
range of pH and osmotic concentration. Consequently, there is a wide variety of albumin 
species and fragments within urine, which make assay standardization a challenge, 
particularly as the prognostic impact of these different moieties is not well-defined. High-
performance liquid chromatography measures consistently higher values for albumin than 
immunoassays, as it also measures some albumin fragments, and may therefore allow 
earlier detection of microalbuminuria (65). Nevertheless, currently there is no international 
reference method or reference material for urine albumin assays (66).  A reference method 
for albuminuria based on liquid chromatography mass spectrometry is being developed by 
the U.S.-based National Kidney Disease Education Project (NKDEP) and other groups. 
 
Protein excretion varies diurnally and with posture, being lowest overnight and when 
supine.  Some adolescents have transient proteinuria when upright, which disappears when 
supine, known as orthostatic proteinuria, which usually resolves (67). Transient proteinuria 
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can also develop in response to fever, exercise and other stressors. A 24-hour urine 
collection is traditionally the accepted gold standard for measuring proteinuria, as it is 
unaffected by diurnal variation. Other timed urine collections (e.g. overnight) have also 
been used. However, timed urine collections have a number of drawbacks. Firstly, they are 
very inconvenient for patients leading to poor collection rates; in one clinical study only 
59% of patients provided the desired overnight sample, and in general clinical practice the 
collection rate may well be lower (68). Secondly, they are often poorly performed, with 
incomplete collections leading to substantial inaccuracy (69, 70). Lastly, they are 
considerably more time consuming to analyse in the laboratory and therefore more 
expensive, with one study finding the cost of analysing a spot sample to be only 15% of 
that of a 24-hour collection (71). 
 
Spot urine samples can be analyzed for total protein or albumin. Although more accurate 
than dipsticks, this still generates a concentration rather than a quantity. Creatinine is 
excreted in urine at a relatively constant rate (30). Thus, if creatinine concentration is also 
measured, a TPCR or ACR can be calculated to adjust for urine concentration. There are 
small studies over the past 20 years assessing the correlation between TPCR and 24-hour 
urinary protein excretion in a variety of populations, including patients with CKD, 
rheumatology out-patients and kidney transplant recipients, which show that TPCR 
performs reliably to quantify significant proteinuria (69, 72-76). The use of TPCR in 
pregnant women has also been studied and found to be a reliable test (77, 78). A systematic 
review, published in 2005 supported the use of TPCR in place of 24-hour urine collections 
to “rule-out” significant proteinuria, however 10 of the 16 included studies were of 
pregnant women, and only 216 patients with CKD were included in total (79).   ACR also 
correlates well with 24-hour urinary albumin excretion, though the research focuses almost 
exclusively on diabetic renal disease (68, 80-82). Spot samples from the first micturition 
after rising are recommended as results from them correlate well with 24-hour excretion 
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(83). However, a random daytime sample will usually give acceptable accuracy (84). 
Inadequate urine volume and freezer storage of specimens may lead to under- and over-
estimation of urine albumin respectively (85). As discussed above, creatinine excretion rate 
varies markedly with muscle mass. In particular, women and the elderly have a lower 
creatinine generation rate and this artificially inflates the ratio of protein or albumin to 
creatinine. For example, an elderly woman with low muscle mass and consequently low 
urine creatinine excretion will have a substantially higher albumin: creatinine ratio than a 
bodybuilder with the same 24-hour albuminuria because his urine creatinine excretion will 
be 2 – 3 times higher. Some use a higher diagnostic threshold for ACR in women to 
partially address this. A similar issue is likely to occur with different races, but there is less 
evidence available (86). Therefore in patients with abnormal muscle mass and resultant 
abnormal creatinine generation, ACR or TPCR may give misleading results, and a 24-hour 
urine estimation should be considered.  
 
1.3.8 Clinical applications of urine protein quantification 
Accurate measurement of proteinuria may be desirable for a number of reasons. It is a core 
feature of renal disease and as such may be utilized in the diagnosis of kidney disease and, 
in particular, glomerular disease (87). Repeated measurements of proteinuria may be useful 
to monitor the natural history of glomerular disease. Proteinuria is also an indication for 
kidney biopsy, and total proteinuria >1 g/day is commonly used as a threshold. This 
threshold will be affected by the overall clinical picture e.g. if associated with haematuria, 
a lower threshold of 450 mg/day may be used (9). Proteinuria thresholds (>0.5-1 g/day) 
may also be used as indications for treatment with angiotensin-converting enzyme 
inhibitors (discussed below in detail), or immunosupression in specific glomerular disease. 
Subsequent response to these therapeutic strategies can also be monitored by quantifying 
ongoing proteinuria. 
 
Chapter 1   46 
In summary, proteinuria is a cardinal sign of kidney disease, and accurate quantification is 
essential for the diagnosis, monitoring and treatment of renal disease. There are multiple 
current methods by which this may be achieved.  
 
1.3.9 Recommendations on the measurement of proteinuria 
In diabetic kidney disease, albuminuria is used for screening, diagnosis and monitoring. 
Studies of the natural history of diabetic nephropathy promoted the concept of 
microalbuminuria as an early marker of nephropathy and subsequent intervention studies 
measured albuminuria, which has resulted in it becoming the accepted marker in patients 
with diabetes. However the early studies did not examine the utility of TPCR levels below 
the laboratory reference range for predicting outcomes (88, 89).  
 
In terms of the measurement of albuminuria, a spot sample for ACR is most convenient, 
but albumin concentration or 24-hour urine excretion is still used by some. The ACR 
appears to be a better predictor of renal outcomes in diabetics than urinary albumin 
concentration or 24h urinary albumin excretion (90). First morning voids are more reliable 
than random spot urines to monitor microalbuminuria (83). 
 
In non-diabetic kidney disease, it is controversial whether total proteinuria or albuminuria 
is the more appropriate test to screen for kidney disease. Most research studies have 
measured 24-hour urinary total protein excretion, and thresholds for risk, investigation and 
intervention have arisen from these studies (91). Measurement of albuminuria has the 
theoretical, technical and clinical advantages outlined above. The theoretical paradigm 
underpinning this is that by using ACR one can measure albumin as a marker of risk (i.e. 
the signal), without measuring physiological proteins (i.e. noise), thus increasing 
sensitivity by minimising the noise: signal ratio. This assumes that the quantity of non-
albumin proteinuria adds no additional information to albumin, and that the quantity of 
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physiological proteinuria is irrelevant to risk. It is not known what level of risk is carried 
by proteinuric patients with low levels of albuminuria but high levels of non-albumin 
proteinuria. Microalbuminuria may not be reliably detected by total protein assays but 
there is limited evidence about which non-diabetic patients should be screened for 
microalbuminuria, and what treatments should be used. 
 
There are various guidelines that make recommendations about the measurement of 
proteinuria. All of them accept the use of spot samples, corrected for urine creatinine, as 
screening tests for proteinuria, but this is not universally accepted in the literature (92, 93). 
The NICE guidelines for England and Wales and the NKF-KDOQI guidelines in the 
United States of America both recommend the universal use of ACR for diabetic and non-
diabetic CKD. They add the caveat that TPCR may be used at elevated levels of ACR 
assuming that the predominant urine protein at these higher levels is albumin (5, 8). 
Conversely, the Scottish Intercollegiate Guidelines Network, the UK CKD guidelines, the 
Welsh Renal National Services Framework recommend TPCR for non-diabetic kidney 
disease, and reserve the use of ACR for diabetic kidney disease only (7, 9, 94). 
 
There are few data directly comparing ACR and TPCR in a kidney disease population. The 
AusDiab study assessed both in a large cross-section of the general population, Collier at al 
assessed the performance in a small sample of 117 clinic patients and Birmingham et al 
focused exclusively on a lupus nephritis cohort (95-97). They found a non-linear 
relationship between albuminuria and total proteinuria. None of these studies reported 
renal or patient outcomes.  
 
A recent study took a different approach and assessed the utility of the albumin: protein 
ratio (APR), derived by dividing the ACR by TPCR. The hypothesis was that a low APR 
(i.e. a high proportion of non-albumin proteins) is predictive of tubulo-interstitial disease 
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on renal biopsy; they found the cut-point to be 0.4, below which the test had an excellent 
sensitivity and specificity for interstitial disease (98).  
 
1.4 Progression of CKD 
In the preceding sections the definition and classification of CKD, along with issues 
regarding optimal measurement of eGFR and proteinuria have been discussed. These 
aspects are essential for the correct diagnosis of CKD, however the most important purpose 
of these measurements is to inform prognosis, both renal outcome and patient mortality. In 
this section the important predictors of renal progression are discussed, and the following 
section deals with cardiovascular and all-cause mortality in patients with CKD.  
 
The most commonly reported outcome measure of renal disease is the commencement of 
RRT. This has strengths and weaknesses. It is easy to define and is recorded accurately and 
therefore easy to document, but it is a treatment not a clinical state and therefore cannot 
take account of those who do not undergo RRT when clinically indicated because of 
extenuating circumstances. The initiation of RRT is also clinician and patient dependant 
and therefore not reproducible. An alternative measure of renal progression is doubling of 
serum creatinine, which correlates with a fall in eGFR of 50% within the individual. The 
third frequently used measure is eGFR slope. The measurement of eGFR slope and 
doubling of serum creatinine are both vulnerable to over interpretation in the context of 
acute kidney injury, eGFR slope more so. This will be more problematic in clinical 
databases than clinical trials with pre-specified measurement points. The ascertainment of 
all-cause mortality is the least problematic (assuming complete recording of deaths, as in 
the UK (99)), however the cause of death may bear no relationship to kidney disease (a 
high noise: signal ratio). Cardiovascular mortality has a stronger correlation with renal 
disease, as described in the following section, but may be inaccurately recorded (100).  
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1.4.1 Proteinuria  
Proteinuria is the single strongest predictor of progressive renal disease (101). It usually 
reflects primary glomerular injury and subsequent tubular toxicity due to exposure to large 
amounts of filtered protein. This leads to interstitial fibrosis and atrophy, reduced nephron 
mass, subsequent intra-glomerular hypertension in the remaining glomeruli and 
progressive injury (102). The role of albuminuria and proteinuria in the progression of 
renal disease has been studied in a variety of populations. The presence of albuminuria is 
an independent predictor of the development of de-novo renal impairment 
(eGFR<60ml/min/1.73m
2
) in the general population (103). In a non-diabetic, hypertensive 
population microalbuminuria was also found to be an independent predictor of 
development of chronic renal insufficiency with a relative risk of 7.61 (95% CI 3.19 – 
8.16) (104). Macroalbuminuria is a superior predictor of renal progression, than a reduced 
baseline eGFR itself (27). In the multiple risk factor intervention trial (MRFIT) of 12,866 
men at high risk of heart disease, dipstick proteinuria of ≥2 + was associated with an 
adjusted hazard ratio of 14.21 (95% CI 9.16 – 22.05) for developing established renal 
failure, and 1+ protein on dipstick with an adjusted hazard ratio of 2.30 (95% CI 1.28 – 
4.13) (105). This finding was supported in a general population screening study in Japan, 
of 107,192 participants which found an adjusted odds ratio of 14.9 (95% CI 10.9 – 20.2) 
for dipstick proteinuria to predict development of end stage renal disease (106). An 
analysis of renal outcomes in the Norwegian HUNT II study found that using eGFR 
criteria alone identified 4.7% of the general population at risk of ESRD and correctly 
identified 69.4% of those progressing to ESRD, whereas combining eGFR and albuminuria 
refined the predictive ability with only 1.4% of the population identified at risk but without 
a significant loss of sensitivity (107). The CKD Prognosis Consortium performed a meta-
analysis of 13 studies (21,688 participants) of cohorts with CKD and found albuminuria to 
be a strong independent predictor of ESRD, adding additional information to that derived 
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from eGFR measurement (108). This evidence has contributed to the decision to add 
albuminuria to the staging of the CKD classification system.  
There is also strong evidence of the role of albuminuria in the progression of diabetic 
kidney disease. Baseline proteinuria is an independent predictor of renal outcome in 
nephropathy associated with Type 1 diabetes mellitus (109) and Type 2 diabetes mellitus 
(110). The presence of microalbuminuria has been found to predict the development of 
clinical proteinuria (88) and is now widely used as a screening test in diabetes (111). 
However the relationship between albuminuria and progressive renal decline in patients 
with diabetes is not uniform. Varying patterns of renal injury have been observed in 
patients with microalbuminuria: in a study of renal biopsies of diabetic patients with 
preserved excretory renal function and a median albumin excretion rate of 
44micrograms/min, only one third were found to have the “typical” histological features of 
diabetic nephropathy, one third showed normal or near normal biopsy appearances and the 
remaining third were described as atypical with only mild glomerular changes but severe 
tubulo-interstitial changes (112). Another report described the phenomenon of non-
albuminuric renal insufficiency in Type 2 diabetes mellitus; in their cohort 39% of those 
with an eGFR<60ml/min/1.73m
2
 had normoalbuminuria but developed progressive renal 
decline at the same rate as those with micro- and macroalbuminuria (113).  
 
There is abundant evidence of a pivotal role for albuminuria and proteinuria play in the 
progression of renal disease, as outlined above. However there are very sparse data 
comparing them as predictors of outcome. A recent post-hoc analysis of the Reduction of 
End Points in Non-insulin-dependant Diabetes Mellitus with the Angiotensin II Antagonist 
Losartan (RENAAL) study compared 24-hour urine total protein excretion (UPE), 24-hour 
urine albumin excretion (UAE), urine albumin concentration (UAC) and 
albumin:creatinine ratio (ACR) as predictors of a renal event (composite of doubling of 
serum creatinine and end-stage renal disease). The hazard ratios are shown in Table 1-6. 
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Disappointingly urine total protein concentration was not measured on the spot samples so 
total protein:creatinine ratio could not be included in the analysis. No mortality data were 
included (90).  
Table 1-6 - Hazard ratios for renal event according to the type of urine protein measurement (90) 
Measurement Hazard ratio for renal event 
UPE 3.02 (2.53 – 3.62) 
UAE 3.16 (2.60 – 3.86) 
UAC 3.23 (2.67 – 3.91) 
ACR 4.36 (3.50 – 5.45) 
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1.4.2 Use of proteinuria as a surrogate end point 
The progression of CKD can be slow therefore hard end points such as development of 
established renal failure may be very distant events from disease onset and their use as trial 
end points may prevent early identification of preventative strategies. Given the strong 
relationship between proteinuria and progression of renal disease, it has been suggested 
that the reduction in proteinuria achieved by medical intervention should be used as a 
surrogate end point for established renal failure in clinical trials. However, the United 
States Food and Drug Administration (FDA) has refused to accept proteinuria as a 
surrogate endpoint. It accepts doubling of serum creatinine as a surrogate endpoint, using 
the rationale that this predicts the onset of established renal failure. In contrast, proteinuria 
is not a necessary intermediate step in the path to ESRD: a patient can develop advanced 
kidney disease requiring dialysis without ever having had proteinuria so its modification 
may not be considered a valid surrogate endpoint. Others argue that in proteinuric renal 
disease, modification of proteinuria is the single strongest predictor of outcome (114), and 
therefore is valid. This has been challenged in studies of diabetes, where the assumption 
was that reduction of microalbuminuria was roughly equivalent to the reduction in risk of 
ESRD (115). In the ACCORD microvascular study of type 2 diabetes (114), 
microalbuminuria was reduced 21% by improved glycaemic control, but ESRD incidence 
fell by only 5% (114).  The use of surrogate markers in other areas of medicine has also 
come under close scrutiny recently, prompted by the withdrawal of rosiglitazone from the 
market, which had performed well when glycated haemoglobin was used as the surrogate 
endpoint rather than survival (116). A scientific work group was established under the 
auspices of the National Kidney Foundation and the FDA and concluded that proteinuria 
could not be used as a surrogate endpoint currently, with a small number of specific 
exceptions (117).  
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1.4.3 Interventions to reduce proteinuria 
There is a strong relationship between hypertension and proteinuria. Reducing systemic 
blood pressure results in a reduction in urine protein excretion and both are major 
therapeutic targets. Blood pressure will be discussed in more detail in the next section. The 
use of agents that interfere with the renin angiotensin aldosterone system reduce 
proteinuria to a greater extent than is accounted for by their blood pressure lowering ability 
alone. The administration of angiotensin converting enzyme inhibitors (ACEi) has been 
shown to reduce progression of renal disease in a large number of randomised control trials 
in non-diabetic renal disease and diabetic nephropathy associated with Type 1 and Type 2 
diabetes (118-121). There are racial differences in the effect of blockade of the renin 
angiotensin aldosterone system, but ACEi have been shown to be effective in reducing 
proteinuria and renal decline in African Americans with renal disease (122). The greatest 
benefit is seen in those with the highest baseline urine protein excretion (118), and the 
residual level of proteinuria, achieved following initiation of therapy, predicts subsequent 
renal outcome (110, 123). However low risk patients, with proteinuria quantified as 
<0.5g/24 hours, do not seem to derive any additional benefit from the administration of 
ACEi, in terms of renal progression (124).   
 
Another class of drugs targeting the renal angiotensin aldosterone system was introduced 
more recently: angiotensin receptor blockers (ARB). They have been shown to have blood 
pressure-independent renoprotective effects in the RENAAL trial and Irbesartan Diabetic 
Nephropathy Trial (IDNT) (125, 126) and be as effective as ACEi in reducing proteinuria 
and progression of renal disease (127). A post hoc analysis of the RENAAL trial 
specifically assessed the interplay of the acute haemodynamic effect of the drug on 
glomerular filtration rate and long-term outcome. It found that the greater the initial fall in 
eGFR, the slower the rate of long-term eGFR decline, independent of blood pressure or 
albuminuria (128). It has also been shown that increasing the dose of ACEi to doses higher 
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than those usually recommended for blood pressure lowering can have additional anti-
proteinuric effects (129-131) but only one study had sufficient follow-up to show a 
reduction in the rate of ESRD (132). 
 
There is a linear relationship between the reduction in albuminuria achieved by inhibitors 
of the renin angiotensin system and the reduction in risk of an adverse renal outcome, as 
demonstrated in figure 1-4 (133). 
 
Figure 1-4 - Relationship between reduction in albuminuria and subsequent risk of renal outcome, 
compared with placebo in a number of landmark trials of renin angiotensin system blockade (133). 
 
Dark grey; ARB trial or combination ACEi and ARB, Light grey; ACEi trial,  White; 
calcium channel blocker trial, grey area represents 95% confidence intervals.  
The following trials are included in this figure: IDNT Amlodipine (126), ONTARGET 
(134), DIABHYCAR (135), ADVANCE (136), IDNT (126), Benazapril trial (132), REIN 
(137), REIN-II (138), RENAAL (125), AIPRI (139). (132) 
Figure reproduced with permission from Elsevier. 
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The combined use of ACEi and ARB should be of theoretical benefit as it should result in 
more complete blockade of the renin angiotensin aldosterone system. This has been 
assessed in a meta-analysis which confirmed an overall additional 25% reduction in 
albuminuria (140). However these studies did not titrate to the maximal anti-albuminuric 
dose of ACEi or ARB prior to introducing the second agent. Therefore the same effect may 
have been achieved by larger doses of one or other agent rather than the combination 
(133). Furthermore, the greatest benefit from dual blockade is derived in those who 
respond well to a single agent; adding a second agent in poor responders is of limited 
utility.   During the conduct of the meta-analysis, the published results of one of the major 
studies of dual renin angiotensin blockade in non-diabetic renal disease (the COOPERATE 
study published in the Lancet (141) ) were found to be inconsistent and the study has 
subsequently been retracted (142). This cast some doubt on the utility of the combination 
of these agents, and this has been further undermined by the findings of the Ongoing 
Telmisartan Alone and in combination with Ramipril Global Endpoint Trial 
(ONTARGET). This is a large study of 25,620 participants at high cardiovascular risk who 
were randomised equally to ramipril (ACEi), telmisartan (ARB) or combination therapy. 
There was no reduction of cardiovascular outcomes in the combination group, but a larger 
number reached the primary and secondary renal endpoints (composite endpoint of death, 
dialysis and doubling of serum creatinine or dialysis and doubling of serum creatinine 
respectively) (134, 143).  There was a particular increase in the need for dialysis for acute 
kidney injury. Proponents of dual renin-angiotensin blockade have highlighted the fact that 
this was a study of patients at high cardiovascular risk, and not specifically a study of 
patients with kidney disease, that the mean albuminuria at baseline was only 0.81 – 
0.83mg/mmol and that there was a trend towards benefit in the subgroup with 
macroalbuminuria. Does this study indicate that the loss of renal auto-regulation with dual 
renin angiotensin system blockade outweighs the anti-proteinuric benefits in those at low 
renal risk? Should we limit the use of dual blockade to the patients with kidney disease and 
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proteinuria or does this trial have more far-reaching consequences? Further studies 
addressing this issue in patients with CKD and diabetes are ongoing (144, 145). 
 
The use of ACEi and ARB prevents suppression of renin via the negative feedback loop 
mechanism. This results in increased plasma renin activity and can cause activation of the 
renin angiotensin system. As a result of this observation, a new class of drugs called direct 
renin inhibitors has been developed. Aliskerin has been shown to reduce albuminuria in 
combination with losartan, independently of blood pressure lowering effects, in patients 
with diabetic nephropathy (146). In the aliskerin trial in type 2 diabetes using cardio-renal 
disease endpoints (ALTITUDE), aliskerin was added to ACEi or ARB therapy in patients 
with type 2 diabetes and either albuminuria or both reduced eGFR and cardiovascular 
disease (147). However safety concerns have been raised and treatment in ALTITUDE was 
discontinued on the recommendation of the data monitoring committee following a 
statistically significant excess of strokes in the aliskerin group. All events have not yet 
been collected and adjudicated and the full results are awaited (148).  
 
Other strategies that have been shown to work in conjunction with ACEi or ARB to reduce 
proteinuria include mineralocorticoid receptor blockade (MRB), a low to moderate sodium 
diet or diuretic therapy (149, 150). One trial comparing anti-proteinuric strategies found 
the combination of an ACEi and MRB (spironolactone) resulted in a greater reduction in 
proteinuria than an ACEi plus ARB (42% versus 16%) (151) There was also an arm in this 
trial including an ACEi, ARB and MRB, which resulted in a 48% reduction in proteinuria, 
however 2 of 11 participants developed marked hyperkalaemia (K≥6.0mmol/L). 
Eplerenone (a selective aldosterone antagonist) has also been shown to be effective at 
reducing proteinuria, in conjunction with an ACEi, in patients with diabetes (152). 
Combinations of these strategies result in further reductions in albuminuria, such as the 
combination of losartan plus low sodium diet plus hydrochlorothiazide led to a 70% 
Chapter 1   57 
reduction in proteinuria in one trial and reduction in dietary sodium can transform a non-
responder to ACEi or ARB into a good responder (150).  
 
Non-dihydropyridine calcium channel blockers may also have a beneficial effect on 
proteinuria when used in conjunction with an ACEi (153). They are effective anti-
hypertensive agents in renal disease and have a superior anti-proteinuric effect when 
compared to dihydropyridine calcium channel blockers (such as amlodipine) and some 
advocate their greater use in renal disease (154).  
 
There are a number of other agents including endothelin antagonists and transforming 
growth factor beta antagonists that are currently being investigated in clinical trials and 
animal models (155).  
 
1.4.4 Hypertension 
Hypertension is common in patients with CKD, and is associated with poorer outcomes 
(156). Experimental studies have shown that systemic hypertension is transmitted to the 
glomeruli and subsequent glomerular hypertension is damaging to the kidney (157) This 
increased glomerular capillary pressure leads to accelerated decline in kidney function. 
Tight blood pressure control slows progression of renal disease in proteinuric patients 
(156).  In particular, the use of renin-angiotensin system blockade normalises the intra-
glomerular hypertension, by attenuating the vasoconstrictive effects of angiotensin II on 
the efferent arteriole. These drugs also reduce proteinuria to a greater extent than their 
blood pressure lowering abilities alone, as described in the preceding section.  The 
relationship between systemic hypertension and urine protein losses is strong, and the 
presence of significant proteinuria requires tighter blood pressure targets. 
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Guidelines recommend maintaining systolic blood pressure (SBP) at 120-139 mmHg, and 
diastolic blood pressure (DBP) <90 mmHg in all patients with CKD (8). In patients with 
proteinuria (TPCR ≥100 mg/mmol; ACR ≥70 mg/mmol), and/or diabetes mellitus, SBP 
should be kept at 120-129 mmHg and DBP <80 mmHg (7, 8).Reducing SBP below 100-
110 mmHg may be detrimental (156).  
 
1.4.5 Dyslipidaemia 
Low levels of high density lipoprotein (HDL) have been shown to be an independent 
predictor of the development of CKD (158), although a post-hoc analysis of the MDRD 
study showed that the relationship between low HDL and development of kidney failure 
was attenuated on multi-variate modelling (159). A meta-analysis of statins and 
albuminuria found that they may have a beneficial effect on pathologic albuminuria, but 
the quality of the evidence was poor (160). Treating dyslipidaemia in CKD, using an HMG 
Co-A reductase inhibitor (statin), with or without a selective cholesterol absorption 
inhibitor (e.g. ezetimibe), has not been shown to retard the progression of CKD in the 
study of heart and renal protection (SHARP) and the protection against nephropathy in 
diabetes with atorvastatin (PANDA) respectively (161, 162). 
 
1.4.6 Glycaemic control 
Diabetic nephropathy is a leading cause of established renal failure requiring dialysis (12). 
Optimal glycaemic control in Type 1 diabetes mellitus has been shown to retard the onset 
and progression of kidney disease in the Diabetes Control and Complications Trial 
(DCCT) (163). This effect has been sustained during the observational follow-up period 
following the formal end of the trial (the Epidemiology of Diabetes Interventions and 
Complications study) (164). A similar effect has been shown in patients with type 2 
diabetes mellitus in the UK Prospective Diabetes Study (UKPDS) (115). No other 
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therapeutic intervention has been shown to be as effective for the primary prevention of 
diabetic nephropathy (165). 
 
1.4.7 Obesity 
Obesity is associated with the development of CKD, independent of possible confounders. 
There is some disagreement as to the optimal measure of obesity; some investigators have 
shown an elevated body mass index to be associated with CKD (166), while others have 
demonstrated that waist: hip ratio is a superior measure of obesity as a predictor of 
progressive CKD (167). Surgical and non-surgical weight loss seems to improve blood 
pressure, reduce proteinuria and reduce hyperfiltration in the kidney. It is not yet known if 
these improvements in surrogate outcomes will translate into long term benefits (168). 
 
1.4.8 Anaemia 
Anaemia is commonly associated with CKD as a result of reduced production of 
erythropoietin (EPO) from the peritubular cells. It is thought to cause tissue hypoxia and 
promote fibrosis. Studies using recombinant human EPO or erythropoietin stimulating 
agents to correct the anaemia of CKD have not shown any beneficial effect on progression 
(169-171). 
 
1.4.9 Metabolic acidosis 
Metabolic acidosis in renal disease results from reduced ammonia production and proton 
excretion in the tubules. It is associated with progression of renal disease (172). Recently it 
has been shown that correcting metabolic acidosis using oral bicarbonate supplementation 
slows the progression of CKD. This may be as a result of reduced maladaptive 
compensatory changes in the remnant tubules of the reduced renal mass (such as increased 
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ammonia production and subsequent complement activation causing tubulo-interstitial 
damage) (173). 
 
1.4.10  Uric acid 
In healthy individuals uric acid is excreted by the kidney; consequently, serum levels rise 
in kidney disease. There has been much debate if raised serum uric acid concentration is 
merely a marker of reduced glomerular filtration, or implicated in the causal pathway.  An 
elevated uric acid has been shown to be an independent risk factor for the development of 
chronic kidney disease in general population cohorts (174, 175). However a post hoc 
analysis of the MDRD study found that uric acid was not associated with progression of 
established CKD (in this analysis it was not an independent predictor for developing 
established renal failure) (176). This finding has been confirmed in other studies (177). 
 
However a recent trial of allopurinol did find that its administration slowed the progression 
of renal disease in a small cohort of patients with established CKD (178). Further data are 
needed to confirm this finding.  
 
1.5 Cardiovascular disease, survival and CKD 
The incidence of cardiovascular disease in patients with established kidney disease 
requiring dialysis is 20 – 100 times higher than in the general population and a leading 
cause of death (3). There is also an increasingly recognised relationship between less 
severe CKD and cardiovascular disease (20, 179). This increased risk may reflect a 
clustering of traditional risk factors such as hypertension and hyperlipidaemia, or may be 
related to factors unique to renal disease including proteinuria and CKD mineral bone 
disorders (CKD MBD). 
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There is abundant evidence of the efficacy of interventions to prevent cardiovascular 
events in the general population. Given the paucity of such evidence in CKD, it is tempting 
to extrapolate from general population evidence and conclude that patients with CKD, a 
group at high cardiovascular risk, will derive great benefit from these interventions. 
However, to date, clinical trials have given conflicting results, and adequately powered 
trials of interventions in specific kidney disease cohorts are essential to guide our future 
management. A number of these factors are discussed in the sections below. 
 
1.5.1 Traditional risk factors for cardiovascular disease: Hypertension 
The relationship between hypertension and increased risk of cardiovascular disease has 
been clearly demonstrated in the general population (180). Hypertension is more common 
in patients with CKD, compared to the general population (age and gender adjusted odds 
ratio 2.1 [95% CI 2.0 – 2.2]) (26) In patients with CKD the relationship with blood 
pressure is complex, as uncontrolled hypertension causes proteinuria and progression of 
renal disease, both of which are associated with increased cardiovascular risk. Therefore 
control of hypertension is a major priority in CKD. It is also assumed to be beneficial in 
reducing cardiovascular risk in proteinuric and non-proteinuric CKD, although there is 
little direct evidence.  
 
1.5.2 Dyslipidaemia 
Hyperlipidaemia is a well recognised cardiovascular risk factor in the general population, 
and treatment with a statin has been shown to reduce cardiovascular death (181). The 
response to statin therapy in CKD is more complex. Neither atorvastatin nor rosuvastatin 
has been shown to be beneficial in patients requiring dialysis in the Deutsche Diabetes 
Dialyse Studie (4D) and a study to evaluate the use of rosuvastatin in subjects on regular 
haemodialysis (AURORA) respectively (182, 183). However the recently published 
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SHARP showed a 17% relative risk reduction in first major atherosclerotic event using 
simvastatin plus ezetimibe in patients with pre-dialysis and dialysis-dependant CKD (161). 
  
1.5.3 Diabetes Mellitus 
Diabetes mellitus is a major cause of cardiovascular disease, and a patient with diabetes 
has an overall risk of death from myocardial infarction three times that of the general 
population (184). While patients with diabetes (especially type 2) often have a clustering of 
cardiovascular risk factors, hyperglycaemia itself has been shown to be directly linked to 
macrovascular disease with a linear relationship (185). The presence of diabetic 
nephropathy (with albuminuria) is associated with an even greater risk of death (186). In 
patients with diabetes, control of blood pressure is the most important intervention to 
reduce cardiovascular events, while glycaemic control improves microvascular 
complications as described above (187). Once a patient with diabetes has developed 
established renal failure, the risk of cardiovascular mortality can be reduced by kidney 
transplantation, and it appears that survival may be improved further by a simultaneous 
kidney and pancreas transplant (188). 
 
1.5.4 Cigarette smoking 
There are few studies assessing cigarette smoking as a modifiable risk factor for 
cardiovascular disease in patients with CKD. An American study of incident dialysis 
patients who were current smokers found smoking to be associated with a 37% increase in 
mortality, after adjustment (189).  
 
1.5.5 Obesity and Physical inactivity 
There is a plethora of evidence regarding the link between obesity, physical inactivity and 
cardiovascular disease in the general population (190, 191). However there is no direct 
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evidence regarding the impact of these factors, and any subsequent interventions, on the 
development of cardiovascular disease in patients with CKD. There is a paradoxical 
relationship between weight and mortality in patients receiving dialysis therapy, with obese 
patients demonstrating a survival advantage (192). There has been a large amount of 
speculation regarding causation, but it most likely reflects obesity as a marker of relative 
health, while weight loss occurs in the unwell patients (for instance those with frequent 
infections or inflammatory conditions).  
 
However given the prevalence of obesity and cardiovascular disease in patients with CKD 
not requiring dialysis, and the limited number of effective interventions, it is widely 
accepted that healthy eating and weight control are desirable (8).  
 
1.5.6 Novel risk factors for cardiovascular disease in CKD: Proteinuria 
Studies have demonstrated the strong independent relationship between proteinuria and 
cardiovascular disease and mortality. The Framingham general population cohort showed 
that dipstick proteinuria in a casual urine specimen was an independent predictor of 
cardiovascular and all-cause mortality (193, 194). The MRFIT cohort of men at high 
cardiovascular risk also measured dipstick proteinuria on casual urine specimens and found 
the same relationship (195). Tonelli et al demonstrated the additive mortality effect of 
dipstick proteinuria at any level of eGFR in people with coronary disease, as shown in 
figure 1-5. However a study of 13,177 community dwelling adults over 75 years old in the 
UK, found dipstick proteinuria to be independently associated with all-cause but not 
cardiovascular mortality (196). 
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Figure 1-5 - Adjusted risk of all cause mortality according to proteinuria and kidney dysfunction (197) 
 
 
Reproduced with permission from the BMJ Publishing Group Ltd. 
 
 
Other studies have used laboratory quantification of albuminuria, rather than dipstick. The 
Alberta Kidney Disease Network used province-wide laboratory data to assess the 
relationship and found ACR to be an independent predictor of myocardial infarction and 
all-cause mortality (198). They also studied dipstick proteinuria and found the same 
relationship. Other studies of laboratory measures of albuminuria have shown the same 
independent relationship with vascular disease (199), and confirmed the relationship in 
subgroups such as the elderly (200). A meta-analysis of proteinuria and coronary risk, 
including 26 studies found a risk ratio of 1.47 (95% CI 1.23 – 1.74) for all proteinuria, with 
a significant dose-dependant effect for micro- versus macroalbuminuria (201).  
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Recently the CKD Prognosis Consortium published a meta-analysis of the relationship of 
albuminuria and eGFR with all-cause and cardiovascular mortality in general population 
cohorts. Over 1.2 million participants were included from 22 studies, with >100,000 urine 
ACR measurements (the remainder being dipstick). This confirmed the independent 
gradated linear relationship between albuminuria (using both ACR and dipstick) and 
cardiovascular mortality. There was no significant interaction with eGFR. The threshold 
value of ACR above which there was an association with increased risk was notably low at 
1.1mg/mmol (20). The CKD prognosis consortium went on to confirm this independent 
relationship between albuminuria and cardiovascular mortality in a further meta-analysis of 
CKD cohorts (108).  
 
There are few data available assessing the relationship between urine total protein and 
outcomes. One Finnish study of 1056 patients with type 2 diabetes mellitus and 1375 non-
diabetic subjects demonstrated an association between spot urine concentration of total 
protein (i.e. not adjusted for creatinine concentration) and subsequent cardiovascular and 
all-cause mortality (202).  
 
In summary, there are a wealth of data describing the strong independent relationship 
between dipstick proteinuria or albuminuria and cardiovascular disease, cardiovascular 
mortality and all-cause mortality. However there are few data about the relationship 
between these outcomes and total proteinuria, and no literature comparing these 
measurements as predictors of outcome. 
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1.5.7 Anaemia 
The anaemia of CKD is associated with left ventricular hypertrophy (LVH) and fibrosis, 
with one study showing the independent risk of LVH being 32% higher for every 0.5g/dL 
decrease in haemoglobin (203). Foley et al studied the impact of anaemia in a cohort of 
patients commencing dialysis therapy and found a strong association between anaemia and 
cardiac abnormalities with a 1g/dL fall in haemoglobin being associated with a 46% higher 
risk of left ventricular dilatation and a 55% higher risk of poor left ventricular ejection 
fraction, and a 14% increase in the likelihood of death after commencing RRT (204). 
 
Therefore it was hypothesised that correction of anaemia with recombinant human EPO or 
erythropoietin stimulating agents would prevent cardiovascular events. Two major studies 
of correction of anaemia in CKD were published simultaneously in 2006; the CREATE 
study compared a high versus a low target haemoglobin in patients with CKD Stages 3 and 
4, using a composite primary end point of cardiovascular events; a haemoglobin of 
approximately 13.5g/dL versus 11.5g/dL was achieved but there was no outcome 
difference between the groups (169).  The CHOIR study had a similar design of high 
versus low target haemoglobin (achieved haemoglobin 13g/dL versus 11.3g/dL) and 
demonstrated an increased event rate in the high haemoglobin group, using a different 
composite primary endpoint of death, myocardial infarction, hospitalisation for congestive 
cardiac failure or stroke (170). Notably the high haemoglobin groups required larger doses 
of EPO and had more hypertension. 
 
More recently, a study of darbepoetin (an erythropoietin stimulating agent) in patients with 
CKD not requiring dialysis, anaemia and type 2 diabetes mellitus was published. This 
study compared treatment with darbepoetin to a target haemoglobin of 13g/dL versus 
placebo (with rescue therapy for Hb<9.0g/dL) and found no improvement in the composite 
primary endpoint of death, myocardial infarction, unstable angina, heart failure and stroke, 
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but a statistically significant increase in stroke in the treatment group(171). This has cast 
further doubt on the use of agents to correct anaemia in patients with CKD not requiring 
dialysis. 
 
1.5.8 CKD associated mineral bone disorders 
CKD is associated with a number of disturbances in calcium and phosphate metabolism 
collectively known as CKD associated mineral bone disorders. These include 
hypovitaminosis D leading to hypocalcaemia, hyperphosphatemia secondary to reduced 
nephron mass, secondary hyperparathyroidism and elevated levels of the phosphaturic 
hormone fibroblast growth factor 23 (FGF-23). This disruption in normal bone mineral 
metabolism may promote vascular calcification and arterial stiffness, mediating 
cardiovascular events (205). There is also increasing evidence of “off target” effects such 
as the relationship between FGF-23 and left ventricular hypertrophy (206).  
 
There are therapeutic interventions available, including activated vitamin D 
supplementation, phosphate binders (both calcium based and non-calcium containing 
binders) and calcimimetic agents.  There is a wealth of evidence of the beneficial effects of 
these agents on biochemical markers of CKD-MBD, but very little in relation to hard 
cardiovascular endpoints. Cinacalcet has been shown to reduce cardiovascular admissions 
in addition to reducing rates of fracture and parathyroidectomy (207).  
 
1.5.9 Metabolic acidosis 
Metabolic acidosis causes increased protein catabolism, decreased protein synthesis, and 
negative nitrogen and total body protein balance. It is associated with a number of adverse 
prognostic indicators, such as hypoalbuminaemia, and is implicated in protein energy 
wasting and malnutrition which is linked to mortality in dialysis patients (208, 209). 
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However the relationship between metabolic acidosis and outcome in maintenance dialysis 
patients is complex, and takes the form of a J-shaped curve. This is thought to be an 
example of reverse epidemiology, with healthier dialysis patients maintaining intake of 
protein, the catabolism of which leads to a mild metabolic acidosis (208).  
 
The metabolic acidosis associated with CKD in non-dialysis patients may be less severe, 
and there is less evidence about its adverse effects. A recent clinical trial assessed 
nutritional parameters following bicarbonate supplementation in CKD patients, and found 
an improvement in the intervention group, but no survival endpoints have yet been 
reported (173). There are potential downsides of bicarbonate supplementation with 
increased prevalence of volume overload and hypertension and potential vascular 
calcification so further studies are needed, but there was no significant increase in blood 
pressure during the study which was reassuring (172, 173). 
 
1.5.10  Uric acid 
The relationship between uric acid and cardiovascular disease is complex and not well 
elucidated. There is increasing evidence that hyperuricaemia causes hypertension. This 
may be one explanation for the conflicting results of laboratory versus clinical studies 
assessing the independent effects of uric acid on cardiovascular outcomes. If uric acid has 
a role in the causal pathway by mediating hypertension, and the study corrects for 
hypertension in the multivariate analysis this effect may be lost (210). There is also 
evidence of a role for uric acid in development of the metabolic syndrome: lowering uric 
acid levels in animal models can prevent or reverse its features (210).  
 
Patients with clinical gout receive treatment with allopurinol to reduce serum uric acid 
levels. There is insufficient evidence at present to support treating patients with 
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asymptomatic hyperuricaemia, however there are clinical trial data emerging that may 
inform decision making in the future (211).  
 
1.6 Management of CKD 
The prevalence of CKD is high, as described above, and the majority of these patients 
will have uncomplicated CKD Stage 3.  In the UK this group is managed in the 
community by the general practice team of doctors and nurses. The identification of 
this group has been facilitated by the widespread reporting of an eGFR measurement 
along with each creatinine measurement in an adult, so increasing recognition of 
patients with early CKD (21). Guidelines have been produced that recommend specific 
strategies for the identification, management and referral of patients with CKD in 
primary care (9, 87). The Quality Outcomes Framework (QOF) of the General Medical 
Services contract in the UK has a structured payment system for primary care for a 
number of chronic illnesses. For patients with CKD the QOF rewards the following; 
the identification of those with CKD; establishing a register of such patients to 
facilitate regular monitoring; regular monitoring of kidney function, proteinuria and 
blood pressure; and the management of blood pressure to specific targets (212). The 
QOF indicators have evolved over time since its introduction in 2006 and the 
inclusions and exclusions, and financial incentives are shown in table 1-7 (213). The 
financial incentives are performance related with the lower percentage being the 
threshold at which some payment is received by the practice and the higher percentage 
is the threshold at which the full available payment will be given. The threshold for the 
upper payment for most QOF indicators in other conditions is 90%.  
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Table 1-7 - Quality Outcomes Framework Indicators for CKD in Primary Care 
 
Indicator  Year 
included 
Year  
Removed 
Points  Payment 
stages  
Records    
CKD1: The practice can produce a register 
of patients aged 18 years and over with CKD 
(US National Kidney Foundation: Stage 3 to 
5 CKD)  
2006  6  
Initial Management    
CKD2: The percentage of patients on the 
CKD register whose notes have a record of 
blood pressure in the previous 15 months  
2006  6  40-90%  
Ongoing Management    
CKD3: The percentage of patients on the 
CKD register in whom the last blood 
pressure reading, measured in the previous 
15 months, is 140/85 or less  
2006  11  40-70%  
CKD4: The percentage of patients on the 
CKD register with hypertension who are 
treated with an angiotensin converting 
enzyme inhibitor (ACE-I) or angiotensin 
receptor blocker (ARB) (unless a 
contraindication or side effects are recorded)  
2006 2008 4  40-80%  
CKD5: The percentage of patients on the 
CKD register with hypertension and 
proteinuria who are treated with an 
angiotensin converting enzyme inhibitor 
(ACE-I) or angiotensin receptor blocker 
(ARB) (unless a contraindication or side 
effect are recorded) 
2008  4 40-80% 
CKD6: The percentage of patients on the 
CKD register whose notes have a record of a 
urine albumin: creatinine ratio (or protein: 
creatinine ratio) test in the previous 15 
months 
2009  6 40-80% 
 
Specific therapeutic targets and recommendations for the management of patients with 
CKD in primary care have been extrapolated from secondary care populations as there 
is comparatively little specific evidence in this group of patients. This is unwise as the 
risk profiles of these groups are unlikely to be comparable, and specific study of 
patients with CKD in primary care is warranted.  
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1.7 Summary 
Chronic kidney disease is a major public health problem with the associated burden of 
renal replacement therapy and premature cardiovascular disease. Early identification of 
patients at risk is essential to prevent the progression of renal disease and attenuate the 
cardiovascular risk. In this chapter I have reviewed what is currently known about the 
accurate measurement of excretory renal function and proteinuria and the factors that 
influence renal and mortality risk.  
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1.8 Aims of this project 
The overall aim of this project is to explore the optimal predictors of renal outcome and 
survival for patients with chronic kidney disease. 
 
1.8.1 Principal aims: 
• To identify the optimal type of proteinuria measurement as a predictor of renal and 
patient outcomes 
• To assess the prevalence of reduced eGFR and examine the optimal measure of 
eGFR 
• To characterise patients in the community with CKD Stage 3 
• To identify predictors of renal disease progression  
• To identify predictors of cardiovascular disease 
 
1.8.2 Secondary aims: 
• To identify the optimal measurement of proteinuria in a CKD population to predict 
significant proteinuria  
• To assess secular trends in prevalence of a reduced eGFR 
• To assess the prevalence of CKD in a hypertension cohort 
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1.9 Hypotheses 
The roles of total proteinuria, albuminuria and non-albumin proteinuria as predictors of 
renal and cardiovascular outcome remain unknown. It is hypothesised that non-albumin 
proteinuria plays an important role in the progression of CKD. 
 
It is hypothesised that renal and cardiovascular risk in CKD Stage 3 (predominantly 
managed in the community), are not homogeneous and can be predicted from other clinical 
factors. 
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2 Chapter 2: Proteinuria: A retrospective cross-
sectional study of protein: creatinine ratio versus 
albumin: creatinine ratio in chronic kidney disease 
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2.1 Introduction 
Accurate identification and quantification of proteinuria are core elements in the diagnosis 
and management of CKD. The choice of TPCR or ACR to quantify proteinuria remains 
controversial, as discussed in chapter 1 (section 1.3.9).  Timed urine collections (usually 
performed over 24 hours) are still considered the gold standard for quantification of 
proteinuria but have major limitations as a result of incomplete or inaccurate collections 
(69, 70) and are no longer recommended as a first line test by national guidelines (5, 7-9, 
214).  
 
The biochemistry laboratory in Glasgow Royal Infirmary routinely analyses urine for both 
ACR and TPCR in samples received from the kidney unit. The aim of this study was to 
examine the relationship between TPCR, ACR and 24-hour urinary protein in a population 
of patients attending a secondary care kidney clinic, and compare the diagnostic 
performance of TPCR and ACR at various thresholds, in order to investigate the optimal 
test to identify significant proteinuria. 
 
Chapter 2  76 
2.2 Methods 
2.2.1 Laboratory assays 
Random spot urine samples are sent from all patients attending the renal clinics. The 
Glasgow Royal Infirmary biochemistry laboratory routinely measures ACR and TPCR, 
and has done consistently since 29
th
 November 1999. Twenty four hour urine collections 
are performed on request, and assayed for volume, protein, albumin and creatinine 
concentration. The electronic patient record (Proton, Clinical Computing UK Ltd, 
Brentford, UK) calculates an eGFR using the four-variable MDRD equation (44, 215). 
 
Prior to August 2006, urine albumin was measured on a Bayer Advia 1650 analyser using 
an immunoturbidimetric method with anti-human albumin antiserum with a mean between 
batch co-efficient of variation (CV) of 4.4% at a concentration of 0.54 g/L. The urine total 
protein assay was performed on the same analyser using the pyrogallol red colorimetric 
method, with a mean between batch CV of 8.32% at a concentration of 0.56 g/L. From 
August 2006, an Abbott Architect 2000 was used. Urinary albumin was measured using an 
immunoturbidimetric method using anti-human albumin antiserum with a mean between 
batch CV of 5.1% at a concentration of 0.111 g/L. Urinary total protein was analysed using 
a turbidimetric method with benzethonium precipitation, with a mean between batch CV of 
1.8% at a concentration of 0.58 g/L. Urine creatinine was assayed using a reaction rate 
Jaffe method with Abbott reagents. The mean between batch CV is 3.4% at a concentration 
of 5.9 mmol/L. In-house comparison was made between the Bayer Advia 1650 and the 
Abbott Architect 2000 results, and no significant differences were found, in precision and 
accuracy between the results obtained before and after the change in instrumentation for 
these analytes. Returns to the United Kingdom External Quality Assurance Scheme 
showed no change in accuracy, precision or bias in the laboratory’s results during this 
period. The laboratory is fully accredited by Clinical Pathology Accreditation (UK) Ltd. 
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2.2.2 Study Population 
Patients attending the renal clinics are entered into the electronic patient record, which also 
receives laboratory data electronically. We retrospectively searched for patients with 
TPCR and ACR measured on the same date. The most recent paired results were used, in 
order to maximise the number of samples analysed using the more recent assays. Patients 
were excluded if they were under 18 years old, on RRT, or the sample was performed 
before 29
th
 November 1999. The following data were also obtained: gender, age at time of 
urine sample, primary renal disease, use of ACEi or ARB, weight, height, blood pressure, 
serum creatinine, eGFR, and contemporaneous 24-hour urine protein (if available). 
 
2.2.3 Ethical Permission 
For the last decade, written consent has been obtained, which states that the data will be 
used for audit and research, in addition to routine clinical care. For this audit, data were 
downloaded and patient identifiers removed prior to further analysis. As this was an audit 
formal ethical approval was not required.  
 
2.2.4 Statistical analysis 
Data were analysed using SPSS 16.0 for Windows (SPSS Inc, Chicago, IL, USA). All data 
were assessed for normality, and appropriate summary statistics are presented. Total 
proteinuria, albuminuria, TPCR and ACR data were log-transformed given the large range 
of values. Correlation was assessed using Spearman’s rho. Bland and Altman’s method 
was used to compare different measures of proteinuria. Receiver-operator characteristic 
(ROC) curves were constructed to allow comparison of assays for key threshold values of 
proteinuria, and comparison of the area under the curve (AUC) was made using Hanley 
and McNeil’s method (216) (MedCalc 10.4 Software, Mariakerke, Belgium). Significance 
testing was performed using the Mann-Whitney-U test. All tests are two-tailed. 
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2.3 Results 
We identified 7830 patients with simultaneous ACR and TPCR results. We excluded 489 
with samples analysed prior to 29
th
 November 1999, as these were performed 
intermittently from 1991, and laboratory assay details were unavailable. We excluded 88 
children <18 years old and 411 patients receiving renal replacement therapy, as shown in 
Figure 2-1.  
 
Figure 2-1 - Flowchart of exclusions 
 
Background data for the remaining 6842 patients are presented (Table 2-1). The data 
regarding race are incomplete, but race is relatively homogeneous in our population: 95.5-
98.9% white, 0.74-3.71% Indo-Asian, 0.09-0.23% black and 0.3-0.59% other minority 
ethnic groups (217). In this cohort, the prevalence of Indo-Asian and black patients is 
0.52% and 0.15% respectively, similar to local population prevalence. 3484 samples were 
analysed prior to August 2006 (date assays changed) and 3358 afterwards.  
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Table 2-1 - Background data. Normally distributed data are presented as mean ± standard deviation. 
Other data are presented as median (interquartile range). The primary renal diagnosis (PRD) is 
categorised according to the European Dialysis and Transplantation Association 
 
Variable 6842 patients Percentage with available data 
Age (years) 61±17 
(range 18-97 ) 
100% 
Gender 51% male 
 
100% 
    Primary Renal Disease 
      Primary glomerulonephritis 
      Interstitial disease 
      Multisystem diseases 
      Diabetic nephropathy 
      Other 
      CKD; aetiology unknown 
 
 
16.1% 
21.4% 
16.7% 
10.3% 
0.2% 
35.3% 
65.3% 
On ACEi and/or ARB 30.7% 
 
100% 
Weight (kg) 77.2±19 
 
83% 
Height (cm) 
 
165 ± 11 87.7% 
Body Surface Area (m
2
) 1.84 ± 0.24 
 
36.1% 
Systolic blood pressure (mmHg) 140±24 
 
80.0% 
Diastolic blood pressure (mmHg) 76±13 
 
79.9% 
Serum creatinine (µmol/L) 134  
(IQR 105-175) 
 
 
91.4% 
eGFR (mL/min/1.73m
2
) 41.3  
(IQR 31.4-58.5) 
 
 
91.4% 
24-hour urine protein (g/day) 0.34  
(IQR 0.15-0.92) 
 
 
24.8% 
TPCR (mg/mmol) 35  
(IQR 17-106) 
 
 
100% 
ACR (mg/mmol) 10  
(IQR 2-48 ) 
 
 
100% 
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The lower limit of detection for ACR changed during the study; at various times ACR was 
reported as <3 or <10 mg/mmol. These values have been analysed as 3 or 10 mg/mmol 
respectively. To ensure this did not affect our findings, the data were re-analysed excluding 
any pair of results that included ACR <10 mg/mmol. This second population was 4462 
patients, and the results were essentially unchanged. 
 
2.3.1 Relationship between ACR and TPCR 
The relationship between ACR and TPCR is non-linear (Figures 2-2 and 2-3). As expected, 
ACR is almost always less than TPCR. The relationship between ACR and non-albumin 
protein: creatinine ratio (NAPCR) (derived by subtracting ACR from TPCR) is presented 
in Figure 2-4. For NAPCR of 10-100 mg/mmol there is a poor correlation with ACR, 
demonstrated by the wide scatter, making it difficult to predict TPCR from ACR.  
 
Chapter 2  81 
Figure 2-2 - Relationship between urine TPCR and ACR. Note both axes are on a logarithmic scale. 
The diagonal line is the line of identity.  
 
 
Figure 2-3 - Bland Altman plot of urine TPCR and ACR. The difference is expressed as a percentage. 
Note the abcissa is a logarithmic scale. 
 
Chapter 2  82 
Figure 2-4 - Relationship between urine NAPCR and ACR. The diagonal is the line of identity. Note 
both axes are a logarithmic scale. Spearman’s rho is 0.674 (p<0.001). 
 
 
 
 
 
2.3.2 TPCR, ACR and 24-hour urine protein 
Contemporaneous ACR, TPCR and 24-hour urine protein results were available in 1696 
patients. TPCR is more highly correlated with 24-hour urine protein though ACR also 
performs well (Figures 2-5 and 2-6). In the range 300-1000 mg/day where clinical 
decisions are made, there is considerably greater scatter with ACR. 
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Figure 2-5 - Relationship between TPCR and 24-hour urine protein. A simple linear regression line is 
shown. Spearman’s rho is 0.91 (p<0.001) for TPCR. Both axes are logarithmic. 
 
Figure 2-6 - Relationship between ACR and 24-hour urine protein. A simple linear regression line is 
shown. Spearman’s rho is 0.84 (p<0.005) for ACR. Both axes are logarithmic. 
 
Chapter 2  84 
We assessed the ability of ACR and TPCR to predict a 24-hour urine protein of >1g/day 
and >500mg/day. For >1g/day of total proteinuria, both ROC curves have highly 
significant AUCs (TPCR: 0.968, p<0.001; ACR: 0.947, p<0.001), however the 
performance of TPCR is significantly superior (p=0.004). Similar AUCs were found for 
0.5g/day (TPCR: 0.967, p<0.001; ACR: 0.951, p<0.001), and again TPCR is significantly 
superior (p=0.001). Guidelines suggest cut-points of TPCR 100 mg/mmol (7, 8) and ACR 
70 mg/mmol (8) to predict proteinuria of >1g/day, and TPCR of 50mg/mmol and ACR 
30mg/mmol to predict >0.5g/day. The performance of these cut-points is presented in table 
2-2 and figures 2-7 and 2-8. TPCR is substantially more sensitive than ACR, but less 
specific. To achieve comparable sensitivity to predict 1g/day using ACR, the cut-point fell 
to 17.5 mg/mmol, with specificity falling below TPCR at 69.8%, and for 0.5g/day an ACR 
of 14.5 mg/mmol must be used, with specificity falling below TPCR at 80.5%. 
 
 
 
Table 2-2 - ROC curve analysis of TPCR and ACR to predict proteinuria of 1g/day and 0.5g/day 
(p<0.005 for all). Using US units of 1g/g (equivalent to a TPCR of 113.6 mg/mmol): sensitivity 91.2%, 
specificity 90.5%. 
 Sn (%) Sp (%) PPV(%) NPV(%) LR+ LR- 
To predict 1 g/day proteinuria 
TPCR   
(100 mg/mmol) 
93.9 88.5 71.0 98.0 8.2 0.07 
ACR  
(70 mg/mmol) 
79.0 95.2 83.5 93.8 16.4 0.06 
To predict 0.5 g/day proteinuria 
TPCR   
(50 mg/mmol) 
91.3 87.5 82.5 94.0 7.3 0.1 
ACR  
(30 mg/mmol) 
78.2 94.6 90.0 87.5 14.5 0.23 
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Figure 2-7 – ROC curves for ACR and TPCR to predict a 24-hour urine protein of >1g/ day 
 
 
Figure 2-8 - ROC curves for ACR and TPCR to predict a 24-hour urine protein of >0.5g/ day. 
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The urinary total protein assay changed in August 2006. However only 293 24-hour urine 
collections (17%) were performed after this date, so direct comparison between pre- and 
post- assay change was not feasible 
 
2.3.3 Completeness of 24-hour urine collections 
The ROC curves rely on 24-hour urine collections as a “gold standard” measure of 
proteinuria. To ensure that incomplete urine collections were not influencing the results, 
we re-analysed the data after excluding low volume collections (<500mls/day) or 
creatinine excretion rates below the laboratory reference range (9-17 mmol/day for males; 
7.5-12.5 mmol/day for females). These exclusions had no major impact on the findings.  
 
2.3.4 Sub-group analysis 
The performance of ACR and TPCR was assessed according to gender, age group, eGFR, 
and use of ACEi/ARB (table 2-3). ACR and TPCR yield higher sensitivity and lower 
specificity in females than males. To achieve 95% sensitivity of TPCR predicting 
proteinuria >1g/day, a cut-point of 78 mg/mmol is required in males (specificity 86%), and 
118 mg/mmol in females (specificity 89%). 
 
With advancing age, TPCR (and to a lesser extent ACR) becomes a more sensitive and less 
specific test; to achieve 95% sensitivity for prediction of total proteinuria >1 g/day requires 
a TPCR of 74 mg/mmol in those <49 years old (specificity 91%) compared to 132 
mg/mmol in those >74 years old (specificity 83%).  
 
When age and sex are combined the differences are amplified. To achieve 95% sensitivity 
for prediction of 1g/day of proteinuria in a man <49 years old, a TPCR of 65 mg/mmol is 
required (specificity 93%), compared to 179 mg/mmol in a woman >74 years.  
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With decreasing eGFR, there is a trend towards falling specificity of TPCR and ACR to 
predict 1 g/day of proteinuria. This is not clearly associated with any change in sensitivity, 
nor is it replicated for proteinuria of 0.5 g/day. 
 
2.3.5 Use of ACEi/ARB 
The sensitivity of TPCR to predict 1.0 g/day of proteinuria is considerably lower in 
patients receiving ACEi /ARB, falling towards the same level as ACR (Table 2-3). No fall 
is seen with ACR (Table 2-3). TPCR is very similar between the groups, but is composed 
of different proportions of non-albumin proteinuria (NAP) and albumin (Table 2-4). The 
NAP level and the proportion of NAP to total proteinuria are significantly lower in the 
ACEi/ARB treated group (Table 2-4). The Bland-Altman plots (Figure 2-9 and 2-10) show 
the difference between TPCR and ACR is less in the ACEi/ARB treated group, especially 
at higher levels of mean TPCR/ACR. 
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Table 2-3 - ROC curve analysis of performance of TPCR and ACR to predict proteinuria of 1g/ day 
according to patient sub-groups  
TPCR n Sn (%) Sp (%) LR+ LR- 
All 1696 93.9 88.5 8.2 0.07 
Male 877 91.0 91.2 10.3 0.10 
Female 819 98.7 86.4 7.3 0.02 
Age ≤49 550 86.8 95.4 18.9 0.14 
Age 49 – 64 430 94.2 92.0 11.8 0.06 
Age 64 – 74 381 96.5 83.6 5.9 0.04 
Age >74 335 97.7 76.1 4.1 0.03 
eGFR<15 167 95.2 45.2 1.7 0.11 
eGFR 15-29 198 94.6 76.1 4.0 0.07 
eGFR 30-59 430 93.2 92.7 12.8 0.07 
eGFR ≥ 60 498 81.8 98.7 62.9 0.18 
ACEi/ARB 233 82.4 96.7 25.0 0.18 
No ACEi/ARB 1463 95.7 87.4 7.6 0.05 
ACR      
All 1696 79.0 95.2 16.4 0.06 
Male 877 77.5 97 25.8 0.23 
Female 819 81.6 93.7 13.0 0.20 
Age ≤49 550 75.8 98.0 37.9 0.25 
Age 49 – 64 430 79.8 98.5 31.9 0.21 
Age 64 – 74 381 81.4 92.5 10.9 0.20 
Age >74 335 78.4 89.9 7.8 0.24 
eGFR<15 167 77.1 81.0 4.1 0.28 
eGFR 15-29 198 76.8 89.4 7.2 0.26 
eGFR 30-59 430 83.0 97.1 28.6 0.18 
eGFR ≥ 60 498 70.5 99.0 70.5 0.30 
ACEi/ARB 233 82.4 96.7 25.0 0.18 
No ACEi/ARB 1463 78.6 95.1 16.0 0.23 
 
Table 2-4 - Baseline demographics of patients receiving angiotensin-converting enzyme inhibitors 
(ACEi) or angiotensin receptor blockers (ARB) versus those who are not. 
 ACEi/ARB 
group 
Non-ACEi/ARB 
group 
Z value 
(Mann-Whitney 
U test) 
p 
value 
SBP (mmHg) 
 
142 ± 23 139 ±25 -5.419 <0.001 
DBP (mmHg) 
 
76 ± 13 76 ± 13 -0.039 0.995 
sCr (mmol) 
 
142 (108 – 190) 139 (95 – 235) -0.239 0.811 
eGFR   
(ml/min/1.73m
2
) 
38.6 (27.5 – 57.3) 41 (22.1 – 66.6) -0.912 0.362 
TPCR (mg/mmol) 
 
35.7 (18.5 – 85.4) 34.5 (15.6 – 118.9) -0.285 0.775 
ACR (mg/mmol) 
 
13 (3 – 51) 9 (2 – 47) -4.893 <0.001 
NAPCR (mg/mmol) 
 
20.2 (11.7 – 37.5) 22.3 (10.8 – 57.2) -4.045 <0.001 
NAPCR:TPCR (%) 
 
56.2 (35.9 – 83.8) 71.1 (45.5 – 88.5) -11.197 <0.001 
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Figure 2-9 - Bland-Altman plots of patients receiving angiotensin-converting enzyme inhibitors or 
angiotensin receptor blockers. Note the ordinate is expressed as a percentage. 
 
 
Figure 2-10 - Bland-Altman plots of patients not receiving angiotensin-converting enzyme inhibitors or 
angiotensin receptor blockers. Note the ordinate is expressed as a percentage. 
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2.4 Discussion 
2.4.1 Findings of this study 
These data show that TPCR is a highly sensitive and reasonably specific test for detection 
of significant proteinuria (total proteinuria >0.5 g/day or >1 g/day) in unselected patients 
attending a hospital kidney clinic. ACR performs significantly less well by ROC curve 
analysis, and is substantially less sensitive, though this is not entirely surprising given that 
TPCR is more closely related to 24-hour total proteinuria than ACR. To improve the 
sensitivity of ACR requires very low thresholds with poorer specificity than TPCR. In 
addition to the use of TPCR and ACR for monitoring glomerular disease and 
prognostication, they are often used as screening tests, so sensitivity is of prime importance 
to avoid under-diagnosis of those at risk of progressive renal decline. Total proteinuria 
cannot be reliably predicted from albuminuria, because of the variable proportion of non-
albumin proteins, particularly in the clinically relevant range of 0.3-1 g/day.  
 
A single cut-point for TPCR or ACR will lead to varying sensitivity and specificity 
according to patient characteristics, and our results quantify the impact. Sensitivity is 
higher with increasing age, and in females, whilst specificity is lower. This is likely due to 
lower muscle mass in these groups (33), resulting in lower creatinine excretion, and thus 
higher TPCR (or ACR) for a given concentration of urinary protein. The findings with 
reducing eGFR were less consistent, but one would expect low muscle mass in CKD stages 
4-5 (218). To predict 1g/day of proteinuria with 95% sensitivity a TPCR threshold of 
65mg/mmol in a young man and 179mg/mmol in an elderly woman is needed. This almost 
three-fold difference means that use of universal cut-points may lead to under-recognition 
and under-treatment of young men with proteinuria. While gender and age specific cut-
points could mitigate this (86), this would undermine the simplicity of TPCR. Clinicians 
should be aware of these limitations and judiciously use 24-hour collections where doubt 
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remains. Similar differences in sensitivity and specificity are likely for different racial 
groups, but we were unable to assess these in our predominantly white population. 
 
2.4.2 Non-albumin proteinuria 
The proportion of NAP is significantly lower in those receiving ACEi/ARB. This suggests 
that ACEi/ARB selectively reduce NAP, or that these drugs are being utilised in patients 
with pre-existing low levels of NAP (for instance if ACR alone is being used to identify 
patients with significant proteinuria). We cannot define the correct option in our cross-
sectional study. However, enalapril reduces the large non-selective pore size in the 
glomerular basement membrane, reducing urinary loss of proteins with a large molecular 
radius, in diabetic and non-diabetic kidney disease (219, 220). This supports the former 
theory, that ACEi/ARBs selectively reduce NAP. The magnitude of decline in proteinuria 
with ACEi therapy predicts the degree of renoprotection (221). In our population, ACR 
failed to identify 22% of patients with significant proteinuria (i.e. those with TPCR >100 
mg/mmol, but ACR <70 mg/mmol). These patients with a high proportion of NAP, may 
gain the largest reduction in proteinuria and thus the largest benefit from ACEi/ARB.  
 
2.4.3 Limitations 
This study has several limitations. It was retrospective, and therefore undetected bias may 
be present. There may have been drift in assays during the study period, but this will affect 
all assays and we have no reason to expect systematic bias. The relationships demonstrated 
may only apply to assays used in our study. A variety of assays are used to measure total 
protein, and even albumin immunoassays have considerable inter-assay and inter-
laboratory variation (70). The vast majority of 24-hour urine collections were performed 
before August 2006, therefore the former assays are over-represented in these results. 
However the pyrogallol red method remains well established and widely used globally. 
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Formal comparison of this technique (used pre-2006) with the turbidimetric method (post-
2006) have shown them to yield comparable results. For the analyses involving 24-hour 
urine samples, the majority of the ACR and TPCR results were calculated from the 24-
hour samples. Our main aim was to compare the relative performance of ACR and TPCR, 
rather than to demonstrate the utility of spot samples, which has been shown before. This 
approach will artificially improve the correlation of TPCR and 24h urine protein, but as the 
assay CV is only 1.8-8.3%, will have a relatively small impact, compared to the dramatic 
variations seen with ACR (e.g. Fig 2-2). Furthermore, as this is a random effect it will not 
systematically bias the calculations of sensitivity and specificity. Lastly ACR was reported 
by the laboratory with no decimal place, whereas TPCR was reported to one decimal place. 
This resulted in loss of granularity at low levels of ACR as seen in figure 2-2, 2-4 and 2-6. 
The strengths of this study are the large numbers, and the representative nature of the 
unselected adult population attending a general nephrology clinic. It may not be 
representative of primary care-based CKD populations. 
 
2.4.4 Guideline recommendations on the monitoring of proteinuria 
Guideline recommendations on measuring proteinuria differ. KDOQI recommends 
monitoring proteinuria using ACR, unless ACR exceeds 500-1000 mg/g (56-113 
mg/mmol), when TPCR is acceptable (5). In England and Wales, the National Institute for 
Health and Clinical Excellence recommends that urine should be analysed for ACR (8). 
The Scottish Intercollegiate Guideline Network (7) recommends TPCR in patients with 
non-diabetic kidney disease, reserving ACR for diabetic patients. Our findings suggest 
cautious use of ACR in all patients, as a significant number with proteinuria >1 g/day will 
not be identified. Given our data, and the additional cost of ACR the converse strategy to 
KDOQI’s recommendations would be more logical: only testing ACR if TPCR is not 
elevated (for instance <50mg/mmol). 
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2.4.5 Conclusion 
In conclusion, TPCR is a more sensitive screening test than ACR to predict clinically 
significant proteinuria (as defined using 24-hour total proteinuria). The diagnostic 
performances of both tests vary substantially with age, gender and to some extent eGFR, 
an effect that is probably related to muscle mass. These results suggest that in order to 
correctly identify significant proteinuria, clinicians should interpret the result with the 
patient’s muscle mass in mind, rather than dutifully observing a single cut-point. Total 
proteinuria cannot be adequately predicted from ACR (as a result of variable levels of non-
albumin proteins which are measured using both TPCR and 24-hour total proteinuria), and 
our results suggest caution is appropriate before utilising ACR in patients with non-
diabetic CKD. 
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3 Chapter 3: Comparison of urinary albumin and 
urinary total protein as predictors of patient outcomes 
in chronic kidney disease 
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3.1 Introduction 
There is extensive evidence that dipstick proteinuria and albuminuria are associated with 
adverse patient outcomes including end stage renal disease, cardiovascular disease and 
mortality, as discussed in the introduction (section 1.4.1 and 1.5.6 respectively). In chapter 
2 TPCR was found to be superior to ACR as a predictor of significant proteinuria. 
However the impact of total proteinuria on mortality has been less well characterised, and 
ACR and TPCR have not been compared as predictors of renal and patient outcomes. 
 
Using the results of a similar cohort of patients from Glasgow Royal Infirmary to those 
described in chapter 2, who routinely had their urine samples analysed for both albumin 
and total protein, we assessed whether TPCR was superior to ACR as a predictor of renal 
outcomes and mortality in CKD patients. 
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3.2 Methods 
3.2.1 Laboratory assays 
The assays used are described in detail in Chapter 2. The biochemistry laboratory has 
measured ACR and TPCR in all samples from the renal service since 29
th
 November 1999.  
 
3.2.2 Study population 
The details of the overall cohort are described in Chapter 2. However the method used to 
extract this cohort from the database was slightly, but importantly, different from chapter 
2. As before we retrospectively searched our database for all patients who had total protein, 
albumin and creatinine measured on a urine sample on the same date. For the majority of 
patients, this was measured in a spot sample, however for the minority who performed a 
24-hour urine collection, the ACR and TPCR were calculated from an aliquot of the 24-
hour urine collection. The earliest available paired results for ACR and TPCR were used 
(unlike the previous analysis in which the most recent paired results for each patient were 
used). The search strategy was changed from that used in chapter 2 in order to maximise 
the period of follow-up available for analysis. The majority of the exclusion criteria were 
the same (samples pre-1999 were excluded, patients under 18 years old and those receiving 
renal replacement therapy). In addition, those who had less than one year’s follow-up 
available were excluded (on the basis that there was insufficient exposure to the variable of 
interest). The same baseline data were also obtained: gender, age at time of urine sample, 
primary renal disease, use of ACEi/ARB, weight, height, blood pressure, serum creatinine, 
eGFR, and contemporaneous 24-hour urine protein (if available). For this longitudinal 
analysis, subsequent measurements of serum creatinine and eGFR were obtained. The 
following outcomes were also recorded: date of death and date of commencing RRT, for 
established renal failure (RRT for acute kidney injury was excluded from this analysis).  
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3.2.3 Ethical Permission 
For the last decade, written consent for use of the electronic patient record has been 
obtained from patients, and the consent specifically states that the data will be used for the 
purposes of audit and research, in addition to routine clinical care. Data were downloaded 
with patient identifiers removed prior to further analysis. The National Health Service 
National Research Ethics Service confirmed that ethical approval was not required for this 
analysis (correspondence available). 
 
3.2.4 Statistical Analyses 
Data were analysed using SPSS 16.0 for Windows (SPSS Inc, www.spss.com). All data 
were assessed for normality, and appropriate summary statistics are presented. A 
hierarchical Cox regression survival analysis was constructed for the outcomes of all cause 
mortality, commencement of renal replacement therapy and doubling of serum creatinine. 
The follow-up was censored at the time that the first outcome was reached for each patient. 
The co-variates of age, gender, blood pressure and serum creatinine were entered in the 
first block, and either ACR, TPCR, 24-hour urine albumin or 24-hour urine total protein 
entered in the second block. TPCR, ACR, 24-hour urine total protein and 24-hour urine 
albumin were converted to a log scale and ACR and TPCR were standardised in order to 
facilitate a fair comparison. TPCR results tend to be higher and this would bias the 
comparison without prior standardisation. The hazard ratios presented for ACR and TPCR 
are for one standard deviation difference (on the log scale). Cases were excluded from the 
Cox regression survival analysis if any of the variables were missing (mostly blood 
pressure). The analyses were repeated with missing variables imputed using regression, to 
ensure there was no influence on the model.  
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The linearity of each continous predictor was tested by calculating Martingale residuals for 
the Cox regression model without the predictor and then plotting these against the 
predictor using lowess smoothing. The proportional hazards assumption was tested by 
creating time dependent covariates for each predictor and including them in the model if 
the interaction was significant. The albumin assay changed in August 2006, therefore a 
sensitivity analysis was performed for the samples prior to the assay change. 
 
Proteinuria was also analysed as a categorical variable, divided into 3 clinically relevant 
groups. Although there is no reliable conversion factor for ACR and TPCR, we defined 
ACR and TPCR groups with approximately equivalent values using recommendations 
from recent guidelines, shown in Table 3-1 (8). A sensitivity analysis was performed, by 
splitting the reference group and using the lower half of normoalbuminuria as the new 
reference group. 
 
Table 3-1 - Equivalent values for 24-hour urine protein excretion, total protein: creatinine ratio and 
albumin: creatinine ratio 
 
Proteinuria  
(g/day) 
TPCR  
(mg/mmol) 
ACR  
(mg/mmol) 
<0.15 <15 <3 
0.15 - 0.5 15 – 50 3 - 30 
0.5 – 0.999 50 – 99 30 – 69 
1.0 – 3.499 100 – 349 70 - 244 
≥3.5 ≥350 ≥245 
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3.3 Results 
 
We identified 8457 patients with ACR and TPCR measured on the same day between 24
th
 
November 1999 and 28
th
 May 2008. A flow diagram of the population and exclusions is 
shown in Figure 3-1. Background data for the remaining 5586 patients are presented in 
Table 3-2. The baseline demographic data of the 1808 patients who performed a 24-hour 
urine collection were not significantly different to the overall group. The data regarding 
race are incomplete, however the prevalence of black patients in this cohort is recorded at 
0.15%, which is similar to the overall prevalence in the local population of 0.09 – 0.23%. 
Additionally the prevalence of Indo-Asian patients is 0.52%, again similar to the local 
population (217). 4402 of the baseline samples were analysed prior to August 2006 (the 
date our laboratory assays changed) and 1184 afterwards. Patients were followed up for a 
median of 3.5 years (interquartile range IQR 2.1 – 6.0 years).  
 
 
Figure 3-1 - Flow diagram of the cohort, exclusions and sub-groups 
Initial Population
(n=8457)
Follow-up < 1yr (n=2313)
Age <18 yrs (n=142)
Cox regression population with urine 
albumin, total protein, urine creatinine 
from spot sample, blood pressure and 
serum creatinine measured (n=3264)
Study population with urine albumin, 
total protein, and creatinine measured 
on spot sample (n=3778)
On RRT (n=416)
Missing data 
(n=132)
Exclusions
Study population with urine albumin, 
total protein, and creatinine measured 
on 24-hr sample (n=1808)
Missing data 
(n=514)
Cox regression population with urine 
albumin, total protein, urine creatinine 
from 24-hour collection, blood pressure 
and serum creatinine measured (n=1676)
n=5586
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Table 3-2 - Baseline descriptive data for 5586 patients with chronic kidney disease attending an 
outpatient clinic. Primary renal disease is classified according to the European Dialysis and 
Transplantation Association primary renal disease codes. Data are presented as mean (standard 
deviation) or where specified, median (interquartile range [IQR]). 
Variable Total cohort 
(n=5586) 
Available 
data 
24-hour 
collection 
group 
(n=1808) 
Available 
data 
Age (years) 59 (16) 
(range 18-97 ) 
100% 56 (16) 100 
Gender 50% male 
 
100% 48% 100 
Primary Renal Disease 
    Primary 
glomerulonephritis 
    Interstitial disease 
    Multisystem diseases 
    Diabetic nephropathy 
    Other 
    CKD; aetiology unknown 
 
 
17.0% 
22.5% 
16.3% 
11.1% 
0.1% 
33.1% 
68.0%  
26.3% 
26.6% 
20.5% 
11.1% 
0.1% 
15.4% 
54.2% 
On ACEi and/or ARB 22.1% 
 
100% 20.8% 100% 
Weight (kg) 77.8 (18.3) 
 
90.5% 78.1 (18.4) 94.8% 
Height (m) 
 
1.65 (0.1) 91.2% 1.65 (0.1) 95.9% 
Body Surface Area (m
2
) 1.9 (0.2) 
 
84.7% 1.9 (0.2) 90.2% 
Systolic blood pressure 
(mmHg) 
144 (27) 
 
91.2% 143 (28) 95.2% 
Diastolic blood pressure 
(mmHg) 
78 (14) 
 
91.2% 79 (13) 95.2% 
Serum creatinine (µmol/L) 140 
(IQR 100-190) 
 
97.0% 130  
(IQR 100 – 
180) 
97.8% 
eGFR (mL/min/1.73m
2
) 41.9 
(IQR 28.2-62.8) 
 
97.0% 46.7 
(IQR 30.8 
– 64.1) 
97.8% 
24-hour urine protein 
(mg/day) 
- - 340  
(IQR 150-
920) 
 
32.4% 
24-hour urine albumin 
(mg/day) 
- - 117.6  
(IQR 16.9-
743.6) 
 
32.4% 
TPCR (mg/mmol) 35  
(IQR 17-106) 
 
 
100% 
32 
(IQR 14 – 
132) 
100% 
ACR (mg/mmol) 10  
(IQR 2-48 ) 
 
 
100% 
12 
(IQR 2 – 
77) 
100% 
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3.3.1 Relationship between ACR and TPCR in this cohort 
 
A scatterplot of ACR versus TPCR is shown in Figure 3-2. 
 
Figure 3-2 - Relationship between baseline urine total protein:creatinine ratio (TPCR) and albumin: 
creatinine ratio (ACR) in 5586 patients with chronic kidney disease. 
 
 
 
 
 Note that both axes are on a logarithmic scale. The line is a regression line using lowess 
smoothing. The values shown in this graph include TPCR and ACR derived from timed 
urine collections and spot urines.  
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3.3.2 Outcomes 
There were 844 deaths during follow-up (15% of the population). Median time to death 
from the time of the baseline urine sample was 3.0 years (IQR 1.8 – 4.7 years). RRT was 
commenced in 468 patients (8%). The median time to commencement of RRT was 1.7 
years (IQR 0.6 – 3.4 years). The serum creatinine of 999 patients (18%) doubled during the 
follow-up period. The median time to doubling of serum creatinine was 2.2 years (1.1 – 3.8 
years).  
 
3.3.3 Comparison of patient outcomes for urine albumin and urine total 
protein: ACR and TPCR derived from spot samples versus ACR and 
TPCR derived from timed urine collections 
Cox regression analyses for death, RRT and doubling serum creatinine are shown in table 
3-3. There are no significant differences between the results for ACR and TPCR derived 
from a spot urine sample when compared with the ACR and TPCR derived from a timed 
urine collection. Adjusted hazard ratios for TPCR were higher than for ACR for all-cause 
mortality and doubling of serum creatinine, and higher for ACR for commencement of 
RRT but the 95% confidence intervals overlapped. Sensitivity analysis of the pre-August 
2006 results (when the assay changed), yielded similar results, and are therefore not 
shown. Repeat analyses with imputed data (using regression) for any missing variables did 
not alter the results significantly. Given the similar predictive ability for ratios derived 
from a random urine sample and timed urine sample, these data were combined and ROC 
curve analyses were performed to compare ACR and TPCR as predictors of mortality, 
renal replacement therapy and doubling of serum creatinine; these are shown in figure 3-3, 
3-4 and 3-5 respectively, and are not significantly different.: the performance of ACR and 
TPCR was almost identical with similar areas under the curve. 
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Table 3-3 - Association of baseline urinary albumin: creatinine ratio (ACR) and total protein: creatinine ratio (TPCR) with subsequent patient outcomes in 5586 patients 
with chronic kidney disease 
 
 Death RRT Doubled sCr 
 HR aHR HR aHR HR aHR 
Spot ACR 
(n=3264) 
 
1.42  
(1.30 – 1.55) 
1.49  
(1.34- 1.66) 
3.28  
(2.87 – 3.76) 
2.41  
(2.06 – 2.83) 
1.90  
(1.75 – 2.06) 
1.95  
(1.78 – 2.08) 
Spot TPCR 
(n=3264) 
 
1.53  
(1.40 – 1.66) 
1.54  
(1.38 - 1.71) 
2.99 
(2.69 – 3.33) 
2.03  
(1.77 – 2.32) 
1.92 
(1.78 – 2.07) 
2.01  
(1.82 – 2.21) 
24-hr ACR 
(n=1676) 
 
1.48  
(1.31 – 1.66) 
1.26  
(1.11- 1.42) 
2.82  
(2.37 – 3.35) 
2.24  
(1.83 – 2.74) 
2.06  
(1.85 – 2.30) 
1.91  
(1.69 – 2.16) 
24-hr TPCR 
(n=1676) 
 
1.51  
(1.37 – 1.66) 
1.28  
(1.14 - 1.44) 
2.68 
(2.32 – 3.09) 
1.88  
(1.59 – 2.23) 
2.03 
(1.85 – 2.23) 
2.12  
(1.84 – 2.45) 
Spot and 24-hr ACR 
(combined) 
(n=4940) 
1.41  
(1.31 – 1.51) 
1.38  
(1.28- 1.50) 
3.00  
(2.69 – 3.36) 
2.33  
(2.06 - 3.01) 
1.94  
(1.81 – 2.08) 
1.92  
(1.78 – 2.08) 
Spot and 24-hr 
TPCR (combined) 
(n=4940) 
1.53  
(1.43 – 1.63) 
1.41  
(1.31 - 1.53) 
2.84 
(2.59 – 3.11) 
1.96  
(1.76 - 2.18) 
1.96 
(1.84 – 2.08) 
2.03  
(1.87 – 2.19) 
Hazard ratios and adjusted hazard ratios (with 95% confidence intervals) from multivariate Cox regression analyses are presented, per one standard 
deviation difference in the variable. Age, gender, blood pressure and serum creatinine are co-variates in all models. Serum creatinine is a time-dependent 
co-variate for renal replacement therapy. Age is a time-dependent co-variate for doubling serum creatinine.  
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Figure 3-3 - Receiver operator characteristic curve for baseline urinary albumin: creatinine ratio 
(ACR) and total protein: creatinine ratio (TPCR) to predict all-cause mortality. Area under curve for 
ACR 0.647 (95% CI 0.628 – 0.667; p<0.001), and for TPCR 0.664 (95% CI 0.644 – 0.683; p<0.001) 
 
Figure 3-4 - Receiver operator characteristic curve for baseline urinary albumin: creatinine ratio 
(ACR) and total protein: creatinine ratio (TPCR) to predict commencement of renal replacement 
therapy. Area under curve for ACR 0.815 (95% CI 0.796 – 0.833; p<0.001), and for TPCR 0.826 (95% 
CI 0.807 – 0.844; p<0.001) 
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Figure 3-5 - Receiver operator characteristic curve for baseline urinary albumin: creatinine ratio 
(ACR) and total protein: creatinine ratio (TPCR) to predict doubling of serum creatinine. Area under 
curve for ACR 0.715 (95% CI 0.697 – 0.732; p<0.001), and for TPCR was 0.713 (95% CI 0.695 – 0.731; 
p<0.001) 
 
 
The receiver operator characteristic curves include the ACR and TPCR derived from timed 
urine collections and spot urines. 
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TPCR and ACR were also analysed as categorical variables (using the combined results 
from random urines and timed urine collections), comparing microalbuminuria (ACR 3 – 
30mg/mmol) and macroalbuminuria (ACR>30mg/mmol) (and TPCR equivalent) to 
normoalbuminuria (ACR<3mg/mmol - the reference group) as described in the methods. 
The performance of ACR and TPCR was similar for all three patient outcomes with 
overlapping 95% confidence intervals. This applied across all the categories examined, 
including microalbuminuria. The Cox regression analyses are shown in table 3-4. A 
sensitivity analysis was performed using 4 categories, with the lower half of 
normoalbuminuria as the reference group (ACR<1.5mg/mmol and TPCR<7.5mg/mmol). 
Again there was no significant difference in performance between TPCR and ACR in these 
categories (table 3-5). 
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Table 3-4 – Association of different categories of baseline urinary TPCR and ACR with subsequent 
patient outcomes (3 groups) 
TPCR 
 
n Death RRT Doubled sCr 
<15 mg/mmol 
 
1470 1.00  
(Reference) 
1.00 
(Reference) 
1.00 
(Reference) 
15.1 – 50 mg/mmol 1687 1.40 
(1.11 – 1.77) 
2.15 
(1.25 – 3.71) 
1.49 
(1.18 – 1.89) 
>50 mg/mmol 1783 2.24 
(1.78 – 2.80) 
6.46 
(3.90 – 10.69) 
3.73 
(3.01 – 4.63) 
ACR 
 
<3.0 mg/mmol 
 
1754 1.00  
(Reference) 
1.00 
(Reference) 
1.00 
(Reference) 
3.1 – 30 mg/mmol 1562 1.47 
(1.19 – 1.83) 
2.51 
(1.48 – 4.25) 
1.70 
(1.36 – 2.13) 
>30 mg/mmol 1624 2.12 
(1.72 – 2.63) 
7.19 
(4.36 – 11.88) 
3.87 
(3.14 – 4.77) 
 
Adjusted hazard ratios (with 95% confidence intervals) from multivariate Cox regression 
analyses are presented. Age, gender, blood pressure and serum creatinine are co-variates in 
all models.  
 
Table 3-5 - Association of different categories of baseline urinary TPCR and ACR with subsequent 
patient outcomes, using the lower half of the laboratory normal range as the reference group 
TPCR 
 
n Death RRT Doubled sCr 
<7.5 mg/mmol 
 
534 1.00 
(Reference) 
1.00 
(Reference) 
1.00 
(Reference) 
7.5 – 15 mg/mmol 929 1.50 
(0.99 – 2.29) 
2.21 
(0.72 – 6.78) 
1.49 
(1.00 – 2.23) 
15.1 – 50 mg/mmol 1687 1.84 
(1.26 – 2.70) 
3.71 
(1.34 – 10.26) 
1.93 
(1.34 – 2.78) 
>50 mg/mmol 1779 2.94 
(2.02 – 4.28) 
11.14 
(4.11 – 30.19) 
4.83 
(3.40 – 6.85) 
ACR 
 
<1.5mg/mmol 
 
1007 1.00 
(Reference) 
1.00 
(Reference) 
1.00 
(Reference) 
1.5 – 3.0mg/mmol 740 1.30 
(0.92 – 1.84) 
1.80 
(0.67 – 4.88) 
1.22 
(0.85 – 1.74) 
3.1 – 30mg/mmol 1562 1.69 
(1.27 – 2.25) 
3.53 
(1.54 – 8.13) 
1.87 
(1.40 – 2.51) 
>30mg/mmol 1620 2.44 
(1.83 – 3.25) 
10.12 
(4.47 – 22.93) 
4.26 
(3.22 – 5.64) 
Adjusted hazard ratios (with 95% confidence intervals) from multivariate Cox regression 
analyses are presented. Age, gender, blood pressure and serum creatinine are co-variates in 
all models. 
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3.3.4 Comparison of patient outcomes for urine albumin and urine total 
protein: 24-hour urinary albumin versus 24-hour urinary total 
protein 
Table 3-6 shows the Cox regression analyses for 24-hour urine albumin compared to 24-
hour urine protein. Adjusted hazard ratios for total proteinuria were not significantly 
different to albuminuria for death and RRT, but was significantly higher for doubling of 
serum creatinine. There was no significant difference between the ROC curve analysis for 
the three outcome measures (figures 3-6 to 3-8). 
 
 
Table 3-6 - Association of baseline measures of proteinuria with subsequent patient outcomes in a 
subset of 1808 chronic kidney disease patients with 24-hour urine samples 
  n Death RRT Doubled sCr 
24-hour urine 
albumin 
1676 1.17 
(1.02 – 1.34) 
2.22 
(1.77 – 2.78) 
1.91 
(1.66 – 2.20) 
24-hour urine 
total protein 
1676 1.27  
(1.05 – 1.54) 
2.46  
(1.86 – 3.25) 
3.04 
(2.40 – 3.85) 
24-hour ACR 
  
1676 1.26 
(1.11 – 1.42) 
2.24 
(1.83 – 2.74) 
1.91 
(1.69 – 2.16) 
24-hour TPCR 1676 1.28  
(1.14 – 1.44) 
1.88  
(1.59 – 2.23) 
2.12  
(1.84 – 2.45) 
Adjusted hazard ratios (with 95% confidence intervals) from multivariate Cox regression 
analyses are presented. The adjusted hazard ratios for ACR and TPCR are per one standard 
deviation difference in the variable.  Age, gender, blood pressure and serum creatinine are 
co-variates in all models. Serum creatinine is a time-dependent co-variate for renal 
replacement therapy (RRT). Age is a time-dependent co-variate for doubling serum 
creatinine (sCr) 
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Figure 3-6 - Receiver operator characteristic curves for baseline 24-hour albuminuria and 24-hour 
total proteinuria to predict all-cause mortality. Area under the curve for 24-hour albuminuria was 
0.608 (95%CI 0.576 – 0.640; p<0.001) and for 24-hour total proteinuria was 0.623 (95%CI 0.591 – 
0.655; p<0.001). 
 
 
Figure 3-7 - Receiver operator characteristic curves for baseline 24-hour albuminuria and 24-hour 
total proteinuria to predict commencement of renal replacement therapy. Area under the curve for 24-
hour albuminuria was 0.760 (0.727 – 0.792; p<0.001) and for 24-hour total proteinuria was 0.772 
(0.740 – 0.804; p<0.001). 
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Figure 3-8 - Receiver operator characteristic curves for baseline 24-hour albuminuria and 24-hour 
total proteinuria to predict doubling of serum creatinine. The area under the curve for 24-hour 
albuminuria was 0.652 (95% CI 0.619 – 0.686; p<0.001) and for 24-hour total proteinuria was 0.655 
(95% CI 0.622 – 0.688; p<0.001). 
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3.3.5 Comparison of patient outcomes for urine albumin and urine total 
protein: Urine Ratios Indexed to Creatinine versus 24-hour Urine 
Samples 
We also compared the performance of ACR and TPCR (derived from the 24-hour samples) 
to the 24-hour urinary albumin and total protein results in this subset of 1808 patients. The 
results of the Cox regression analyses are in table 3-6. The adjusted hazard ratios for ACR 
and TPCR derived from a timed urine collection were similar to the aHR of the 24-hour 
albumin or total protein excretion. The ROC curves comparing ACR and TPCR (derived 
from a timed urine collection) to 24-hour urine albumin and total protein showed no 
significant difference for either analyte, so have not been shown.  
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3.4 Discussion 
3.4.1 Findings of the study 
Our study shows that total urinary protein and albumin are equally powerful predictors of 
all-cause mortality and renal outcomes in patients with CKD attending a hospital kidney 
clinic. We demonstrated this when assessing albuminuria or total proteinuria with ACR 
and TPCR respectively, derived from a random urine sample. This was confirmed it in a 
large subgroup with both ACR and TPCR derived from a timed urine collection, and 24-
hour urine albumin and total protein excretion results. The analysis held true whether 
TPCR and ACR were assessed as continuous or categorical variables. Unexpectedly, 
TPCR also performed well at low levels (TPCR of 15-50 mg/mmol, equivalent to 0.15-0.5 
g/day of total proteinuria), where albuminuria has traditionally been seen as the superior 
marker of risk and this finding persisted when the lower half of the normal range was used 
as the reference group in the survival analysis. 
 
3.4.2 Albuminuria, total proteinuria and outcomes 
The literature comparing albuminuria and total proteinuria is discussed in the introduction 
(chapter 1). It is limited and none of the studies assessed patient outcomes in a CKD 
population. A post-hoc analysis of the RENAAL study compared 24-hour total proteinuria, 
albuminuria and ACR to predict a composite renal end-point in patients with Type 2 
diabetes mellitus and found that ACR was superior. TPCR was not measured and mortality 
data were not included (90). There are 2 studies in the renal transplant population; the first 
compared albuminuria and non-albumin proteinuria as a predictor of graft loss (222) and 
found both were independent predictors and provided different information. The second 
study compared 24-hour albuminuria and proteinuria and found albuminuria to be the 
superior predictor of graft loss (223). The study presented here demonstrates that both are 
equally predictive of patient outcomes in chronic kidney disease, at all levels of 
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proteinuria, in a mixed population of patients attending a general nephrology clinic, who 
predominantly have non-diabetic kidney disease.  
 
There is extensive literature linking albuminuria with cardiovascular disease and mortality 
in both renal and general populations (88, 199-201). The CKD prognosis consortium 
performed large meta-analyses of renal and general population studies of albuminuria and 
dipstick proteinuria (which also predominantly measures albuminuria (70)) and showed a 
strong association with cardiovascular and all-cause mortality (20, 108).  Several other 
studies (193, 195-197) have also demonstrated a link between dipstick proteinuria and 
mortality. The relationship between total proteinuria and all cause mortality, demonstrated 
in this chapter, is less well documented. One Finnish study demonstrated an association 
between spot urine concentration of total protein (i.e. not adjusted for creatinine 
concentration) and subsequent cardiovascular and all-cause mortality (202). 
 
3.4.3 The role of non-albumin proteinuria 
In urine, total protein is comprised predominantly of albumin, but also of physiological 
proteins (such as uromodulin) and other non-albumin proteins of various molecular 
weights. The proportions of these proteins vary widely in pathological states, and non-
albumin proteins are less well-defined compared to albumin. There is less inter- and intra-
laboratory variation in albumin assays than total protein assays (70), and efforts are 
underway to standardise the albumin assay across laboratories (66), however ACR is 2 – 
10 times more costly than TPCR. Given the technical challenges, it is perhaps surprising 
that TPCR performed as well as ACR in predicting risk in our study. High molecular 
weight proteinuria has been shown to correlate more strongly with rate of progression of 
renal disease than intermediate molecular weight, low molecular weight or even total 
proteinuria. This is thought to be as a result of increased tubular toxicity, though an 
alternative hypothesis would be that this finding is simply a consequence of loss of 
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glomerular size selectivity (224). The fractional excretion of Immunoglobulin G (a high 
molecular weight protein) has also been shown to be a strong predictor of adverse 
outcomes in patients with CKD, as a result of loss of glomerular size selectivity (225). 
Other specific non-albumin proteins (low molecular weight proteins) can be measured in 
the urine such as retinol binding protein, and alpha-1 and beta-2-microglobulin, the former 
being more stable at a range of pH (226). Alpha-1-microglobulin has been shown to be a 
marker of tubular pathology and can rise to significant levels in disease states (227). 
However these are specialist immunoassays that are not widely available for screening 
purposes, so are not currently a viable alternative to the total protein assay for the detection 
of non-albumin proteinuria. 
 
There is substantial variation in the amount of non-albumin proteinuria between 
individuals at clinically significant levels of albuminuria. We have shown in chapter 2 that 
using only ACR to identify patients with significant proteinuria (>1g/ day) would lead to 
over one fifth of patients (22%) being undetected, who would otherwise have been 
identified using TPCR as a result of high proportions of non-albumin proteinuria. The non-
albumin proteinuria may carry some additional prognostic significance which is not 
captured by measuring albumin alone. 
 
3.4.4 24-hour urine collections – the gold standard? 
A subsidiary finding in our study was that TPCR and ACR were as powerful as 24-hour 
urine protein and albumin respectively at predicting patient outcomes. Traditionally, 24-
hour urine samples have been seen as the “gold standard” method to measure total 
proteinuria or albuminuria, but spot urine samples are more convenient for patients, 
clinicians and laboratories. The ability of spot urine TPCR and ACR to predict 24-hour 
total proteinuria and albuminuria respectively has been investigated, and shown to be 
accurate, reliable and reproducible (79). One study has examined the comparative 
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performance of ACR and 24-hour albuminuria and proteinuria to predict renal outcomes, 
and found ACR to be superior (90). The study did not include TPCR measurements. There 
are two possible explanations for the excellent performance of TPCR and ACR: 24-hour 
urine collections are difficult for patients to collect accurately, and so spot urines may 
represent a more accurate estimate of true 24-hour urine protein excretion; second, the 
urinary creatinine may also be contributing to the predictive power of the test. Creatinine 
excretion correlates with muscle mass (218), so malnutrition or muscle wasting would lead 
to a higher TPCR or ACR for any given level of urinary protein excretion and may 
contribute to the risk. Urine creatinine excretion has been shown to be an independent 
predictor of cardiovascular and all-cause mortality in the general population (228). In a 
retrospective study we cannot differentiate between these explanations. Furthermore, this 
analysis should be replicated in a study comparing random spot urine samples to 24-hour 
urine samples. 
 
3.4.5 Limitations 
Our study has several limitations, some of which were outlined in relation to the study in 
chapter 2 given that they were derived from a similar cohort. It was retrospective in nature. 
Our lack of complete data on race and primary renal disease has hampered our ability to 
produce subgroup analyses. Twenty-four hour urine collections were available in 
approximately one third of patients. There may have been drift in the assays over such a 
prolonged period, but this will affect all assays and we have no reason to expect a 
systematic bias. These issues affect our assessment of ACR and TPCR equally. The 
relationships demonstrated may only apply to the assays used in our study. However, 
strengths of this study include the large number of patients, and the representative nature of 
the population; an unselected adult population attending a general nephrology clinic. It is 
not representative of primary care-based CKD populations, which have a lower prevalence 
of proteinuria, and a different age distribution.  
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3.4.6 Conclusion 
Total proteinuria and albuminuria perform equally as predictors of renal outcomes and 
mortality in patients with CKD. ACR and TPCR were as effective as 24-hour urine 
samples at predicting outcomes, and are more convenient for patients, clinicians and 
laboratories.  TPCR also performed well in the “microalbuminuria” range. Both ACR and 
TPCR are useful tools to stratify risk in CKD. 
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4 Chapter 4: Stratifying Risk in Chronic Kidney 
Disease: an Observational Study of UK Guidelines for 
Measuring Total Proteinuria and Albuminuria 
 
Chapter 4  118 
 118 
4.1 Introduction 
We have shown in Chapter 2 that TPCR is a superior predictor of 24-hour total proteinuria. 
In Chapter 3 we have demonstrated that proteinuria is associated with adverse outcomes, 
and spot urines predict this equally well as 24-hour urine collections. TPCR and ACR 
perform equally as predictors of renal and patient outcome in a mixed population attending 
a nephrology clinic. However the optimal method to measure proteinuria remains 
uncertain. Intervention studies in diabetic kidney disease have traditionally measured 
albuminuria (146, 229, 230) while those in non-diabetic kidney disease have used total 
proteinuria (124). Two key thresholds have been identified in the management of 
proteinuria; 1g/day of total proteinuria, above which aggressive blood pressure control has 
been demonstrated to reduce progression to end-stage kidney disease (156) and 0.5g/day of 
total proteinuria above which the use of angiotensin converting enzyme inhibitors have 
been found to be specifically beneficial, over and above their blood pressure lowering 
effects, to retard progression of kidney disease (221).  
 
The NICE guidelines in England and Wales and NKF-KDOQI guidelines in the United 
States recommend quantifying proteinuria using ACR in all patients with CKD, whereas 
the Scottish guidelines (SIGN) recommend TPCR in non-diabetic patients (5, 7, 8). The 
relationship between total protein and albumin in the urine is non-linear, but this study uses 
the same equivalent levels as outlined in chapter 3: >1 g/day proteinuria (equivalent to 
ACR >70 mg/mmol or TPCR >100 mg/mmol) and >0.5 g/day proteinuria (equivalent to 
ACR >30 mg/mmol or TPCR >50 mg/mmol) (8). 
 
The aim of this study was to compare the outcomes of patients identified as having 
significant proteinuria, according to the thresholds described above by ACR and TPCR (as 
recommended by the differing national guidelines). 
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4.2 Methods 
4.2.1 Laboratory Assays 
The laboratory assays used in this analysis are described in section 2.2.1. 
4.2.2 Study population  
The population studied in this analysis are the same patient cohort described in section 
3.2.2.  
 
4.2.3 Ethical Permission 
This is described in section 3.2.3. 
 
4.2.4 Statistical Analysis 
Data were analysed using SPSS 16.0 for Windows (SPSS Inc, Chicago, IL, USA, 
www.spss.com). All data were assessed for normality, and appropriate summary statistics 
are presented. As before, TPCR and ACR data were log-transformed given the skewed 
distribution of values. Comparison of the groups was performed using 2 sample T test, 
analysis of variance, Mann-Whitney U test and the Kruskall Wallis test as appropriate.  
 
Proteinuria was defined as significant using the two thresholds of 0.5 g/day or 1g/day 
(0.5g/day being equivalent to ACR ≥30 mg/mmol, and TPCR ≥50 mg/mmol and 1g/day 
being equivalent to ACR ≥70 mg/mmol and TPCR ≥100 mg/mmol). Mild proteinuria was 
defined as below the thresholds described, and above the laboratory reference range (ACR 
3-29mg/mmol and TPCR 15-49mg/mmol (i.e. microalbuminuria) for the 0.5g/day 
threshold and ACR 3-69mg/mmol and TPCR 15-99mg/mmol for the 1g/day threshold).  
No proteinuria was defined as less than the laboratory reference range (ACR <3mg/mmol 
and TPCR <15mg/mmol). Kaplan-Meier survival plots were constructed. A similar 
statistical technique was employed as for chapter 3, namely hazard ratios were calculated 
for the main outcome measures (all-cause mortality, commencement of RRT and doubling 
of serum creatinine) using a hierarchical Cox regression survival analysis with age, gender, 
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blood pressure and serum creatinine as co-variates entered in the first block, and either 
ACR or TPCR entered in the second block. The hazard ratios presented are for a 10-fold 
increase in the variable measured (due to the use of a logarithmic scale). Cases were 
excluded from the Cox regression survival analysis if any of the variables were missing 
(mostly blood pressure). The analyses were repeated with missing variables imputed using 
regression, to ensure there was no influence on the model. The linearity of each continous 
predictor was tested by calculating martingale residuals for the Cox regression model 
without the predictor and then plotting these against the predictor using lowess smoothing. 
The proportional hazards assumption was tested by creating time dependent co-variates for 
each predictor and including them in the model if the interaction was significant.  
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4.3 Results 
4.3.1 Demographics  
The cohort and overall demographic data is identical to that described in Chapter 3. A flow 
diagram of the population, exclusions and grouping according to proteinuria for this 
analysis is shown in Figure 4-1. Baseline data for the 5586 patients are presented in Table 
4-1, divided according to level of proteinuria. The primary renal disease was available in 
68% of the total cohort as described in chapter 3 (defined according to the European Renal 
Association- European Dialysis and Transplantation Association codes). Of the patients in 
Group 4 (discordant group) 72% had a PRD recorded. The proportion of primary 
glomerulonephritis was lower (7.2% v 17% in the overall cohort), interstitial disease was 
considerably higher (39.5% v 22.5% in the overall cohort) multisystem disease and 
diabetic nephropathy lower (4.8% v 16.3% and 8.4% v 11.1% respectively) and CKD 
cause unknown was higher (40.1% v 33.1%). Of note 26 patients in the total cohort had a 
PRD of myelomatosis and of these 5 patients were in Group 4 (discordant group). Patients 
were followed up for a median of 3.5 years (IQR 2.1 – 6.0 years).  
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Figure 4-1 – Flowchart of population and exclusions, showing the cohort divided into groups according 
to degree of proteinuria 
Initial Population
(n=8,457)
Follow-up < 1yr (n=2,313)
Age <18 yrs (n=142)
Cox Regression Population
(n=4,824)
Study Population
(n=5,586)
On RRT (n=416)
Missing data (n=762)
1g/day Proteinuria Groups
Thresholds: ACR 70mg/mmol
TPCR 100mg/mmol
Gp 1 ACR and TPCR in reference range (n=1001)
Gp 2 Low ACR, low TPCR (n= 3069) 
Gp 3 High ACR, high TPCR (n= 1250)
Gp 4 Low ACR, high TPCR (n= 231)
Gp 5 High ACR, low TPCR (n= 35)
0.5g/day Proteinuria Groups
Thresholds: ACR 30mg/mmol
TPCR 50mg/mmol
Gp 1 ACR and TPCR in reference range (n=1001)
Gp 2 Low ACR, low TPCR (n= 2357 ) 
Gp 3 High ACR, high TPCR (n= 1785)
Gp 4 Low ACR, high TPCR n= 368)
Gp 5 High ACR, low TPCR (n= 75)
Missing data (n=762)
Cox Regression Population
(n=4,824)
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Table 4-1 - Demographics for the population, divided according to the described groups (as per the 
thresholds for 1g/day) 
 Group 1 
No 
proteinuria 
 
(ACR/ 
TPCR 
within 
reference 
range) 
Group 2 
Mild 
proteinuria 
 
(low ACR,  
low TPCR) 
Group 3 
Significant 
proteinuria 
 
(High ACR,  
high TPCR) 
Group 4 
Discordant 
 
 
(Low ACR,  
high TPCR) 
Group 5 
Discordant 
 
 
(High ACR,  
low TPCR) 
P value 
Number 1001 3069 1250 231 35 - 
Age 
(years) 
53.2 
(± 17) 
60.6 
(±16.4) 
58.3 
(±15.5) 
64.4 
(±14.3) 
51.7 
(±16.1) 
p<0.001 
Sex 
 
49% male 48% male 46% male 46% male 63% male p=0.001 
sCr 
(µmol/l) 
107 
(90 – 138) 
155 
(100 – 180) 
170 
(120 – 257) 
250 
(174 – 380) 
130 
(100 – 200) 
p<0.001 
MDRD 
(ml/min/ 
1.73m
2
) 
59.8 
(42.4 – 73.3) 
41.8 
(29.4 – 61.8) 
33.3 
(20.7 – 51.9) 
20.8 
(12.4 – 32.0) 
46.8 
(28.4 – 68.4) 
p<0.001 
SBP 
(mmHg) 
134 (±23) 143 (±26) 154 (±29) 145 (±28) 147 (±25) p<0.001 
DBP 
(mmHg) 
76 (±12) 77 (±14) 81 (±14) 77 (±14) 86 (±15) p<0.001 
ACR 
(mg/mmol) 
1 (1 – 2) 4.6 (3 – 18) 188 (120-351) 44 (21 – 57) 79 (75 – 92) p<0.001 
TPCR 
(mg/mmol) 
8.4 
(5.7 – 11.1) 
26.3 
(18.2 – 44.4) 
275.0 
(181.8 – 
500.0) 
142.9 
(117.7 – 
200.0) 
92.4 
(87.0 – 97.0) 
p<0.001 
NAPCR 
(mg/mmol) 
7.4 
(4.3 – 9.9) 
17.8 
(11.0 – 26.6) 
81.3 
(45.3 – 153.1) 
108.1 
75.0 – 169.1) 
10.9 
(-2 – 19.8) 
p<0.001 
ACEi/ARB use 
(%) 
5.2 22.6 24.3 12.1 28.6 p<0.001 
Demographics expressed as mean (± standard deviation) or median (interquartile 
range).Significance testing performed using analysis of variance and Kruskall Wallis test 
as appropriate. 
 
 
4.3.2 Patient Outcomes 
The patient outcomes of the cohort are described in chapter 3.  
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4.3.3 Cohort Subgroups: Clinically important thresholds of proteinuria: 
1g/day 
The cohort was divided into three groups with concordant ACR and TPCR results:  
• Group 1: no proteinuria (within laboratory reference range of ACR<3mg/mmol and 
TPCR<15mg/mmol) (n=1001) 
• Group 2: mild proteinuria (<1g/day equivalent) (n=3069)  
• Group 3: significant proteinuria (>1g/day equivalent) (n=1250).  
Two groups with discordant results by ACR and TPCR were also defined:  
• Group 4: significant proteinuria by TPCR but not ACR (urine total protein over 
1g/day equivalent, but low urine albumin) (n=231)  
• Group 5: significant proteinuria by ACR but not TPCR (urine total protein <1g/day 
equivalent, but high urine albumin) (n=35).  
 
The numbers in Group 5 are very small and have therefore been excluded from the results 
presented here. However when Group 5 was included, the results did not alter significantly. 
The demographics of Groups 3 and 4 were compared using a 2 sample T test and Mann-
Whitney U test, as appropriate. Group 4 (discordant proteinuria) was significantly older 
with lower eGFRs (p<0.001), while Group 3 (significant proteinuria) had significantly 
higher blood pressures and proteinuria, measured by ACR and TPCR (p<0.001). There was 
no difference in gender between the groups (p=0.936). Kaplan-Meier survival plots were 
constructed for all-cause mortality (Figure 4-2), renal survival (Figure 4-3) and doubling of 
serum creatinine (Figure 4-4). Patient survival of Group 4 (discordant proteinuria) was 
significantly worse than Groups 2 (mild proteinuria) and 3 (significant proteinuria) (log 
rank test, p<0.001). Renal survival for Group 4 (discordant proteinuria) is similar to Group 
3 (significant proteinuria), and significantly worse than Group 2 (mild proteinuria) 
(p<0.001).  
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Figure 4-2 - Kaplan Meier survival plot for all-cause mortality for the groups according to 
ACR and TPCR 
 
Figure 4-3 - Kaplan Meier survival plot for renal survival for the groups according to 
ACR and TPCR 
 
 
Reference Group ACR<3mg/mmol and TPCR<15mg/mmol.  
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Figure 4-4 - Kaplan Meier survival plot for doubling of serum creatinine for the groups 
according to ACR and TPCR 
 
 
Reference Group ACR<3mg/mmol and TPCR<15mg/mmol.  
 
 
 
A multi-variate analysis was performed using Cox regression analyses for all-cause 
mortality, RRT and doubling serum creatinine, with age, sex, kidney function and blood 
pressure as co-variates (Table 4-2). The risk of all cause mortality for Group 4 (discordant 
proteinuria) compared to Group 3 (significant proteinuria) is attenuated by the multi-
variate analysis, but the risk does not fall to that of Group 2 (mild proteinuria). The same 
pattern is seen for commencement of RRT and doubling of serum creatinine. Repeat 
analyses with imputed data (using regression) for any missing variables did not alter the 
results significantly, and are therefore not shown. 
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Table 4-2 – Association of baseline urinary ACR and TPCR with subsequent patient outcomes in 4824 
patients with CKD, (using thresholds approximately equivalent to 1g/day of proteinuria) 
 
 Group 1 
No proteinuria 
 
 
(ACR and TPCR 
within reference 
range)  
Group 2 
Mild proteinuria 
 
 
(low ACR,  
low TPCR) 
Group 3 
Significant 
proteinuria 
 
(High ACR,  
high TPCR) 
Group 4 
Discordant 
proteinuria 
 
(Low ACR,  
high TPCR) 
Death 1.00 1.57 
(1.18 – 2.09) 
2.59 
(1.91 – 3.50) 
1.91 
(1.29 – 2.83) 
RRT 1.00 2.06 
(1.07 – 3.97) 
7.91 
(4.15– 15.08) 
4.40 
(2.17 – 8.91) 
Doubled sCr 1.00 1.70 
(1.28 – 2.25) 
5.07 
(3.82 – 6.74) 
3.56 
(2.43 – 5.20) 
Adjusted hazard ratios (with 95% confidence intervals) from multivariate Cox regression 
analyses are presented, for a ten-fold increase in the variable measured. Age, gender, 
blood pressure and serum creatinine are co-variates in all models. Serum creatinine is a 
time-dependent co-variate for RRT. Age is a time-dependent co-variate for doubling sCr. 
 
4.3.4 Cohort subgroups: Clinically important thresholds of proteinuria: 
0.5g/day 
The same process was applied to the 0.5g/day threshold, using the appropriate cut-points 
(see Figure 4-1 for a description of Groups 1 - 5). There were 2228 patients with total 
proteinuria >0.5g/day using either measure (i.e. the patients with ACR≥30mg/mmol or 
TPCR≥50mg/mmol) and 2153 patients with TPCR≥50mg/mmol, of which 368 had an 
ACR <30mg/mmol, i.e. the discordant group (16.5% and 17.1% of the total respectively 
depending on the denominator). Kaplan Meier plots were also constructed for the three 
outcome measures using a proteinuria threshold of 0.5g/day (see figure 4-5, 4-6 and 4-7 
respectively). For the outcome of all-cause mortality, Group 4 (discordant proteinuria) had 
a significantly worse outcome than Groups 2 (mild proteinuria) and 3 (significant 
proteinuria); (p<0.001), and for renal survival and doubling of serum creatinine, Group 4 
had a significantly worse outcome than Group 2 (mild proteinuria), but performed better 
than Group 3 (significant proteinuria) (p<0.001). 
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Figure 4-5 - Kaplan Meier survival plot for all-cause mortality for the groups according to ACR and 
TPCR to predict 0.5g/day of total proteinuria 
 
Figure 4-6 - Kaplan Meier survival plot for renal survival for the groups according to ACR and TPCR 
to predict 0.5g/day of total proteinuria 
 
Reference Group ACR<3mg/mmol and TPCR<15mg/mmol. 
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Figure 4-7 - Kaplan Meier survival plot for doubling of serum creatinine for the groups according to 
ACR and TPCR to predict 0.5g/day of total proteinuria 
 
 
Reference Group ACR<3mg/mmol and TPCR<15mg/mmol. 
 
A multi-variate analysis was also performed for the 0.5g/day proteinuria threshold using 
Cox regression analyses for all-cause mortality, RRT and doubling serum creatinine, with 
age, sex, kidney function and blood pressure as co-variates, (Table 4-3). The same pattern 
of results is seen as for the 1g/day threshold. Repeat analyses with imputed data (using 
regression) for any missing variables did not alter the results significantly. 
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Table 4-3 – Association of baseline urinary ACR and TPCR with subsequent patient outcomes in 4824 
patients with CKD (using thresholds approximately equivalent to 0.5g/day of proteinuria) 
 
 Group 1 
No proteinuria 
 
 
(ACR and TPCR 
within reference 
range)  
Group 2 
Mild proteinuria 
 
 
(low ACR,  
low TPCR) 
Group 3 
Significant 
proteinuria 
 
(High ACR,  
high TPCR) 
Group 4 
Discordant 
proteinuria 
 
(Low ACR,  
high TPCR) 
Death 1.00 1.49 
(1.11 – 1.99) 
2.48 
(1.86 – 3.32) 
2.34 
(1.63 – 3.35) 
RRT 1.00 2.28 
(1.08 – 4.77) 
8.46 
(4.14 – 17.26) 
2.90 
(1.31 – 6.43) 
Doubled 
sCr 
1.00 1.47 
(1.11 – 1.95) 
4.11 
(3.14 – 5.38) 
2.35 
(1.62 – 3.40) 
 
Adjusted hazard ratios (with 95% confidence intervals) from multivariate Cox regression 
analyses are presented, for a ten-fold increase in the variable measured. Age, gender, 
blood pressure and serum creatinine are co-variates in all models. Serum creatinine is a 
time-dependent co-variate for RRT. Age is a time-dependent co-variate for doubling sCr.  
Chapter 4  131 
 131 
4.4 Discussion 
4.4.1 Findings of the study 
In this cohort of patients attending a hospital kidney clinic, ACR failed to identify 231 
patients with significant proteinuria who were identified with TPCR. This represents 15% 
of patients with significant proteinuria (defined as TPCR and/or ACR >1g/day equivalent 
of urine protein, n=1516) or 16% of patients who would have been identified by TPCR 
alone (231/ 1481). The same pattern was seen when using the 0.5g/ day total proteinuria 
threshold with the unidentified proportion using ACR alone being 16.5% and 17% 
respectively. This subgroup of patients (with significant proteinuria by TPCR but not 
ACR) had a higher rate of interstitial disease and lower rate of glomerular disease than the 
overall cohort. This supports TPCR detecting non-albumin proteins (“tubular proteinuria”), 
undetected by measuring ACR alone. This group has a high risk of renal events and death, 
with comparable renal survival and poorer patient survival than those with significant 
proteinuria by both TPCR and ACR. This increased risk for the subgroup of patients with 
significant proteinuria by TPCR but not ACR remains when the lower threshold of 0.5 
g/day of proteinuria was used. 
 
With multivariate analysis, some of the excess risk is abolished, with the risk of all-cause 
mortality, commencement of RRT and doubling of serum creatinine falling below that of 
the significant proteinuria group (Group 3), but remaining higher than the low proteinuria 
group, (Group 2). This can be explained, in part, by the differences in the demographics of 
the groups, with Group 4 being significantly older and with a lower eGFR. However, 
Group 4 (discordant proteinuria) still represents a high risk group that would be identified 
using an appropriate total proteinuria threshold, but not using an equivalent albuminuria 
threshold. 
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4.4.2 Guideline recommendations on the measurement of proteinuria 
 
NICE currently recommends that ACR should be used to screen all patients with CKD 
annually, with thresholds for action of 30 and 70 mg/mmol (8). NKF-KDOQI similarly 
recommends the use of ACR, although allows the use of TPCR when ACR is >56 
mg/mmol equivalent (5). However, SIGN recommends using TPCR for CKD patients 
without diabetic nephropathy using action thresholds of 50 and 100 mg/mol (7). Our data 
illustrate the potential impact of these differing recommendations on an unselected adult 
population attending a general nephrology clinic. Simply reducing the albuminuria 
threshold to improve sensitivity is ineffective, as it leads to unacceptably low specificity as 
shown in chapter 2. Microalbuminuria (around 30-300mg of urine albumin per day) has an 
established role in detecting early diabetic nephropathy (88), and has been shown to predict 
cardiovascular mortality in the general population (20). However we have shown in 
chapter 3 that total proteinuria is also predictive at equivalent levels in a mixed population 
(albeit predominantly non-diabetic patients) with CKD. The arguments put forward to 
justify the recommendations of the NICE guidelines are firstly of simplicity; the same test 
should be used for diabetic and non-diabetic CKD to aid implementation and interpretation 
across medical disciplines (diabetologists, other physicians and primary care). Secondly, 
there is less inter- and intra-laboratory variation in albumin assays than total protein assays 
and efforts are underway to standardise the albumin assay across laboratories (70).  
However ACR is 2 – 10 times more costly than TPCR, and also has methodological 
shortcomings such as fragmentation and the variable measurement of non-immunoreactive 
albumin in the urine. Also the evidence is lacking regarding the role of albuminuria in the 
progression of non-diabetic CKD. Therefore it is incumbent upon the proponents of ACR 
to justify its use and associated extra costs, rather than vice versa. Only TPCR takes 
account of the non-albumin protein component of urine that consists of a less well-defined 
group of proteins compared to albumin. Furthermore, there is substantial variation in the 
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amount of non-albumin proteinuria between individuals at clinically significant levels of 
albuminuria, as we have shown in chapter 2. 
 
4.4.3 Limitations 
Our study has several limitations. It was retrospective, and the number of patients in Group 
4 was relatively small. There may have been drift in the assays over such a prolonged 
period, but this will affect all assays and we have no reason to expect a systematic bias. As 
before, the relationships demonstrated may only apply to the assays used in our study, 
which is of particular importance in an analysis of this nature as it may limit its 
generalisability. However strengths of this study include the large numbers of patients, and 
the representative nature of the population, namely an unselected adult population 
attending a general nephrology clinic. Although our study population is based on a 
secondary care cohort of patients there are clear lessons from this study for both primary 
and secondary care practitioners who adhere to a referral pattern based solely on level of 
ACR.  
 
Prospective studies are required to clarify the roles of total proteinuria and albuminuria as 
predictors of patient outcomes. Interventional studies in CKD should also assess the impact 
on both ACR and TPCR. Further research should examine the importance of specific non-
albumin proteins in the urine both for prognostication, and to shed light on underlying 
pathophysiology. 
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4.4.4 Conclusion 
In conclusion, screening with ACR alone will fail to identify 16% of patients with 
significant levels of proteinuria who would be identified by TPCR. This subgroup is at 
higher risk of death and renal outcomes than those with low proteinuria (low ACR, low 
TPCR) and merit identification. The current approach to measuring proteinuria 
recommended by guidelines should be reconsidered. The non-albumin component of 
proteinuria may have pathophysiological significance, and both should be taken into 
account. 
135 
5 The Impact of Muscle Mass on the Assessment of 
Proteinuria in Chronic Kidney Disease 
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5.1 Introduction 
In chapter 2 we showed that TPCR and ACR correlate well with 24-hour urine protein or 
albumin, but their predictive ability markedly varies with age and gender. In chapter 3 and 
4 we showed that TPCR and ACR both identify patients at high risk of progressive renal 
disease and death.  
 
Urine total protein:creatinine ratio and albumin:creatinine ratio  are derived values: urine 
protein or albumin concentration is divided by urine creatinine concentration. As creatinine 
is generated at a relatively constant rate in individuals, it can act as a correction for urine 
flow rate. The observed differences in performance of the tests between subgroups (e.g. 
age, gender) is thought to relate to differing creatinine excretion as a consequence of 
muscle mass. For any given level of protein excretion per litre, the TPCR or ACR will be 
correspondingly higher in patients with lower muscle mass. There are three possible 
consequences of this:  
1. muscle mass may confound the ability of TPCR or ACR to predict 24-hr urine protein 
excretion and subsequent outcomes;  
2. muscle mass may add to the prognostic ability of the test either by acting as a surrogate 
of general health or by correcting for body size;  
3. muscle mass may have a neutral effect, as a consequence of a combination of these 
factors, or neither. 
 
To investigate this, we assessed the impact of adjusting TPCR or ACR for creatinine 
excretion in a large cohort of patients with chronic kidney disease. We examined the 
ability of the adjusted spot samples to quantify proteinuria accurately (by predicting 1 
g/day of total urine protein). We then examined prediction of outcomes relevant to 
patients, including renal survival and patient survival.  
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5.2 Methods 
5.2.1 Laboratory assays 
The laboratory assays used in this analysis, are described in section 2.2.1. 
5.2.2 Study Population 
The population studied in this analysis are the same patient cohort described in section 
3.2.2.  
 
5.2.3 Ethical Permission 
This is described in section 3.2.3. 
 
5.2.4 Statistical Analyses 
Data were analysed using SPSS 18.0 for Windows (IBM Inc, http://www-
01.ibm.com/software/analytics/spss/) and MedCalc version 12.0 (MedCalc Software, 
www.medcalc.org). All data were assessed for normality, and appropriate summary 
statistics are presented.  
 
In order to adjust the ACR and TPCR for creatinine excretion, a number of derived or 
predicted values were calculated as follows: 
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Estimated creatinine excretion: 
Creatinine excretion was measured directly from a 24-hour urine collection (urine 
creatinine concentration per litre multiplied by volume) in those patients who performed 
one. 
 
Estimated creatinine excretion (ECE) was calculated for all patients, using 5 prediction 
equations, as follows:  
      1. Ix (equation D) (41): 
• 879.89+12.51 x weight (kg) – 6.19 x age + (34.51 if black) – (379.42 if female) 
 
2. Cockcroft and Gault formula (32): 
• 24-hr creatinine excretion (g) = (140-age) x weight (kg) x 0.0002 [x 0.85 if female] 
 
3. Goldwasser formula(39): 
• [23.6-(age/8.3)(+1.9 if black)] x weight (kg) 
 
4. Walser formula (38): 
• Male: (28.2-0.172 x age) x weight (kg)   
• Female: (21.9-0.115 x age) x weight (kg) 
 
5. Rule (Mayo Quadratic) Formula (40): 
• {exp[7.26-0.26(if female) – (0.011 x (age – 55) if age>55)]} xBSA/1.73 
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Secondly, in addition to calculating ECE using actual body weight (ABW), ideal and lean 
body weight were also used in the equations. The rationale for this was that not all of the 
formulae are explicit regarding the most appropriate measure of body weight to use, and 
there are a number of issues related to body mass, as outlined in the introduction (chapter 
1). Ideal body weight (IBW) and lean body weight (LBW) were calculated for each patient 
as follows (231-233): 
Ideal body weight = 22 x Height (m)
2  
 
Lean Body Weight (men) =  
 (1.10 x Weight (kg)) - 128 ( Weight
2
/(100 x Height(m))
2
) 
 
Lean Body Weight (women) =  
 (1.07 x Weight (kg)) - 148 ( Weight
2
/(100 x Height(m))
2
)  
 
Finally TPCR was adjusted for ECE, by multiplying the original value by the ECE using 
the following equation: 
Adjusted TPCR = (P/V)/(C/V)*ECE = [P]/[C]*ECE = g/day 
  
where: 
[P] = urine protein concentration = protein/ volume = P/V 
[C] = urine creatinine concentration = creatinine/ volume = C/V 
PCR=protein/ creatinine ratio = [P]/[C] 
ECE = estimate of 24-hour Creatinine  
 
The equivalent equation was used to calculate adjusted ACR. 
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This adjustment to TPCR and ACR was performed using ECE calculated, in turn, using the 
3 weight variables as described above.  This produced eight variables (four variables for 
each of TPCR and ACR) as follows:  
1. raw: TPCRraw and ACRraw 
2. adjusted for ECE using actual body weight: TPCRABW and ACRABW 
3. adjusted for ECE using ideal body weight: TPCRIBW and ACRIBW 
4. adjusted for ECE using lean body weight: TPCRLBW and ACRLBW 
 
ROC curves were constructed to compare the performance of TPCRraw and ACRraw with 
the adjusted variables as predictors of 24-hr total proteinuria and patient outcomes of all-
cause mortality, commencement of renal replacement therapy and doubling of serum 
creatinine. The AUC was compared using the method of Delong et al (234). Then, in 
addition to ROC curves, The Net Reclassification Index (NRI), a relatively new technique 
to compare the performance of tests as predictors of dichotomous outcomes, was also 
calculated for the patient outcomes described above (235). The NRI indicates the 
proportion of patients correctly reclassified into high or low risk groups using a new 
biomarker (in this case the adjusted TPCR and ACR compared to the raw value). The 
threshold for significant proteinuria of 1g/day equivalent was used to classify the groups 
into high and low risk for the purposes of the NRI.  
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5.3 Results 
5.3.1 Demographics 
A flowchart of the study population and exclusions in shown in figure 5-1. Baseline data 
for this cohort of 5586 patients with ACR and TPCR measured on the same day between 
24
th
 November 1999 and 28
th
 May 2008 are described in chapter 3 (table 3-1). Twenty four 
hour urine collections were performed by 1808 patients (32% of the cohort) and the 
baseline demographics of this group are also described in the same table in chapter 3. 
Additional baseline measurements of the cohort, pertinent only to this analysis, are shown 
in table 5-1.  
 
Figure 5-1 - Flowchart of study population and exclusions 
Initial Population
(n=8,457)
Follow-up < 1yr (n=2,313)
Age <18 yrs (n=142)
Adjusted ECE Population (n=3286 )
Study Population
(n=5,586)
On RRT (n=416)
Height and/ or weight 
missing (n=492)
Study population with urine 
albumin, total protein and 
creatinine measured on spot 
sample (n=3778)
Study population with urine 
albumin, total protein and 
creatinine measured on 24-hr 
sample (n=1808)
Adjusted ECE Population (n=1703)
Height and/ or weight 
missing (n=105)
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Table 5-1 - Selected demographic information for the cohort of 5586 patients attending a nephrology 
clinic 
 Total cohort 
(n=5586) 
% 
available 
Cohort with  
24-hr urine  
(n=1808) 
% 
available 
Height  
(m; ± SD) 
1.65 ± 0.1 90.5 1.65 ± 0.1 95.9 
Actual body 
weight  
(kg; ± SD) 
77.8 ± 18.3 90.5 78.1 ± 18.4 94.8 
Ideal body weight 
(kg; ± SD) 
60.3 ± 7.3 91.2 60.8 ± 7.4 96.0 
Lean body weight 
(kg; ± SD) 
53.0 ± 10.3 89.3 53.6 ± 10.6 94.2 
Measured urine 
creatinine  
(mmol/day; IQR) 
- - 9.3  
(7.0 – 12.4) 
100 
Estimated 
creatinine 
excretion using 
ABW 
(mmol/day; IQR) 
11.1  
(8.9 – 14.2) 
90.5 11.7  
(9.3 – 14.7) 
98.4 
Estimated 
creatinine 
excretion using 
IBW 
(mmol/day; IQR) 
8.8  
(7.1 – 10.8) 
91.2 9.3  
(7.6 – 11.3) 
95.9 
Estimated 
creatinine 
excretion using 
LBW 
(mmol/day; IQR) 
7.7  
(6.0 – 9.8) 
89.3 8.1  
(6.3 – 10.2) 
94.2 
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5.3.2 Outcomes 
As described in chapter 3 (844 deaths at median of 3.0 years [IQR 1.8 – 4.7 years], 468 
patients commencing RRT at 1.7 years [IQR 0.6 – 3.4 years], and serum creatinine 
doubling in 999 patients at 2.2 years [1.1 – 3.8 years]). 
 
5.3.3 24-hour Creatinine Excretion 
The median 24-hr excretion of creatinine (in those who had performed timed urine 
collections) was 9.3mmol/day (7.0 – 12.4). The estimated creatinine excretion was 
calculated using five predictive equations (and actual body weight) (32, 38-41), and 
correlated with the measured creatinine excretion: Ix 0.638 (p<0.005), Cockcroft and Gault 
0.619 (p<0.005), Goldwasser 0.562 (p<0.005), Walser 0.562 (p<0.005), Rule 0.555 
(p<0.005), using Pearson’s correlation co-efficient. Both the Cockcroft & Gault formula 
and the Ix formula performed well with correlations >0.6 (figure 5-2 and 5-3). As 
Cockcroft and Gault is the established equation in most widespread use, we used it to 
calculate ECE for all subsequent analyses. A Bland-Altman plot of ECE (Cockcroft and 
Gault) and measured creatinine excretion is shown in figure 5-4. In addition, the 
scatterplots of the measured creatinine excretion and the estimated creatinine excretion 
using Cockcroft and Gault, but using the alternative weight measurements of ideal and lean 
body weight are show in figures 5-5 and 5-6; the correlation co-efficient was highest when 
lean body weight was used.  
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Figure 5-2 - Simple scatterplot of measured 24-hr creatinine excretion, versus predicted 24-hr 
creatinine excretion using the Cockcroft and Gault formula and actual body weight (Pearson’s 
correlation coefficient 0.619 [p<0.005]) 
 
 
 
Figure 5-3 - Simple scatterplot of measured 24-hr creatinine excretion, versus predicted 24-hr 
creatinine excretion using the Ix Equation D formula (Pearson’s correlation coefficient 0.638 
[p<0.005]) 
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Figure 5-4 - Bland Altman plot of estimated creatinine excretion using Cockcroft and Gault formula 
(and actual body weight) versus measured creatinine excretion in timed urine collections 
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Figure 5-5 - Simple scatterplot of measured 24-hr creatinine excretion, versus predicted 24-hr 
creatinine excretion using the Cockcroft and Gault formula and ideal body weight (Pearson’s 
correlation coefficient 0.566 [p<0.005]) 
 
Figure 5-6 - Simple scatterplot of measured 24-hr creatinine excretion, versus predicted 24-hr 
creatinine excretion using the Cockcroft and Gault formula and lean body weight (Pearson’s 
correlation coefficient 0.651 [p<0.005]) 
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5.3.4 Prediction of 24-hr urine protein and albumin excretion: Impact of 
adjusting for estimated creatinine excretion 
ROC curves were constructed for TPCR and ACR to predict 1g/day of urine total protein 
(as measured in the 24-hour urine collection), with no adjustment (“raw”) or adjusted for 
estimated creatinine excretion (ECE). ECE was calculated using actual, ideal and lean 
body weight, as described in the methods. Areas under the curve were compared. 
Adjustment for ECE results in a statistically significant improvement in the performance of 
both TPCR (p<0.001 for all weight measurements) and ACR (p<0.05 except ACR adjusted 
for ideal body weight, p=0.078). The cohort was also divided according to age, gender and 
eGFR, and further ROC curves constructed (Table 5-2 and 5-3). The performance of raw 
TPCR and ACR to predict 1 g/day of urine protein varies according to age and kidney 
function, with an inferior test performance in the elderly and those with advanced renal 
impairment. Adjustment for ECE generally improved performance in the sub-group 
analysis similar to the overall cohort.  Of the variables used for body weight, actual body 
weight produces the largest increment in AUC (i.e. improvement in test performance). The 
cohort was also divided according to body mass index and the test performance in those 
with a BMI<20kg/m
2
 was markedly inferior to the overall cohort (AUC -0.020), but was 
improved by adjustment for ECE (AUC +0.013 for actual body weight). 
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Table 5-2 – Performance of urine TPCR to predict 1g/day of urine total protein, adjusted for estimated 
creatinine excretion using the Cockcroft and Gault prediction equation. Actual (ABW), lean (LBW) 
and ideal body weights (IBW) have each been used in the equation. The figures shown are the AUC of 
the ROC Curve 
 
TPCR N Raw ∆All ABW ∆Raw LBW ∆Raw IBW ∆Raw 
All 
 
1636 0.986 
(0.98-
0.99) 
N/A 0.994 
(0.99-
1.00) 
+0.008 0.993 
(0.99-
1.00) 
+0.007 0.992 
(0.99-
1.00) 
+0.006 
Male 
 
858 0.988 
(0.98-
0.99) 
+0.002 0.993 
(0.99-
1.00) 
+0.005 0.993 
(0.99-
1.00) 
+0.005 0.991 
(0.99-
1.00) 
+0.003 
Female 
 
778 0.991 
(0.99-
1.00) 
+0.005 0.995 
(0.99-
1.00) 
+0.004 0.994 
(0.99-
1.00) 
+0.003 0.993 
(0.99-
1.00) 
+0.002 
Age  
≤49 
551 0.992 
(0.99-
1.00) 
+0.006 0.996 
(0.99-
1.00) 
+0.004 0.996 
(0.99-
1.00) 
+0.004 0.995 
(0.99-
1.00) 
+0.003 
Age  
49 – 64 
469 0.985 
(0.98-
0.99) 
-0.001 0.993 
(0.99-
1.00) 
+0.008 0.992 
(0.99-
1.00) 
+0.007 0.990 
(0.98-
1.00) 
+0.005 
Age  
64 – 74 
426 0.990 
(0.98-
1.00) 
+0.004 0.995 
(0.99-
1.00) 
+0.005 0.994 
(0.99-
1.00) 
+0.004 0.993 
(0.99-
1.00) 
+0.003 
Age  
>74 
190 0.973 
(0.95-
0.99) 
-0.013 0.984 
(0.97-
1.00) 
+0.011 0.989 
(0.98-
1.00) 
+0.016 0.985 
(0.97-
1.00) 
+0.012 
BMI 
<20 
68 0.966 
(0.93-
1.00) 
-0.020 0.979 
(0.95-
1.01) 
+0.013 0.976 
(0.94-
1.01) 
+0.010 0.978 
(0.95 – 
1.01) 
+0.012 
BMI 
20-25 
464 0.994 
(0.99-
1.00) 
+0.008 0.997 
(0.99-
1.00) 
+0.003 0.997 
(0.99-
1.00) 
+0.003 0.996 
(0.99-
1.00) 
+0.002 
BMI 
25-30 
608 0.988 
(0.98-
0.99) 
+0.002 0.994 
(0.99-
1.00) 
+0.006 0.995 
(0.99-
1.00) 
+0.007 0.995 
(0.99-
1.00) 
+0.007 
BMI 
>30 
563 0.986 
(0.98-
0.99) 
- 0.992 
(0.99-
1.00) 
+0.006 0.993 
(0.99-
1.00) 
+0.007 0.993 
(0.99-
1.00) 
+0.007 
eGFR 
<15 
85 0.936 
(0.88-
0.99) 
-0.050 0.983 
(0.96- 
1.00) 
+0.047 0.981 
(0.95- 
1.00) 
+0.045 0.972 
(0.94- 
1.00) 
+0.036 
eGFR  
15-29 
307 0.974 
(0.96-
0.99) 
-0.012 0.988 
(0.98-
1.00) 
+0.014 0.987 
(0.98-
1.00) 
+0.013 0.981 
(0.97-
0.99) 
+0.007 
eGFR  
30-59 
721 0.993 
(0.99-
1.00) 
+0.007 0.996 
(0.99-
1.00) 
+0.003 0.996 
(0.99-
1.00) 
+0.003 0.995 
(0.99-
1.00) 
+0.002 
eGFR 
 ≥ 60 
523 0.993 
(0.99-
1.00) 
+0.007 0.996 
(0.99-
1.00) 
+0.003 0.997 
(0.99-
1.00) 
+0.004 0.995 
(0.99- 
1.00) 
+0.002 
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Table 5-3 – Performance of ACR to predict 1g/day of urine total protein, adjusted for estimated 
creatinine excretion using the Cockcroft and Gault prediction equation. Actual (ABW), lean (LBW) 
and ideal body weights (IBW) have each been used in the equation. The figures shown are the AUC of 
the ROC Curve 
 
 n Raw ∆All ABW ∆Raw LBW ∆Raw IBW ∆Raw 
All 
 
1636 0.985 
(0.98-
0.99) 
N/A 0.987 
(0.98-
0.99) 
+0.002 0.987 
(0.98-
0.99) 
+0.004 0.986 
(0.98-
0.99) 
+0.003 
Male 
 
858 0.985 
(0.98-
0.99) 
- 0.984 
(0.98-
0.99) 
-0.001 0.985 
(0.98-
0.99) 
- 0.984 
(0.98-
0.99) 
-0.001 
Female 
 
778 0.988 
(0.98-
0.99) 
+0.003 0.990 
(0.98-
1.00) 
+0.002 0.989 
(0.98-
1.00) 
+0.001 0.988 
(0.98-
0.99) 
- 
Age  
≤49 
551 0.989 
(0.98-
1.00) 
+0.004 0.991 
(0.99-
1.00) 
+0.002 0.991 
(0.98-
1.00) 
+0.002 0.990 
(0.98-
1.00) 
+0.001 
Age  
49 – 64 
469 0.984 
(0.97-
0.99) 
-0.003 0.987 
(0.98-
0.99) 
+0.003 0.987 
(0.98-
0.99) 
+0.003 0.986 
(0.98-
0.99) 
+0.002 
Age  
64 – 74 
426 0.989 
(0.98-
1.00) 
+0.004 0.992 
(0.99-
1.00) 
+0.003 0.991 
(0.99-
1.00) 
+0.002 0.990 
(0.98-
1.00) 
+0.001 
Age  
>74 
190 0.964 
(0.94-
0.99) 
-0.021 0.969 
(0.94-
0.99) 
+0.005 0.974 
(0.95-
1.00) 
+0.010 0.972 
(0.95-
0.99) 
+0.008 
BMI 
<20 
68 0.966 
(0.93–
1.00) 
-0.019 0.975 
(0.94–
1.01) 
+0.009 0.978 
(0.95–
1.01) 
+0.012 0.969 
(0.93–
1.01) 
+0.003 
BMI 
20-25 
464 0.991 
(0.98-
1.00) 
+0.006 0.991 
(0.98–
1.00) 
+0.006 0.991 
(0.98–
1.00) 
+0.006 0.990 
 (0.98–
1.00) 
+0.005 
BMI 
25-30 
608 0.985 
(0.98-
0.99) 
- 0.988 
(0.98-
0.99) 
+0.003 0.988 
(0.98-
0.99) 
+0.003 0.988 
(0.98-
0.99) 
+0.003 
BMI 
>30 
563 0.985 
(0.98-
0.99) 
- 0.984 
(0.98-
0.99) 
-0.001 0.986 
(0.98-
0.99) 
+0.001 0.986 
(0.98-
0.99) 
+0.001 
eGFR 
<15 
85 0.924 
(0.87-
0.98) 
-0.061 0.943 
(0.90-
0.99) 
+0.019 0.946 
(0.90-
0.99) 
+0.022 0.942 
(0.90-
0.99) 
+0.018 
eGFR  
15-29 
307 0.970 
(0.95-
0.98) 
-0.015 0.980 
(0.97-
0.99) 
+0.010 0.977 
(0.96-
0.99) 
+0.007 0.973 
(0.96-
0.99) 
+0.003 
eGFR  
30-59 
721 0.991 
(0.98-
1.00) 
+0.006 0.993 
(0.99-
1.00) 
+0.002 0.994 
(0.99-
1.00) 
+0.003 0.993 
(0.99-
1.00) 
+0.002 
eGFR 
 ≥ 60 
523 0.991 
(0.98-
1.00) 
+0.006 0.991 
(0.98-
1.00) 
- 0.991 
(0.98-
1.00) 
- 0.991 
(0.98-
1.00) 
- 
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5.3.5 Prediction of patient outcomes: Impact of adjusting TPCR and ACR 
for estimated creatinine excretion 
ROC curves were then constructed for TPCR and ACR, for the total study population of 
4989 patients who had measurements available, to predict the three major outcomes of all-
cause mortality, commencement of RRT and doubling of serum creatinine, with no 
adjustment (“raw”) or adjusted for estimated creatinine excretion, using ABW, IBW and 
LBW, as before. The AUCs were compared (Table 5-4) and the ROC curves for TPCR are 
shown in Figure 5-7 to 5-9. For all three outcome measures, the adjustments for ECE 
resulted in a statistically significant fall in test performance as represented by a smaller 
area under the ROC curve (except PCRIBW to predict RRT p=0.08).  
 
Table 5-4 – Performance of ACR and TPCR using ROC curve analysis to predict the outcomes of all-
cause mortality, commencement of RRT and doubling of SCr, comparing the unadjusted values with 
those adjusted for estimated creatinine excretion using actual body weight (ABW), lean body weight 
(LBW) and ideal body weight (IBW). The area under the ROC curve is shown (with 95% confidence 
intervals). * denotes a statistically significant (p<0.005) difference from the raw measurement 
 
TPCR ACR  
Raw ABW LBW IBW Raw ABW LBW IBW 
Death 0.669 
(0.65-
0.69) 
0.637* 
(0.62-
0.66) 
0.640* 
(0.62-
0.66) 
0.641* 
(0.62-
0.66) 
0.653 
(0.63-
0.67) 
0.629* 
(0.61-
0.65) 
0.632* 
(0.61-
0.65) 
0.632* 
(0.61-
0.65) 
RRT 0.829 
(0.81-
0.85) 
0.818* 
(0.80-
0.84) 
0.820* 
(0.80-
0.84) 
0.824 
(0.80-
0.84) 
0.816 
(0.80-
0.83) 
0.807* 
(0.79-
0.83) 
0.808* 
(0.79-
0.83) 
0.811* 
(0.79-
0.83) 
Doubled 
sCr 
0.728 
(0.71-
0.75) 
0.719* 
(0.70-
0.74) 
0.718* 
(0.70-
0.74) 
0.717* 
(0.70-
0.74) 
0.730 
(0.71-
0.75) 
0.723* 
(0.70-
0.74) 
0.722* 
(0.70-
0.74) 
0.722* 
(0.70-
0.74) 
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Figure 5-7 - ROC curves comparing the ability of unadjusted (raw) TPCR and TPCR adjusted for 
ideal body weight (IBW) to predict all-cause mortality. The curves for TPCR adjusted for actual body 
weight and lean body weight are coincident with that of TPCR adjusted for ideal body weight and are 
therefore not shown 
 
 
Figure 5-8 - ROC curves comparing the ability of unadjusted (raw) TPCR and TPCR adjusted for 
ideal body weight (IBW) to predict commencement of RRT. The curves for TPCR adjusted for actual 
body weight and lean body weight are coincident with that of PCR adjusted for ideal body weight and 
are therefore not shown 
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Figure 5-9 - ROC curves comparing the ability of unadjusted (raw) TPCR and TPCR adjusted for 
ideal body weight (IBW) to predict doubling of serum creatinine. The curves for TPCR adjusted for 
actual body weight and lean body weight are coincident with that of TPCR adjusted for ideal body 
weight and are therefore not shown 
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We went on to investigate this relationship further using the technique of net 
reclassification index, and the results are presented in table 5-5. They confirm that 
adjustment for ECE produces at best no difference in test performance and often a 
significantly inferior performance for prediction of renal and patient survival. 
 
Table 5-5 – Net Reclassification Index (NRI) analysis of TPCR and ACR comparing the unadjusted 
values with those adjusted for estimated creatinine excretion using actual body weight (ABW), lean 
body weight (LBW) and ideal body weight (IBW) to predict the outcomes of all-cause mortality, 
commencement of RRT and doubling of SCr, The NRI is shown (with significance test) using the 
unadjusted TPCR and ACR as the reference value respectively 
 
NRI (%) for raw TPCR versus 
adjusted TPCR 
NRI (%) for raw ACR versus 
adjusted ACR 
 
ABW LBW IBW ABW LBW IBW 
Death -2.3 
(p=0.0017) 
-4.47 
(p<0.001) 
-3.09 
(p<0.001) 
-3.52 
(p<0.001) 
-4.06 
(p<0.001) 
-3.36 
(p<0.001) 
RRT -2.75 
(p=0.0014) 
-5.45 
(p<0.001) 
-2.40 
(p=0.018) 
-0.18 
(p=0.560) 
-3.61 
(p=0.002) 
-3.31 
(p=0.001) 
Doubled 
sCr 
-1.59 
(p=0.022) 
-3.97 
(p<0.001) 
-2.58 
(p<0.001) 
-0.48 
(p=0.261 ) 
-2.84 
(p<0.001) 
-2.01 
(p=0.002) 
 
The cohort was again divided according to age, gender and eGFR, and further ROC curves 
constructed for the three patient outcomes and the AUCs for TPCR and ACR to predict all-
cause mortality are shown in table 5-6 and 5-7 respectively, AUCs for TPCR and ACR to 
predict commencement of RRT are shown in table 5-8 and 5-9 respectively, and TPCR and 
ACR to predict doubling of serum creatinine in table 5-10 and 5-11. 
 
On sub-group analysis, the performance of TPCR to predict all-cause mortality is superior 
in women, those <49 years and those with eGFR≥60ml/min/1.73m
2
 compared with the 
total cohort. However adjustment for ECE results in inferior performance in all sub-groups 
except those >64 years, using lean or ideal body weight. For the prediction of 
commencement of RRT, the performance of raw TPCR also varies. The performance is 
superior in males, those <64 years and those with eGFR>30ml/min/1.73m
2
, compared with 
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the overall cohort. When adjustment is made for ECE, the performance of the tests 
generally fell, except in the eGFR subgroups where there was a trend towards 
improvement (not statistically significant).The cohort was also divided according to body 
mass index, and within these subgroups, the pattern remained that adjustment for actual, 
lean or ideal body weight led to an inferior test performance. 
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Table 5-6 - Sub-group analysis of the impact of gender, age, body mass index and kidney function on the performance of TPCR to predict all-cause mortality comparing the 
unadjusted values with those adjusted for estimated creatinine excretion using actual body weight (ABW), lean body weight (LBW) and ideal body weight (IBW) in the 
Cockcroft and Gault prediction equation 
 n Raw ∆All ABW ∆Raw LBW ∆Raw IBW ∆Raw 
All 4989 0.669 
(0.65-0.69) 
N/A 0.637 
(0.62-0.66) 
-0.032 0.640 
(0.62-0.66) 
-0.029 0.641 
(0.62-0.66) 
-0.028 
Male 2498 0.661 
(0.63-0.69) 
-0.008 0.625 
(0.60-0.65) 
-0.036 0.627 
(0.60-0.65) 
-0.034 0.630 
(0.60-0.66) 
-0.031 
Female 2491 0.676 
(0.64-0.71) 
0.007 0.640 
(0.61-0.67) 
-0.036 0.642 
(0.61-0.67) 
-0.034 0.643 
(0.61-0.67) 
-0.033 
Age ≤49 1454 0.755 
(0.68-0.83) 
0.106 0.748 
(0.67-0.83) 
-0.007 0.748 
(0.67-0.82) 
-0.007 0.749 
(0.67-0.88) 
-0.006 
Age 49-64 1299 0.668 
(0.62-0.71) 
-0.001 0.666 
(0.62-0.71) 
-0.002 0.668 
(0.62-0.71) 
0 0.668 
(0.62-0.71) 
0 
Age 64-74 1281 0.649 
(0.61-0.68) 
-0.020 0.647 
(0.61-0.68) 
-0.002 0.651 
(0.62-0.69) 
0.002 0.653 
(0.62-0.69) 
0.004 
Age >74 955 0.665 
(0.62-0.70) 
-0.004 0.659 
(0.62-0.70) 
-0.006 0.666 
(0.63-0.70) 
0.001 0.668 
(0.63-0.71) 
0.003 
BMI <20 224 0.697 
(0.62-0.78) 
0.028 0.656 
(0.57-0.74) 
-0.041 0.658 
(0.57-03.74) 
-0.039 0.656 
(0.57-0.74) 
-0.041 
BMI 20-25 1246 0.662 
(0.62-0.70) 
-0.007 0.626 
(0.59-0.67) 
-0.036 0.628 
(0.59-0.67) 
-0.034 0.626 
(0.58-0.67) 
-0.036 
BMI 25-30 1821 0.662 
(0.63-0.70) 
-0.007 0.638 
(0.60-0.67) 
-0.024 0.639 
(0.60-0.68) 
-0.023 0.638 
(0.60-0.67) 
-0.024 
BMI >30 1698 0.674 
(0.64-0.71) 
0.005 0.652 
(0.62-0.69) 
-0.022 0.653 
(0.62-0.69) 
-0.021 0.651 
(0.62-0.69) 
-0.023 
eGFR<15 311 0.545 
(0.48-0.61) 
-0.124 0.515 
(0.45-0.58) 
-0.030 0.517 
(0.45-0.58) 
-0.028 0.508 
(0.44-0.57) 
-0.037 
eGFR 15-29 1100 0.587 
(0.53-0.63) 
-0.082 0.568 
(0.53-0.61) 
-0.019 0.576 
(0.54-0.61) 
-0.011 0.576 
(0.54-0.61) 
-0.011 
eGFR 30-59 2100 0.610 
(0.57-0.64) 
-0.059 0.594 
(0.56-0.63) 
-0.016 0.599 
(0.56-0.63) 
-0.011 0.599 
(0.56-0.63) 
-0.011 
eGFR≥60 1366 0.687 
(0.61-0.77) 
0.018 0.658 
(0.58-0.74) 
-0.029 0.661 
(0.58-0.74) 
-0.026 0.661 
(0.58-0.74) 
-0.026 
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Table 5-7 - Sub-group analysis of the impact of gender, age, body mass index and kidney function on the performance of ACR to predict all-cause mortality comparing the 
unadjusted values with those adjusted for ECE using actual body weight (ABW), lean body weight (LBW) and ideal body weight (IBW) in the Cockcroft and Gault 
prediction equation 
 n Raw ∆ All ABW ∆Raw LBW ∆Raw IBW ∆Raw 
All 4989 0.653 
(0.63-0.67) 
N/A 0.629 
(0.61-0.65) 
-0.024 0.632 
(0.61-0.65) 
-0.021 0.632 
(0.61-0.65) 
-0.021 
Male 2498 0.635 
(0.61-0.66) 
-0.018 0.608 
(0.58-0.64) 
-0.027 0.610 
(0.58-0.64) 
-0.025 0.611 
(0.58-0.64) 
-0.024 
Female 2491 0.669 
(0.64-0.70) 
0.016 0.643 
(0.61-0.67) 
-0.026 0.645 
(0.61-0.68) 
-0.024 0.646 
(0.61-0.68) 
-0.023 
Age ≤49 1454 0.751 
(0.67-0.83) 
0.098 0.742 
(0.66-0.82) 
-0.09 0.741 
(0.66-0.82) 
-0.010 0.742 
(0.66-0.82) 
-0.09 
Age 49-64 1299 0.661 
(0.62-0.70) 
0.008 0.659 
(0.61-0.70) 
-0.002 0.660 
(0.62-0.70) 
-0.001 0.661 
(0.62-0.70) 
0 
Age 64-74 1281 0.650 
(0.62-0.68) 
-0.003 0.648 
(0.61-0.68) 
-0.002 0.651 
(0.62-0.68) 
0.001 0.653 
(0.62-0.69) 
0.003 
Age >74 955 0.658 
(0.62-0.70) 
0.005 0.654 
(0.61-0.69) 
-0.004 0.657 
(0.62-0.70) 
-0.001 0.660 
(0.62-0.70) 
0.002 
BMI <20 224 0.637 
(0.55-0.72) 
-0.016 0.608 
(0.52-0.70) 
-0.029 0.608 
(0.52-0.70) 
-0.029 0.607 
(0.52-0.70) 
-0.030 
BMI 20-25 1246 0.646 
(0.61-0.68) 
-0.007 0.619 
(0.58-0.66) 
-0.027 0.620 
(0.58-0.66) 
-0.026 0.619 
(0.58-0.66) 
-0.027 
BMI 25-30 1821 0.646 
(0.61-0.68) 
-0.007 0.628 
(0.59-0.66) 
-0.018 0.629 
(0.59-0.66) 
-0.017 0.628 
(0.59-0.66) 
-0.018 
BMI >30 1698 0.670 
(0.64-0.70) 
0.017 0.652 
(0.62-0.69) 
-0.018 0.653 
(0.62-0.69) 
-0.017 0.653 
(0.62-0.69) 
-0.017 
eGFR<15 311 0.513 
(0.45-0.58) 
-0.140 0.487 
(0.42-0.55) 
-0.026 0.491 
(0.423-0.56) 
-0.022 0.487 
(0.42-0.55) 
-0.026 
eGFR15-29 1100 0.584 
(0.54-0.62) 
-0.069 0.572 
(0.53-0.61) 
-0.014 0.576 
(0.54-0.61) 
-0.008 0.576 
(0.54-0.61) 
-0.008 
eGFR 30-59 2100 0.610 
(0.58-0.64) 
-0.043 0.598 
(0.56-0.63) 
-0.012 0.602 
(0.57-0.63) 
-0.008 0.602 
(0.57-0.64) 
-0.008 
eGFR≥60 1366 0.693 
(0.62-0.77) 
0.040 0.666 
(0.59-0.74) 
-0.027 0.668 
(0.59-0.75) 
-0.025 0.668 
(0.59-0.75) 
-0.025 
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Table 5-8 - Sub-group analysis of the impact of gender, age, body mass index and kidney function on the performance of TPCR to predict commencement of RRT comparing 
the unadjusted values with those adjusted for ECE using actual body weight (ABW), lean body weight (LBW) and ideal body weight (IBW) in the Cockcroft and Gault 
prediction equation 
 n Raw ∆ All ABW ∆Raw LBW ∆Raw IBW ∆Raw 
All 4989 0.829 
(0.81-0.85) 
N/A 0.818 
(0.80-0.84) 
-0.011 0.820 
(0.80-0.84) 
-0.009 0.824 
(0.80-0.84) 
-0.005 
Male 2498 0.841 
(0.82-0.86) 
0.012 0.836 
(0.81-0.86) 
-0.005 0.840 
(0.81-0.86) 
-0.001 0.842 
(0.82-0.87) 
0.001 
Female 2491 0.818 
(0.79-0.85) 
-0.011 0.808 
(0.78-0.84) 
-0.010 0.814 
(0.79-0.84) 
-0.004 0.815 
(0.79-0.84) 
-0.003 
Age ≤49 1454 0.856 
(0.82-0.89) 
0.027 0.847 
(0.81-0.88) 
-0.009 0.848 
(0.81-0.88) 
-0.008 0.850 
(0.81-0.89) 
-0.006 
Age 49-64 1299 0.834 
(0.80-0.86) 
0.005 0.817 
(0.78-0.85) 
-0.017 0.824 
(0.79-0.86) 
-0.010 0.832 
(0.80-0.86) 
-0.002 
Age 64-74 1281 0.803 
(0.77-0.84) 
-0.026 0.799 
(0.76-0.84) 
-0.004 0.795 
(0.76-0.83) 
-0.008 0.797 
(0.76-0.83) 
-0.006 
Age >74 955 0.803 
(0.75-0.86) 
-0.026 0.792 
(0.74-0.84) 
-0.011 0.794 
(0.74-0.85) 
-0.009 0.798 
(0.74-0.85) 
-0.005 
BMI <20 224 0.818 
(0.75-0.89) 
-0.011 0.823 
(0.75-0.90) 
0.005 0.823 
(0.75-0.90) 
0.005 0.821 
(0.74-0.90) 
0.003 
BMI 20-25 1246 0.793 
(0.75-0.83) 
-0.036 0.792 
(0.75-0.83) 
-0.001 0.790 
(0.75-0.83) 
-0.003 0.791 
(0.75-0.83) 
-0.002 
BMI 25-30 1821 0.835 
(0.80-0.87) 
0.006 0.831 
(0.80-0.86) 
-0.004 0.829 
(0.80-0.86) 
-0.007 0.832 
(0.80-0.86) 
-0.003 
BMI >30 1698 0.859 
(0.83-0.89) 
0.030 0.847 
(0.82-0.88) 
-0.012 0.844 
(0.81-0.87) 
-0.015 0.847 
(0.82-0.88) 
-0.012 
eGFR<15 311 0.608 
(0.54-0.67) 
-0.221 0.628 
(0.56-0.69) 
0.020 0.631 
(0.57-0.69) 
0.023 0.626 
(0.563-0.690) 
0.018 
eGFR15-29 1100 0.749 
(0.71-0.79) 
-0.080 0.760 
(0.72-0.78) 
0.011 0.763 
(0.73-0.80) 
0.014 0.765 
(0.73-0.80) 
0.016 
eGFR 30-59 2100 0.864 
(0.82-0.91) 
0.035 0.865 
(0.82-0.91) 
0.001 0.868 
(0.82-0.91) 
0.004 0.871 
(0.82-0.92) 
0.007 
eGFR≥60 1366 0.835 
(0.68-0.99) 
0.006 0.870 
(0.76-0.97) 
0.035 0.880 
(0.78-0.98) 
0.045 0.881 
(0.80-0.98) 
0.046 
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Table 5-9 – Sub-group analysis of the impact of gender, age, body mass index and kidney function on the performance of ACR to predict commencement of RRT comparing 
the unadjusted values with those adjusted for ECE using actual body weight (ABW), lean body weight (LBW) and ideal body weight (IBW) in the Cockcroft and Gault 
prediction equation 
 n Raw ∆ All ABW ∆Raw LBW ∆Raw IBW ∆Raw 
All 4989 0.816 
(0.80-0.83) 
N/A 0.807 
(0.79-0.83) 
-0.009 0.808 
(0.79-0.83) 
-0.008 0.811 
(0.79-0.83) 
-0.005 
Male 2498 0.824 
(0.80-0.85) 
0.008 0.819 
(0.79-0.85) 
-0.005 0.822 
(0.-80-0.85) 
-0.002 0.824 
(0.80-0.85) 
0 
Female 2491 0.814 
(0.79-0.84) 
-0.002 0.808 
(0.78-0.83) 
-0.006 0.811 
(0.78-0.84) 
-0.003 0.811 
(0.79-0.84) 
-0.003 
Age ≤49 1454 0.852 
(0.82-0.89) 
0.036 0.846 
(0.81-0.88) 
-0.006 0.847 
(0.81-0.88) 
-0.005 0.848 
(0.81-0.88) 
-0.004 
Age 49-64 1299 0.806 
(0.77-0.84) 
-0.010 0.794 
(0.76-0.83) 
-0.012 0.798 
(0.76-0.83) 
-0.008 0.804 
(0.77-0.84) 
-0.002 
Age 64-74 1281 0.799 
(0.76-0.83) 
-0.017 0.795 
(0.76-0.83) 
-0.004 0.793 
(0.76-0.83) 
-0.006 0.795 
(0.76-0.83) 
-0.004 
Age >74 955 0.792 
(0.74-0.84) 
-0.024 0.783 
(0.73-0.83) 
-0.009 0.784 
(0.73-0.83) 
-0.008 0.789 
(0.74-0.84) 
-0.003 
BMI <20 224 0.816 
(0.74-0.90) 
0 0.810 
(0.72-0.88) 
-0.006 0.806 
(0.72-0.89) 
-0.010 0.808 
(0.72-0.89) 
-0.008 
BMI 20-25 1246 0.788 
(0.75-0.83) 
-0.028 0.786 
(0.75-0.83) 
-0.002 0.785 
(0.74-0.82) 
-0.003 0.785 
(0.74-0.83) 
-0.003 
BMI 25-30 1821 0.822 
(0.79-0.85) 
0.006 0.819 
(0.80-0.85) 
-0.003 0.817 
(0.79-0.85) 
-0.005 0.819 
(0.79-0.85) 
-0.003 
BMI >30 1698 0.845 
(0.82-0.87) 
0.029 0.834 
(0.81-0.86) 
-0.011 0.832 
(0.80-0.86) 
-0.013 0.835 
(0.81-0.86) 
-0.010 
eGFR<15 311 0.652 
(0.60-0.71) 
-0.164 0.659 
(0.60-0.72) 
0.007 0.661 
(0.60-0.72) 
0.009 0.659 
(0.60-0.72) 
0.007 
eGFR 15-29 1100 0.765 
(0.73-0.80) 
-0.051 0.772 
(0.74-0.81) 
0.007 0.774 
(0.74-0.81) 
0.009 0.776 
(0.74-0.81) 
0.011 
eGFR 30-59 2100 0.865 
(0.81-0.91) 
0.049 0.866 
(0.82-0.91) 
0.001 0.867 
(0.82-0.92) 
0.002 0.869 
(0.82-0.92) 
0.004 
eGFR≥60 1366 0.839 
(0.67-1.00) 
0.023 0.856 
(0.72-0.99) 
0.017 0.867 
(0.74-0.99) 
0.028 0.869 
(0.74-1.00) 
0.030 
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Table 5-10 - Sub-group analysis of the impact of gender, age, body mass index and kidney function on the performance of TPCR to predict doubling of serum creatinine 
comparing the unadjusted values with those adjusted for ECE using actual body weight, lean body weight and ideal body weight in the Cockcroft and Gault prediction 
equation 
 n Raw ∆All ABW ∆Raw LBW ∆Raw IBW ∆Raw 
All 4989 0.728 
(0.71-0.75) 
N/A 0.719 
(0.70-0.74) 
-0.009 0.718 
(0.70-0.74) 
-0.010 0.717 
(0.70-0.74) 
-0.011 
Male 2498 0.715 
(0.69-0.74) 
-0.013 0.708 
(0.68-0.73) 
-0.007 0.706 
(0.68-0.73) 
-0.009 0.704 
(0.68-0.73) 
-0.011 
Female 2491 0.741 
(0.71-0.77) 
0.013 0.729 
(0.70-0.46) 
-0.012 0.730 
(0.70-0.76) 
-0.011 0.730 
(0.70-0.76) 
-0.011 
Age ≤49 1454 0.780 
(0.74-0.82) 
0.052 0.778 
(0.74-0.81) 
-0.002 0.776 
(0.74-0.81) 
-0.004 0.776 
(0.74-0.81) 
-0.004 
Age 49-64 1299 0.744 
(0.71-0.78) 
0.016 0.741 
(0.71-0.77) 
-0.003 0.744 
(0.71-0.78) 
0 0.746 
(0.71-0.78) 
0.002 
Age 64-74 1281 0.728 
(0.69-0.76) 
0 0.732 
(0.70-0.77) 
0.004 0.730 
(0.70-0.76) 
0.002 0.728 
(0.69-0.76) 
0 
Age >74 955 0.606 
(0.56-0.66) 
-0.102 0.607 
(0.56-0.66) 
0.001 0.605 
(0.56-0.65) 
-0.001 0.602 
(0.55-0.65) 
-0.004 
BMI<20 224 0.730 
(0.65-0.80) 
0.002 0.697 
(0.61-0.78) 
-0.033 0.700 
(0.62-0.78) 
-0.030 0.702 
(0.62-0.78) 
-0.028 
BMI 20-25 1246 0.751 
(0.71-0.79) 
0.023 0.742 
(0.70-0.78) 
-0.009 0.740 
(0.70-0.78) 
-0.011 0.741 
(0.70-0.78) 
-0.010 
BMI 25-30 1821 0.724 
(0.69-0.76) 
-0.004 0.713 
(0.679-0.747) 
-0.011 0.712 
(0.68-0.74) 
-0.012 0.713 
(0.68-0.75) 
-0.011 
BMI>30 1698 0.714 
(0.68-0.75) 
-0.014 0.710 
(0.68-0.74) 
-0.004 0.710 
(0.68-0.74) 
-0.004 0.708 
(0.68-0.74) 
-0.006 
eGFR<15 311 0.558 
(0.49-0.6) 
-0.170 0.572 
(0.50-0.64) 
0.014 0.573 
(0.50-0.64) 
0.015 0.572 
(0.50-0.64) 
0.014 
eGFR 15-29 1100 0.703 
(0.67-0.74) 
-0.025 0.711 
(0.68-0.74) 
0.008 0.713 
(0.68-0.75) 
0.010 0.713 
(0.68-0.75) 
0.010 
eGFR 30-59 2100 0.700 
(0.67-0.73) 
-0.028 0.698 
(0.6-0.73) 
-0.002 0.695 
(0.66-0.73) 
-0.005 0.694 
(0.66-0.73) 
-0.006 
eGFR≥60 1366 0.725 
(0.66-0.78) 
-0.003 0.723 
(0.66-0.78) 
-0.002 0.726 
(0.67-0.78) 
0.001 0.723 
(0.66-0.78) 
-0.002 
160 
Table 5-11 - Sub-group analysis of the impact of gender, age, body mass index and kidney function on the performance of ACR to predict doubling of serum creatinine 
comparing the unadjusted values with those adjusted for ECE using actual body weight, lean body weight and ideal body weight in the Cockcroft and Gault prediction 
equation 
 n Raw ∆ All ABW ∆Raw LBW ∆Raw IBW ∆Raw 
All 4989 0.730 
(0.71-0.75) 
N/A 0.723 
(0.70-0.74) 
-0.007 0.722 
(0.70-0.74) 
-0.008 0.722 
(0.70-0.74) 
-0.008 
Male 2498 0.718 
(0.69-0.74) 
-0.012 0.711 
(0.68-0.74) 
-0.007 0.710 
(0.68-0.74) 
-0.008 0.709 
(0.68-0.73) 
-0.009 
Female 2491 0.747 
(0.72-0.77) 
0.017 0.738 
(0.71-0.76) 
-0.009 0.739 
(0.71-0.76) 
-0.008 0.739 
(0.71-0.76) 
-0.008 
Age ≤49 1454 0.796 
(0.76-0.83) 
0.066 0.794 
(0.76-0.83) 
-0.002 0.793 
(0.76-0.83) 
-0.003 0.793 
(0.76-0.83) 
-0.003 
Age 49-64 1299 0.738 
(0.70-0.77) 
0.008 0.736 
(0.70-0.77) 
-0.002 0.737 
(0.70-0.77) 
-0.001 0.738 
(0.70-0.77) 
0 
Age 64-74 1281 0.744 
(0.71-0.78) 
0.014 0.746 
(0.71-0.78) 
0.002 0.744 
(0.71-0.78) 
0 0.744 
(0.71-0.78) 
0 
Age >74 955 0.621 
(0.57-0.67) 
-0.109 0.622 
(0.58-0.67) 
0.002 0.621 
(0.57-0.67) 
0 0.620 
(0.57-0.67) 
-0.001 
BMI<20 224 0.694 
(0.61-0.77) 
-0.036 0.673 
(0.59-0.76) 
-0.021 0.672 
(0.59-0.76) 
-0.022 0.674 
(0.59-0.76) 
-0.020 
BMI 20-25 1246 0.747 
(0.71-0.78) 
0.017 0.739 
(0.70-0.78) 
-0.008 0.738 
(0.70-0.78) 
-0.009 0.738 
(0.70-0.78) 
-0.009 
BMI 25-30 1821 0.732 
(0.70-0.76) 
0.002 0.724 
(0.69-0.76) 
-0.008 0.723 
(0.69-0.75) 
-0.009 0.724 
(0.69-0.76) 
-0.008 
BMI>30 1698 0.725 
(0.69-0.76) 
-0.005 0.721 
(0.69-0.75) 
-0.004 0.721 
(0.69-0.75) 
-0.005 0.720 
(0.69-0.75) 
-0.005 
eGFR<15 311 0.576 
(0.50-0.65) 
-0.154 0.581 
(0.509-0.653) 
0.005 0.585 
(0.51-0.66) 
0.009 0.582 
(0.51-0.65) 
0.006 
eGFR 15-29 1100 0.716 
(0.68-0.75) 
-0.014 0.721 
(0.69-0.75) 
0.005 0.721 
(0.69-0.75) 
0.005 0.722 
(0.69-0.75) 
0.006 
eGFR 30-59 2100 0.706 
(0.67-0.74) 
-0.024 0.704 
(0.67-0.73) 
-0.002 0.702 
(0.67-0.73) 
-0.004 0.701 
(0.67-0.73) 
-0.005 
eGFR≥60 1366 0.753 
(0.70-0.81) 
0.023 0.748 
(0.69-0.80) 
-0.005 0.748 
(0.69-0.80) 
-0.005 0.746 
(0.69-0.80) 
-0.007 
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5.3.6 Impact of adjusting TPCR or ACR for measured creatinine excretion 
Given that adjusting for ECE gave inferior test performance in predicting patient 
outcomes, we repeated the analysis using actual measured creatinine excretion (MCE) in 
the subpopulation with 24h urine results available, to ensure the accuracy of the creatinine 
excretion prediction equation was not influencing the results itself. 24-hr creatinine 
excretion was available in the subgroup of 1808 patients who performed timed urine 
collections. ROC curves were constructed, as above, and the AUC calculated. For each 
outcome the pattern was the same: the AUC for TPCR adjusted for measured creatinine 
excretion was lower than that of TPCR adjusted for estimated creatinine excretion, which 
was lower in turn than the unadjusted (raw) TPCR. The ROC curves are shown in figures 
5-10 – 5-12. The same relationships were demonstrated for ACR, for all 3 of the outcome 
measures. Excluding urine collections with biologically implausible 24-hr creatinine 
excretion (<3mmol/day or >30mmmol/day) did not alter the results.  
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Figure 5-10 - ROC curves comparing the ability of unadjusted (raw) TPCR, TPCR adjusted for ECE 
using actual body weight (ABW) and TPCR adjusted for measured creatinine excretion (MCE) to 
predict all cause mortality. 
 
 
 
Figure 5-11 - ROC curves comparing the ability of unadjusted (raw) TPCR, TPCR adjusted for ECE 
using actual body weight (ABW) and TPCR adjusted for measured creatinine excretion (MCE) to 
predict commencement of renal replacement therapy.  
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Figure 5-12 - ROC curves comparing the ability of unadjusted (raw) TPCR, TPCR adjusted for ECE 
using actual body weight (ABW) and TPCR adjusted for measured creatinine excretion (MCE) to 
predict doubling of serum creatinine. 
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Secondly, the predictive ability of the actual 24-hr total protein excretion versus the 24-hr 
total protein excretion corrected for body weight, were compared. There was no 
statistically significant difference in test performance between 24-hr total protein corrected 
for actual body weight and raw 24-hr total protein excretion, to predict all-cause mortality 
(AUC 0.626 (95%CI 0.592 – 0.659) v 0.623 (95%CI 0.590 -0.657)) and commencement of 
RRT (0.786 (95%CI 0.755 – 0.817) v 0.777 (95%CI 0.745 – 0.809). Using IBW or LBW 
did not afford any further improvement in performance.  
Chapter 5  165 
 165 
 
5.4 Discussion 
5.4.1 Findings of this study 
In chapter 2 we showed that TPCR and ACR perform well as predictors of significant 
proteinuria (≥1 g/day) in a cohort of adults attending a nephrology clinic. However, 
performance is inferior in the elderly, females and those with advanced kidney disease. 
This was presumed to be due to the confounding influence of lower muscle mass on the 
TPCR/ACR result: patients with low muscle mass will have lower creatinine excretion and 
therefore higher TPCR/ACR for any given degree of protein excretion. In this analysis, 
adjustment of TPCR and ACR for estimated creatinine excretion (using the Cockcroft and 
Gault formula), improves the performance of these tests. This held true, whether estimated 
creatinine excretion was calculated using actual body weight, lean body weight or ideal 
body weight. The largest improvement in AUC was seen in the elderly and those with 
advanced kidney disease (eGFR <15ml/min/1.73m
2
), i.e. the groups with the poorest 
baseline test performance. This effect was particularly pronounced, using lean body weight 
in place of actual body weight in the >74 years group, which may reflect the increase in fat 
as a proportion of actual body weight with increasing age (38). 
 
However, what is potentially more important than the prediction of urine protein excretion 
is whether these adjustments improve the ability of TPCR and/or ACR to predict patient-
relevant outcomes. Our results suggest that the converse is true, with  performances of 
“raw” TPCR and ACR (i.e. unadjusted) significantly superior to the values adjusted for 
ECE, to predict the clinically important end-points of all-cause mortality, commencement 
of RRT and doubling of serum creatinine. This was confirmed using a net reclassification 
index analysis. Again, there were important differences within sub-group analysis, as for 
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prediction of 24-hr urine protein excretion, but the effects of adjusting for ECE were not 
consistent across the groups, and no subgroup gained statistically improved prediction of 
outcomes with adjustment for ECE.  
As a confirmatory analysis in the subgroup with 24h urine samples available, we used the 
actual measured creatinine excretion to adjust the TPCR or ACR. This confirmed that 
adjusting TPCR or ACR for creatinine excretion gave an inferior performance compared to 
unadjusted TPCR or ACR. Furthermore, the performance of TPCR and ACR adjusted for 
measured 24-hour creatinine excretion was inferior to that of the spot samples adjusted for 
estimated creatinine excretion (calculated using the Cockcroft & Gault equation), which in 
turn was inferior to the “raw” TPCR/ACR.  
 
It is conceivable that 1g/day of proteinuria may carry a higher prognostic risk in a 50 kg 
frail, elderly woman, than in a 120 kg young, muscular man. Thus, one explanation for the 
unadjusted TPCR/ACR predicting risk more effectively is that the denominator corrects to 
some extent for weight. To assess that further we examined the prognostic risk associated 
with 24-hour total protein excretion compared with that adjusted for actual, ideal or lean 
body weight (rather than adjusted for creatinine excretion). No difference was found 
between the two approaches in their ability to predict mortality, RRT or doubling of serum 
creatinine.  
 
5.4.2 The role of urine creatinine 
Low creatinine excretion as a result of low muscle mass will result in a low denominator in 
TPCR or ACR, leading to a higher result for any given protein excretion. The converse is 
also true: for example, in a young man with high creatinine excretion, the TPCR will 
underestimate 24-hr protein excretion (as demonstrated in chapter 2). Therefore adjusting 
for this, by taking account of estimated creatinine excretion in the derived formulae, will 
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reduce these important discrepancies between subgroups, and improve the overall 
predictive ability of the spot samples to accurately quantify 24-hr proteinuria, as we have 
demonstrated here. However the accurate prediction of 24-hour urine protein is not 
necessarily the ultimate goal, as many would argue that it is only a surrogate end-point 
used to identify those at risk of renal decline and increased risk of mortality. The goal is to 
identify the optimal measure of urine protein that accurately predicts renal and patient 
survival.  
 
Why should it be the case that adjustment of spot urine samples for estimated creatinine 
excretion improves the prediction of 24-hr urine protein excretion, but not outcomes such 
as all-cause mortality or commencement of RRT? Timed urine collections have been 
considered the gold standard for the measurement of proteinuria, but have a number of 
acknowledged technical and practical drawbacks such as incomplete collection. It may be 
that a spot sample corrected for urine creatinine (e.g. TPCR) is a superior measure of 24-
hour urine protein than the timed urine collection itself.  The additional finding that 
adjusting the TPCR/ACR for estimated creatinine excretion had a superior predictive 
performance than adjusting TPCR/ACR for measured creatinine excretion, goes some way 
to supporting this hypothesis. 
 
An alternative hypothesis is that urine creatinine excretion per se may have a role in 
predicting patient outcome, other than just correcting proteinuria for urine concentration. A 
post hoc analysis of the PREVEND study from the Netherlands demonstrated that urine 
creatinine excretion is an independent predictor of cardiovascular disease and mortality in 
a general population cohort (228). A study of patients with established cardiovascular 
disease also showed creatinine excretion to be an independent predictor of mortality (236).  
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The performance of “raw” TPCR/ACR is superior to the adjusted TPCR/ACR, but raw 24-
hour total urine protein is not superior to 24-hour total urine protein adjusted for body 
weight. The notable difference between these analyses is the absence of urine creatinine in 
the latter analysis. Therefore, in our cohort, is the urine creatinine component of the TPCR 
and ACR acting as an independent predictor of outcome, rather than as a correction for 
urine flow rate alone? This might account for the marked fall in test performance following 
adjustment for ECE, for all-cause mortality when compared to renal outcomes? Therefore 
is TPCR/ACR the optimal measurement as it inadvertently includes two markers of 
outcome; the total protein/ albumin and the urine creatinine?  
 
5.4.3 Implications of the study 
Whether these are, or are not, the correct mechanisms to explain the phenomenon 
described here, the practical implications are clear. Adjustment for estimated creatinine 
excretion improves the identification of significant proteinuria in those with low muscle 
mass such as females and the elderly. However, it does not significantly improve the 
ability of TPCR or ACR to predict outcomes in this cohort. Therefore the utility of this 
technique is entirely dependant on the proposed application of the result; if the TPCR/ACR 
will be used to identify those above a proteinuria threshold who may benefit from the use 
of ACE inhibitors (where the evidence is derived from measurements in 24-hour 
collections and therefore the accurate quantification of urine protein is paramount) then 
adjustment of TPCR/ACR will be advantageous. However, if the TPCR/ACR is being 
utilised as a prognostic marker, then the unadjusted value, with the influence of the urine 
creatinine, will be more informative.   
 
The optimal method of assessment of proteinuria is an ongoing challenge in nephrology. 
The proposed addition of proteinuria to the international CKD staging system underlines 
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the importance of this. Major national and international guidelines recommend screening 
for the presence of proteinuria using spot samples (either TPCR or ACR) (5, 7, 8, 214). 
Therefore clarification regarding the need for refinement of TPCR and ACR is urgently 
needed. The findings of this study contribute to that. 
 
5.4.4 Limitations 
 This study has limitations. Those relating to the cohort have already been outlined in 
previous chapters.  Of particular relevance to this analysis, only one third (approximately) 
of the cohort performed 24-hr urine collections, from which actual 24-hr creatinine 
excretion was measured. We do not have any additional measurements of muscle mass, in 
addition to actual body weight. A number of formulae have been used in this analysis, all 
of which are based on a number of assumptions that may be inaccurate. The cohort is a 
predominantly white population attending a hospital nephrology clinic and may not be 
representative of other populations. This is of particular importance given that the MDRD 
eGFR prediction equation using serum creatinine has a factor of 1.2 for black race. It will 
be important to examine these issues in other racial groups.  
 
5.4.5 Direction of further research  
Further research is required to clarify the role of urine creatinine in the prediction of 
outcomes in patients with chronic kidney disease. The results of this study should be 
confirmed prospectively, and in other populations. 
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5.4.6 Conclusion 
Adjusting TPCR and ACR for estimates of muscle mass including estimated creatinine 
excretion improves the prediction of significant proteinuria in sub-groups with low muscle 
mass (such as the elderly and females). However, adjustment does not improve prediction 
of renal outcome or mortality in patients with chronic kidney disease.  
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6 Chapter 6: Estimated glomerular filtration rate: A 
retrospective study of the prevalence of CKD in the 
general population and secular trends: the impact of 
the MDRD and CKD-EPI Formulae 
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6.1 Introduction 
The NKF-KDOQI classification of CKD was rapidly adopted internationally after its 
publication in 2002, and is primarily based on a reduced glomerular filtration rate, or in 
combination with other markers of kidney damage at GFR >60ml/min/1.73m
2
 (5) (as 
described in detail in chapter 1). To allow the use of the NKF-KDOQI classification in the 
UK, it has been recommended that eGFR be reported routinely with serum creatinine 
measurements in adults (21) Most laboratories use the Modification of Diet in Renal 
Disease four variable formula, which estimates GFR from serum creatinine, age, sex and 
race (if available) (44, 215) 
 
The MDRD4 formula was derived from a United States (US) CKD cohort with a mean 
GFR of 40 mL/min/1.73m
2
, and underestimates higher GFRs (237, 238). Some have 
concerns that this formula may lead to overdiagnosis of CKD, particularly in the elderly 
and in women (239). The Chronic Kidney Disease Epidemiology Collaboration recently 
derived a series of new eGFR equations with improved accuracy at higher GFRs as 
described in detail in chapter 1 (47)
 
 
 
This study has two aims: the primary aim was to compare the impact of the MDRD4 and 
CKD-EPI formulae on estimates of CKD prevalence in a United Kingdom population, and 
the secondary aim was to examine the impact on secular trends in CKD prevalence over a 
five year period. 
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6.2 Methods 
6.2.1  Laboratory Assays 
Serum creatinine was measured using Roche Modular reagent Jaffe method, with a mean 
between batch coefficient of variation of 2.3% at a sCr concentration of 148 µmol/L and 
1.7% at 326 µmol/L. In 2004, serum creatinine was measured by the O’Leary 
modifications of picrate method of Jaffe. The between-day CVs were <2.0% at 
concentrations of 100 and 485mmol/l. Both assays were performed using Roche Modular P 
Units. We used the adjustment factors produced by the UK National External Quality 
Assessment Service for each creatinine assay, to produce IDMS-traceable serum creatinine 
values (43).  
 
6.2.2 Study Population 
NHS Ayrshire & Arran provides healthcare for its geographically defined population in the 
West of Scotland, with only limited coverage by other providers at the boundaries. 
Biochemistry services are provided by a single laboratory in University Hospital 
Crosshouse, Kilmarnock. We downloaded all serum creatinine results reported between 
1/4/2009 and 31/3/2010. Individual patients were identified using unique community 
health index (CHI) numbers, which are utilised in 98% of samples received by the 
laboratory. Samples with no CHI number, patients below 18 years of age and those 
receiving RRT were excluded. The lowest serum creatinine available for each individual 
over the year was selected, to minimise the potential effects of acute illness on kidney 
function. For analysis of secular trends, we performed the same data extraction for the 
period 1/1/2004 – 31/12/2004. 
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eGFR was calculated using the IDMS traceable versions of the MDRD4 and CKD-EPI 
formulae, (see chapter 1 for the formulae). No modification was made for race as our 
population is relatively homogeneous (99.35% white, 0.44% Indo-Asian, 0.04% black, and 
0.20% other)(217). CKD stage was classified using the modified version of the NKF-
KDOQI CKD classification (7, 8), with stage 3 subdivided into 3A (45-59 
mL/min/1.73m
2
) and 3B (30-44 mL/min/1.73m
2
). Local population statistics were obtained 
from the General Register Office for Scotland (240).  
  
6.2.3 Statistical Analyses 
Data were analysed using SPSS 16.0 for Windows (SPSS Inc, Chicago, IL, USA). 
Appropriate summary statistics were obtained and comparison tables constructed. 
Agreement between the estimated GFR predicted by each formula was assessed using the 
Bland-Altman method.  
 
We compared the prevalence in our study population with that of representative population 
studies (US National Health and Nutrition Examination Survey [NHANES] 1999-2006 
data (47) and from the Health Survey for England [HSE]) in order to calculate the 
prevalence in the unbled proportion of our population that would be necessary to produce 
the same overall prevalence as NHANES/HSE. Specifically we used the CKD-EPI 
formulae with age-adjusted data from 2009 and estimated the expected prevalence of CKD 
in our population. We then used the difference between the CKD prevalence from our 
laboratory data and the expected prevalence from the NHANES and HSE data to calculate 
the necessary prevalence in the population with no blood sample taken in the study year. 
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6.3 Results 
The adult population of Ayrshire and Arran in 2009 was 293,880 (240). Between April 
2009 and March 2010, 438,872 serum samples were analysed for creatinine. Following 
removal of repeat samples on individuals, and application of the exclusion criteria, the 
study population was 123,121 (figure 6-1 and table 6-1). The population distribution and 
percentage with serum creatinine results by age band is shown in figure 6-2. Overall 42% 
of the adult population, and 71% of those over 65 years old had serum creatinine measured 
in the year. 
 
 
Figure 6-1 - Flowchart of the study populations and exclusions 
   2004     2009/10                          
 
 
Initial population 
438,872 
Study population 
123,121 
Duplicates: 
308, 847 
 
RRT: 361 
<18 yrs: 6543 
Initial population 
341,928 
Study population 
102,322 
Duplicates: 
234,184 
 
RRT: 253 
< 18 yrs: 5169 
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Table 6-1 –Population characteristics. The results are shown as mean ± standard deviation 
(SD) or median (interquartile range) 
 
 2004 2009-2010 
Adult population 289,386 293,880 
Study population 102,322 123,121 
Sex (% male) 43 44 
Age (years)  
[range] 
60±18 
 [18-105] 
59±18 
 [18-109] 
Serum creatinine (µmol/L) 88 (79-99) 75 (64-88) 
eGFR MDRD4 (mL/min/1.73m
2
) 81 (67-95) 84 (69-100) 
eGFR CKD-EPI (mL/min/1.73m
2
) 86 (70-100) 89 (73-102) 
 
 
 
Figure 6-2 - Population distribution by age in Ayrshire and Arran 2009-10 (240) and the 
proportion with serum creatinine checked 
0
5000
10000
15000
20000
25000
30000
1
8
-1
9
2
0
-2
4
2
5
-2
9
3
0
-3
4
3
5
-3
9
4
0
-4
4
4
5
-4
9
5
0
-5
4
5
5
-5
9
6
0
-6
4
6
5
-6
9
7
0
-7
4
7
5
-7
9
8
0
-8
4
8
5
-8
9
9
0
+
0
10
20
30
40
50
60
70
80
90
100
A&A adult
population
Population with
serum creatinine
checked
% Population with
serum creatinine
checked
 
Chapter 6  177 
 177 
The relationship between eGFR as estimated by the MDRD4 formula and the CKD-EPI 
formulae are shown in figures 6-3 and 6-4. The prevalence of CKD stages 3-5 fell from 
13.4% of our study population when using the MDRD4 formula, to 11.8% using the CKD-
EPI formulae. The impact on prevalence by CKD stage, age and gender is shown in table 
6-2 and 6-3. The difference between eGFR as estimated by the different formulae in 
relation to age is shown in Figure 6-5. 
 
The CKD prevalence that would be required in the unbled population in order to match 
NHANES and HSE data is shown in table .6-4  
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Figure 6-3 - Comparison of eGFR calculated using the CKD-EPI formulae and the MDRD4 study 
formula in a population of 123,121 adults in Ayrshire. The line is the line of identity. 
 
Figure 6-4 - Bland-Altman plot of eGFR calculated using the CKD-EPI formulae and the MDRD4 
formula 
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Table 6-2 - Observed frequencies of CKD stage, age, proportion of females and difference by eGFR formula. Bold figures are observed frequencies of agreement. Percentages 
of the study population (i.e. those patients with blood samples taken during the study year) are shown for each CKD stage by eGFR formula 
 CKD stage (MDRD4) 
CKD stage 
(CKD-EPI) 
eGFR 
≥90 
eGFR 60-89 3A 3B 4 5 Total 
eGFR ≥90 n=44965 
F 52.4% 
Age 48.6±16.6 
n=14339 
F 64.5% 
Age 48.4±11.6 
-- -- -- -- 59304 
(48.1%) 
eGFR 60-89 n=4155 
F 64.8% 
Age 80.4±6.3 
n=42921 
F 54.6% 
Age 65.8±12.9 
n=2307 
F 81.1% 
Age 59.4±11.4 
-- -- -- 49384 
(40.1%) 
3A -- n=481 
F 32.0% 
Age 86.2±5.4 
n=8769 
F 64.0% 
Age 74.6±10.6 
n=334 
F 85.6% 
Age 60.1±10.7 
-- -- 9584 
(7.8%) 
3B -- -- n=368 
F 50.0% 
Age 86.4±5.6 
n=3447 
F 67.5% 
Age 77.6±10.6 
n=28 
F 75.0% 
Age 55.5±10.7 
-- 3843 
(3.1%) 
4 -- -- -- n=153 
F 60.1% 
Age 86.6±5.5 
n=755 
F 67.1% 
Age 75.8±13.0 
n=6 
F 83.3% 
Age 46.5±10.3 
914 
(0.7%) 
5 -- -- -- -- n=15 
F 60.0% 
Age 83.9 ± 5.3 
n=87 
F 57.3% 
Age 70.6±14.3 
102 
(0.1%) 
Total 49120 
(39.9%) 
57741 
(46.9%) 
11444 
(9.3%) 
3934 
(3.2%) 
798 
(0.7%) 
94 
(0.1%) 
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Table 6-3 – Change in the prevalence of CKD in the study population (i.e. those patients with blood samples 
taken during the study year) when using CKD-EPI formulae instead of MDRD4 eGFR formula 
 
 
Figure 6-5 - Relationship between age and the difference in eGFR calculated using the CKD-EPI formulae 
and the MDRD4 study formula 
 
 
 
Sex 
 
Age (years) 
 
CKD stage 
 
Overall 
 M F < 20 20-39 40-59 60-69 ≥70 
eGFR 
≥90 
 
8.1% 
 
4.4% 
 
11.2 
 
7.3% 
 
17.7% 
 
21.4% 
 
9.9% 
 
-10.7% 
eGFR 
60-89 
 
-6.6% 
 
-4.1% 
 
-8.6% 
 
-7.1% 
 
-16.9% 
 
-19.1% 
 
-6.5% 
 
10.6% 
3A  
-1.6% 
 
-0.4% 
 
-2.5% 
 
-0.2% 
 
-0.7% 
 
-1.9% 
 
-2.9% 
 
-0.8% 
3B  
-0.1% 
 
0.2% 
 
-0.3% 
 
-- 
 
-0.1% 
 
-0.2% 
 
-0.5% 
 
0.5% 
4  
0.1% 
 
0.1% 
 
0.1% 
 
-- 
 
-- 
 
-- 
 
-- 
 
0.3% 
5  
-- 
 
-0.01% 
 
0.01% 
 
-- 
 
-- 
 
-- 
 
-- 
 
0.1% 
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Table 6-4 - Measured and derived CKD prevalence in NHS Ayrshire & Arran (A&A) in 2009-10. 
Calculations based on laboratory eGFR (using the CKD-EPI formulae), census population estimates, 
(240)and the application of prevalence estimates from the NHANES (47) and the HSE to the NHS A&A 
population 
 
Age Band 20-39 yrs 40-59 yrs 60-69 yrs ≥70 yrs 
CKD stage 3 4 3 4 3 4 3 4 
Prevalence in NHANES 
population (%) 
0.17 0.01 2.04 0.05 10.06 0.72 35.33 2.44 
Prevalence in HSE 
population (%) 
0.10 ----- 0.89 0.11 3.66 1.08 28.26 0.58 
Identified prevalence in 
A&A population (% ) 
0.15 0.02 0.85 0.07 5.03 0.21 20.84 1.52 
A&A unbled population 
(n) 64,967 68,311 18,994 10,103 
Predicted prevalence in 
A&A unbled 
population (NHANES 
data) 0.02 ----- 1.86 ----- 12.3 1.24 69.42 
 
4.39 
Predicted prevalence in 
A&A unbled 
population (HSE data) 
 
----- ----- 0.06 0.07 ----- 2.12 35.54 ----- 
182 
6.3.1 Comparison of 2004 and 2009-2010 cohorts 
The characteristics of the 2004 cohort are shown in table 6.1. The proportion bled by age 
group has been published previously (241). From 2004 to 2009-10, the number of serum 
samples analysed for creatinine in our laboratory has increased by 28% from 341,928 to 
438,872. The total adult population has grown by 0.5%, whereas the number of individual 
adults having their serum creatinine measured increased by 20% from 102,322 to 123,121. 
The change in prevalence of CKD between the two time periods is shown in table 6-5 
below, according to MDRD4 and CKD-EPI formulae. 
 
Table 6-5 – Change in general adult population CKD prevalence between 2004 and 
2009-10. eGFR was calculated using the MDRD4 formula or the CKD-EPI formulae 
 
MDRD 4 CKD EPI  
eGFR 
2004 2009/10 
Prevalence 
Change 
2004 2009/10 
Prevalence 
Change 
≥ 90 11.7% 16.9% 5.2% 15.1% 20.4% 5.3% 
60-89 18.2% 19.8% 1.6% 15.3% 17.0% 1.7% 
3A 3.8% 3.9% 0.1% 3.3% 3.3% -- 
3B 1.3% 1.4% 0.1% 1.3% 1.3% -- 
4 0.3% 0.3% -- 0.3% 0.3% -- 
5 0.04% 0.03% -0.01% 0.04% 0.04% -- 
Stages 3-5 5.44 5.63 +0.19 4.94 4.94 -- 
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6.4 Discussion 
 
6.4.1 Findings of this study  
Our study shows that changing from the MDRD4 formula to the CKD-EPI formulae to 
measure eGFR in a UK population, would result in a small reduction in the overall 
prevalence of CKD stage 3A by 0.6% (from 5.6% to 4.9%), with most of these patients 
reclassified to eGFR >60 mL/min/1.73m
2
. There is relatively little reclassification of CKD 
stage seen with more severe kidney disease. The 17014 (5.8% of the adult population) 
patients reclassified to milder stages of CKD are mainly female (67%) with a mean age of 
50±12.2 years. Additionally, we found that the CKD-EPI formulae reclassified 5,172 
(1.8%) of patients to more severe CKD stages, mostly affecting elderly females (mean age 
81.5±6.6 years). Kidney function was assessed in a remarkably large proportion of the 
adult population with 42% assessed in 2009-10 (compared to 35% in 2004), rising to a 
peak of 86% in those aged 85-89 years. Of note, there was no rise in population CKD 
prevalence between 2004 and 2009-10 when eGFR was assessed by the CKD-EPI 
formulae, and only a small rise of 0.2% when using the MDRD4 formula, despite the 
increasing numbers being assessed. 
 
6.4.2 Other studies of CKD prevalence  
The CKD-EPI formulae were derived in 5504 subjects from 10 studies with formal GFR 
measures performed. The formulae were validated in 2750 additional subjects from the 
same studies, and also against an external set of 3896 subjects from 16 other studies. The 
mean GFR from the combined populations was 68 mL/min/1.73m
2
, 44% were female, 
71% were white and the mean age was 48 years. The CKD-EPI formulae in these studies 
estimated GFR as accurately as the MDRD4 formula in subjects with eGFR <60 
mL/min/1.73m
2
, but was more accurate at higher levels of eGFR. Precision remained 
relatively poor.  
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Levey and colleagues assessed the impact of the different formulae on CKD prevalence, 
using the NHANES 1999-2006 population (47). They found a rise in mean eGFR of 6.9 
mL/min/1.73m
2
, and a fall of 1.5% in prevalence of stage 3 CKD using the CKD-EPI 
formulae. Women and those aged 20-69 years had a disproportionate reduction in 
prevalence of CKD. An Italian study of 38,188 patients calculated eGFR using both 
formulae (242). The estimated prevalence of CKD fell by 1.6% using the CKD-EPI 
formulae, with a significant drop in the prevalence of stage 2 disease (15.3%). In a cohort 
of 14,427 Spanish patients, the mean eGFR was 0.6 mL/min/1.73m
2
 higher with CKD-EPI 
than MDRD4, and CKD-EPI led to reclassification of patients to lower stages of CKD, 
particularly affecting stages 2, 3A and 3B, women and those <70 years old. In keeping 
with our study, they found some reclassification of older females to higher CKD stages 
with CKD-EPI (243). Similarly a Dutch population based cross-sectional survey of 6097 
participants concluded that the CKD-EPI formulae provide higher estimates of GFR than 
the MDRD4 formula. However, women >75 and men >70 years had lower median eGFR 
values (244). A Belgian screening study of 1,992 volunteers aged between 45-84 years old 
showed mean eGFR to be 2 mL/min/1.73m
2
 higher with CKD-EPI, and prevalence of 
CKD stage 3 fell from 11.04 to 7.98%, with greater impact in women(245). Compared to 
these studies, we found a relatively small change in CKD prevalence when using the CKD-
EPI formulae. This is at least in part because our population is substantially older, and the 
reduction in CKD amongst adults under 70 years old is partially offset by the increased 
prevalence amongst the elderly, as could be predicted from Figure 5. Two other UK 
studies, in Oxfordshire and East Kent, have both reported similar findings regarding the 
relationship of lower CKD-EPI eGFR estimation with increasing age (246, 247). Of note, 
only 0.6% of the CKD-EPI population were >80 years old, and only 5.3% over 70 years 
old. A recent large UK primary care study found an overall reduction in CKD prevalence 
using CKD-EPI, but fluctuation in eGFR measurements accounted for a greater proportion 
of the change in prevalence, than changing formulae (248).  
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6.4.3 Limitations 
This study has a number of limitations. There was no formal GFR measurement performed 
to allow direct comparison with the prediction formulae. The serum creatinine assay 
changed between the two study periods but both were converted to the IDMS-traceable 
serum creatinine value before the eGFR was calculated, thereby minimising bias. We 
defined patients as having CKD on the basis of a single eGFR, rather than two samples 
>90 days apart, but we minimised the impact of this by using the lowest serum creatinine 
available for each patient in the study year. Nevertheless, we may have over-diagnosed 
CKD in some patients. The strength of our study is its size, and that the population is 
unselected and clinically relevant. 
 
Our study cohort comprised patients who have had kidney function assessed for a clinical 
indication, raising the possibility of some selection bias. To ascertain true population 
prevalence would require a population survey. In order to explore this we calculated the 
required prevalence in the unbled population to produce comparable prevalence to the 
NHANES population (adjusting for our older population). Using this method the 
prevalence in the unbled population is high. Whilst there will be some unidentified CKD, it 
seems unlikely to be the complete explanation. Compared to the NHANES population, our 
population has a slightly higher proportion of females, and a far higher proportion of 
whites, both of which should lead to higher rather than lower CKD prevalence. 
Furthermore, NHANES excluded adults living in institutions, who have a high prevalence 
of CKD (249), whereas our data includes such patients. It therefore seems likely that our 
population has a genuinely lower prevalence of CKD than in the USA. Previous estimates 
of the prevalence of kidney disease in the UK have varied substantially (250). Despite the 
different methodological approach of the Health Survey for England, and allowing for their 
relatively small sample size (n=2,171), our CKD prevalence rates are similar (251). This 
suggests that age-adjusted CKD prevalence is genuinely lower in the UK than in the USA. 
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A study with a similar design to this one, from the South of England, found similar 
prevalence at 4.4% with the CKD-EPI formulae and 4.9% using MDRD4 (247). Larger 
population-based surveys of CKD prevalence would be warranted in the UK to give more 
precise estimates of prevalence over time. 
 
6.4.4 Outcomes and the CKD-EPI formulae 
Three studies have assessed clinical outcomes in patients who have been reclassified by the 
CKD-EPI formulae. The AUSDIAB study compared outcomes in three categories of 
patients: those with CKD by both equations, those with CKD only by MDRD4 and those 
without CKD by either formula (252). In keeping with our study, they found that those 
reclassified were mainly women. They found no evidence of increased all-cause mortality 
in the reclassified group, suggesting that they are low-risk individuals. A similar post hoc 
analysis of the ARIC study (253) found reclassified individuals were more likely to be 
female, middle-aged and white. Moreover the reclassification of this sub-group was more 
appropriate with regard to their comparable risk of unfavourable outcomes such as end-
stage renal disease, all cause mortality, coronary heart disease and stroke. An analysis of 
the participants of the kidney early evaluation programme (KEEP), a community based 
CKD screening programme in the Unites States, found the reclassified group to be 
younger, less likely to have chronic conditions and had a lower risk of mortality (254).  
There are no outcome studies from the UK. In our study population, 1.8% of subjects were 
reclassified to higher stages of CKD – no patients in ARIC and few in AUSDIAB were 
reclassified in this way. It will be of importance to examine outcomes in this group before 
the equation is implemented in clinical laboratories. 
 
In practical terms, the implementation of the routine use of eGFR CKD-EPI formulae in 
place of the MDRD4 formula in the United Kingdom, would result in fewer people being 
identified as suffering from CKD, without apparent increased risk to those reclassified to 
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milder disease (though this should be confirmed in a UK population). The resultant fall in 
the number undergoing routine monitoring may result in reduced medicalisation of 
patients, and reduce the financial burden and workload in primary care. However, a large 
proportion of those on primary care CKD registers also suffer from hypertension, vascular 
disease and/or diabetes mellitus and would continue to receive similar monitoring as a 
result of these other conditions. The magnitude of any potential saving would have to be 
directly assessed. Implementation costs would be low, as it requires no change to 
instrumentation or assays. 
 
6.5 Conclusion  
Measurement of eGFR using the CKD-EPI equation reduced the overall prevalence of 
CKD, in particular stage 3A, in a predominantly Caucasian general population cohort. This 
was particularly prominent in females and those middle-aged. Using the MDRD4 formula, 
there is an apparent rise in CKD prevalence over the study time period, but this is not seen 
when using the CKD-EPI formulae. The CKD-EPI formulae may reduce overdiagnosis of 
CKD, but further assessment in the elderly is required before widespread implementation. 
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7 Chapter 7: Assessing Patient Outcomes In 
Hypertension: The Predictive Ability Of Proteinuria 
And Estimated Glomerular Filtration Rate 
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7.1 Introduction 
Impaired excretory renal function and proteinuria are associated with an increased risk of 
cardiovascular morbidity and mortality as described in detail in the introduction. This has 
been shown in the general population (20) and in groups already at increased risk of 
vascular disease (255-257). In hypertensive patients, reduced renal function is associated 
with a greater likelihood of all cause and cardiovascular mortality, (258, 259). 
Furthermore, albuminuria predicts cardiovascular risk in this group (260), even at levels 
below the traditional threshold for microalbuminuria (5, 261). There is limited evidence of 
the effects of these markers in combination in a hypertensive population, with only 2 
studies to date having evaluated the combination of these risk markers in a hypertensive 
population (262, 263) and this study extends the scope of those findings with the results 
from the Glasgow Blood Pressure Clinic (GBPC), a large secondary and tertiary care 
hypertensive cohort.  Kidney function and urine protein have been recorded, in this large 
cohort of hypertensive patients in the West of Scotland since the 1960’s.  
 
In chapters 2-5 we have focused on proteinuria in patients with CKD and chapter 6 focused 
on how to measure eGFR in the general population. The aim of this study was to assess the 
utility of eGFR and proteinuria as individual and combined predictors of all-cause and 
cardiovascular mortality in a high risk hypertensive population.  
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7.2 Methods 
7.2.1 Clinical Measurements and Laboratory Assays 
Blood pressure was measured manually by specialist hypertension nurses. Patients were 
asked to rest for five minutes in the supine position before blood pressure was recorded, 
using standard mercury sphygmomanometers. It was measured three times and the mean of 
the last two measurements recorded. Blood pressure was recorded between 09:00 hours 
and 11:00 hours for all patients.  
 
Proteinuria was measured by urine dipstick and considered to be positive if it was greater 
than or equal to “1+”. This correlates to approximately greater than or equal to 0.3g/L of 
urinary protein.  
 
Laboratory measurements were performed using standard operating procedures in the 
biochemistry and haematology laboratories of the Western Infirmary, Glasgow. The 4 
variable MDRD formula was used to calculate eGFR (44, 215). It was not possible to 
calculate IDMS traceable values for serum creatinine. Data regarding race were not 
available, but the population of the West of Scotland is predominantly Caucasian with less 
than 0.25% being black. (217) 
 
7.2.2 Participants and Setting 
The Glasgow Blood Pressure Clinic is a secondary and tertiary referral clinic for patients 
with hypertension in the West of Scotland. It has a computerised database of all patients 
attending the clinic since November 1968, on which demographic and clinical data are 
prospectively recorded. The records of more than 11 000 patients are held. For the 
purposes of this analysis, the last new patient was added to the database on 17
th
 September 
2003, and followed up until February 2009.  
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Patients with at least one measure of serum creatinine and urine protein were included in 
the study. Patients were excluded from the analysis if they were less than 18 years old, or 
had a baseline eGFR of less than 15ml/min/1.73m
2
. Baseline clinical and demographic data 
recorded included age, gender, blood pressure (BP) and serum creatinine, dipstick 
urinalysis, body mass index, haemoglobin, serum albumin, total cholesterol, diagnosis of 
diabetes or vascular disease. Subsequent measurements of blood pressure were also 
downloaded. Outcome data were obtained from the General Register Office for Scotland 
which records date and cause of death (according to the International Classification of 
Disease 9 and 10). All patient data were anonymised.  
 
7.2.3 Ethical Permission 
Ethical approval has been received for analysis of the GBPC cohort. 
 
7.2.4 Statistical Analysis 
Data were analysed using SPSS Version 15 (SPSS Inc, Chicago, Ill, USA). Renal 
dysfunction was classified according to the international CKD Staging System (5), using 
eGFR and other markers of kidney damage such as urinary or structural abnormalities.  
 
Smoking was recorded as current smoker, ex-smoker or lifelong non-smoker. Diabetes was 
defined as random blood glucose ≥11.1mmol/L, receiving diabetic medication or patient 
reported diagnosis. Vascular disease was defined as a definitive vascular event or 
angiographically proven peripheral vascular disease. Cardiovascular mortality was defined 
as a cardiovascular cause listed in Part I of the death certificate (according to ICD 9 and 10 
codes). The cohort was divided into two groups according to eGFR (≥60ml/min/1.73m
2 
or 
<60ml/min/1.73m
2 
as this is the important clinical threshold) and the presence or absence 
of dipstick proteinuria, producing four groups. Summary statistics are presented as mean ± 
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standard deviation or median (interquartile range). Significance testing was performed 
using one way analysis of variance (ANOVA) with post-hoc tests (Tukey), the Chi squared 
test, Fisher’s exact test and paired t-test as appropriate.  Survival analysis was performed 
using Cox proportional hazards regression, using a forward stepwise conditional model. 
The assumptions of proportionality were assessed using log minus log plots and 
Schoenfeld residuals. There was no violation of these assumptions. To take account of 
variation between time periods, a variable was constructed which divided the cohort into 
quintiles according to the date of baseline measurements with the first quintile being the 
earliest, and this was included in the survival model (quintile 1; 1968 – 1975, quintile 2; 
1976 – 1983, quintile 3; 1984 – 1989, quintile 4; 1990 – 1995, quintile 5; 1996 – 2003) . 
The analyses were repeated, excluding those with follow-up <2 years, to ensure the 
findings were robust. 
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7.3 Results 
7.3.1 Demographics of the cohort  
A total of 11397 patients who attended the Glasgow Blood Pressure Clinic between 6
th
 
November 1968 and 17
th
 September 2003 were identified. One thousand four hundred and 
sixteen patients were excluded as they had no recorded measure of kidney function, and a 
further 1445 patients were excluded as they did not have a documented measure of urinary 
protein. Those under 18 years of age (n=29) and those with an eGFR <15ml/min/1.73m
2
 at 
baseline (n=31) were also excluded. A flowchart of the exclusions is shown in Figure 7-1. 
The baseline demographics of the remaining 8476 participants are presented in Table 7-1. 
One thousand nine hundred and fifty three (23.0%) had a baseline eGFR of 
<60ml/min/1.73m
2
, 1827 (21.6%) had proteinuria detected by dipstick and 545 (6.4%) had 
both. Median follow-up was 15.2 years (interquartile range 9.4, 22.9). Those with a 
reduced eGFR (<60ml/min/1.73m
2
) were older, more hypertensive, and had a greater 
burden of diabetes and vascular disease at baseline (p<0.001).  
Figure 7-1 - Flowchart of the population and exclusions 
Initial Population
(n=8,536)
eGFR< 15ml/min/1.73m2
(n=31)
Age <18 yrs (n=29)
Cox Regression Population
(n= 8092)
Study Population
(n=8,476)
Missing data 
(n= 384)
Reference gp eGFR>60ml/min/1.73m2, p- (n=5241)
Group 1 eGFR>60ml/min/1.73m2, p+ (n=1282)
Group 2 eGFR<60ml/min/1.73m2, p- (n=1408)
Group 3 eGFR<60ml/min/1.73m2, p+ (n=545)
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Table 7-1 – Baseline demographics for the 8476 participants. Results are presented as mean ±standard 
deviation, median (interquartile range) or percentage of cohort with the described characteristic 
 
Variable 
 
All eGFR 
>60, p- 
eGFR 
>60, p+ 
eGFR 
<60, p- 
eGFR 
<60, p+ 
Sig % 
available 
n 
 
8476 5242 1282 1407 545 - - 
Age  
(years) 
50.3 ± 
13.3 
47.9 ± 
12.5 
46.9 ± 
13.4 
59.3 ± 
10.3 
58.6±  
13.1 
P<0.001 100 
Gender  
(% male) 
48 49 56 34 50 P<0.001 100 
Serum creatinine 
(µmol/l) 
89  
(77 – 
104) 
82  
(73 – 94) 
86  
(78 – 98) 
114  
(97 – 130) 
128  
(110 – 
159) 
P<0.001 100 
eGFR  
(ml/min/1.73m
2
) 
73  
(61-85) 
78  
(69 – 90) 
77  
(68 – 88) 
52  
(46 – 57) 
47  
(37 – 55) 
P<0.001 100 
Diabetes  
(%) 
7 6 9 8 12 P<0.001 100 
SBP  
(mmHg) 
169 ± 29 167 ± 27 164 ± 27 179 ± 31 181 ± 32 P<0.001 100 
DBP  
(mmHg) 
100 ± 15 100 ± 14 100 ± 14 101 ±  16 101 ±  18 P=0.021 100 
Pulse pressure 
(mmHg) 
69 ± 23 67 ± 21 64 ± 21 78 ± 25 80 ± 27 P<0.001 100 
BMI  
(kg/m
2
) 
27.6  
±5.3 
27.4 ±5.2 28.7± 6.1  27.4 ± 5.0 27.9 ± 5.2 P<0.001 98.4 
Vascular disease at 
baseline (%) 
 
10 8 7 16 17 P<0.001 100 
Current smoker  
(%) 
29 30 26 26 28 P<0.001 95.5 
Cholesterol  
(mmol/L) 
6.1 ± 1.3 6.0 ± 1.2 5.9 ± 1.2 6.4 ± 1.3 6.3 ± 1.5 P<0.001 80.7 
Haemoglobin  
(g/dL) 
 
14.4 ± 
1.5 
14.6 ± 1.4 14.5 ± 1.5 14.1 ± 1.6 13.8 ± 1.8 P<0.001 93.5 
Serum Albumin  
(g/L) 
44 ± 4 44 ± 3 45 ± 3 43 ± 4 43 ± 4 NS 64.8 
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7.3.2 Hypertension 
The baseline and last follow-up blood pressure recordings are presented, divided into four 
groups according to eGFR (≥60 or <60ml/min/1.73m
2
 and presence (+) or absence (-) of 
proteinuria) in figure 7-2. There were significant differences in the baseline systolic BP 
between the four groups using an ANOVA with post-hoc analysis (except between 
eGFR<60 p- and eGFR<60 p+ groups). On follow-up, mean systolic and diastolic BP was 
significantly lower than baseline in all groups (paired t-test). However the differences in 
follow-up systolic BP between the groups remained statistically significant (p<0.005) 
except between eGFR<60 p- and eGFR<60 p+, as before. When the analysis was limited to 
the modern era of blood pressure targets (baseline measurements from 1990 onwards, 
n=3333), the initial and follow-up blood pressures were lower but the relationship of 
higher baseline and follow-up blood pressure, depending on severity of renal disease, 
remained. 
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Figure 7-2 - Baseline and follow up blood pressures divided according to eGFR (threshold 
60ml/min/1.73m
2
) and presence of proteinuria 
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7.3.3 Outcomes 
A total of 3562 participants died during the follow-up period. Of these, 2522 (70.8%) died 
as a result of vascular disease. Overall median time to death from baseline blood pressure 
measurement was 11.7 years (interquartile range 6.2, 18.5). Increasing age, male gender, 
reduced GFR and /or urinary protein, diabetes, smoking, higher baseline systolic BP, 
higher baseline diastolic BP, higher cholesterol at baseline and the presence of vascular 
disease at baseline (Table 7-2) were individually associated with increased all cause and 
cardiovascular mortality. Joining the cohort in an earlier era was also associated with 
increased all-cause and cardiovascular mortality, and this was subsequently included in the 
multivariate model to take account of this influence. These variables were then entered into 
a multivariate Cox regression (Table 7-3). For all-cause mortality diastolic BP and 
cholesterol were not included as independent predictors of outcome while for 
cardiovascular mortality diastolic BP was no longer included.  Both low eGFR and 
presence of proteinuria were associated with a greater likelihood of both outcomes.  
Survival curves from the multivariate Cox regression for all cause mortality and 
cardiovascular mortality, according to these markers of kidney disease, are shown in figure 
7-2 and 7-3 (respectively). Exclusion of those with < 2 years follow-up did not influence 
the model. 
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Table 7-2 – Univariate analyses derived from a Cox regression model for all-cause mortality and 
cardiovascular (CV) mortality, with hazard ratios and 95% confidence intervals shown in brackets 
 
 All-cause 
mortality 
Significance CV mortality Significance 
Age 
(per 10 years) 
1.95 
(1.089 – 2.00) 
P<0.001 1.93 
(1.87 – 2.00) 
P<0.001 
Male Sex 1.41 
(1.32 - 1.50) 
P<0.001 1.52 
(1.41 - 1.65) 
P<0.001 
 eGFR< 60 
(ml/min/1.73m
2
) 
2.17 
(2.02 – 2.32 ) 
P<0.001 2.27 
(2.09 – 2.46 ) 
P<0.001 
Presence of 
urinary protein 
1.25 
(1.15 - 1.36) 
P<0.001 1.25 
(1.13 - 1.38) 
P<0.001 
Diabetes 
 
1.47 
(1.31 - 1.65) 
P<0.001 1.60 
(1.40 - 1.83) 
P<0.001 
SBP 
(per 10 mmHg) 
1.14 
(1.13 - 1.16) 
P<0.001 1.16 
(1.14 - 1.17) 
P<0.001 
DBP 
(per 10 mmHg) 
1.13 
(1.11 - 1.15) 
P<0.001 1.17 
(1.14 - 1.20) 
P<0.001 
Current smoker 1.85 
(1.72 – 2.00) 
P<0.001 1.96 
(1.79 – 2.14) 
P<0.001 
Cholesterol  
(per mmol/L) 
1.11 
(1.08 – 1.15) 
P<0.001 1.15 
(1.11 – 1.19) 
P<0.001 
Presence of 
vascular disease 
at baseline 
2.51 
(2.30 - 2.75) 
P<0.001 2.95 
(2.67 – 3.26) 
P<0.001 
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Table 7-3 – Multivariate analyses derived from a Cox regression model for all-cause mortality and 
cardiovascular (CV) mortality, with hazard ratios and 95% confidence intervals shown in brackets 
 
 All-cause 
mortality 
Significance CV mortality Significance 
Age 
(per 10 years) 
2.01 
(1.94 – 2.09) 
P<0.001 2.06 
(1.96 – 2.17) 
P<0.001 
Male Sex 1.60 
(1.49 – 1.72) 
P<0.001 1.78 
(1.61 – 1.96) 
P<0.001 
 eGFR< 60 
(ml/min/1.73m
2
) 
1.25 
(1.16 – 1.35) 
 P<0.001 1.32 
(1.19 – 1.46) 
P<0.001 
Presence of 
urinary protein 
1.37 
(1.26 – 1.50) 
P<0.001 1.47 
(1.30 – 1.65) 
P<0.001 
Diabetes 
 
1.25 
(1.11 – 1.41) 
P<0.001 1.35 
(1.16 – 1.57) 
P<0.001 
SBP 
(per 10 mmHg) 
1.04 
(1.03 – 1.05) 
P<0.001 1.05 
(1.03 – 1.07) 
P<0.001 
Current smoker 1.84 
(1.70 – 1.98) 
P<0.001 1.88 
(1.69 – 2.08) 
P<0.001 
Cholesterol  
(per mmol/L) 
- - 1.08 
(1.04 – 1.12) 
P<0.001 
Presence of 
vascular disease 
at baseline 
1.46 
(1.33 – 1.60) 
P<0.001 1.84 
(1.63 – 2.08) 
P<0.001 
 Quintile 1 
(earliest era) 
1 (Ref gp) - 1 (Ref gp) - 
Quintile 2 0.80 
(0.74 – 0.88) 
P<0.001 0.78 
(0.70 – 0.88) 
P<0.001 
Quintile 3 0.58 
(0.53 – 0.65) 
P<0.001 0.54 
(0.47 – 0.63) 
P<0.001 
Quintile 4 0.51 
(0.45 – 0.57) 
P<0.001 0.39 
(0.33 – 0.46) 
P<0.001 
Quintile 5 0.38 
(0.32 – 0.45) 
P<0.001 0.32 
(0.26 – 0.40) 
P<0.001 
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Figure 7-3 - Survival curve for all cause mortality according to the presence of proteinuria and 
reduced eGFR 
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Figure 7-4 - Survival curve for cardiovascular mortality according to the presence of proteinuria and 
reduced eGFR 
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p- - no proteinuria detected on dipstick; p+ - proteinuria detected on dipstick 
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In order to combine urinary protein and eGFR as predictors of outcome, the cohort was 
divided into 4 groups using eGFR (greater or less than 60ml/min/1.73m
2
) and presence or 
absence of proteinuria, and then entered into the model as a categorical variable, with age, 
sex, smoking, cholesterol, SBP, history of diabetes, history of vascular disease and the time 
quintiles as covariates. The group with eGFR>60ml/min/1.73m
2 
and no detectable 
proteinuria was the reference group, and the results are shown in table 7-4.  
 
Table 7-4 – Adjusted hazard ratios derived from a multivariate Cox regression model, using eGFR and 
proteinuria as combined categorical variables for all-cause and cardiovascular (CV) mortality. 95% 
confidence intervals shown in brackets 
 
 All-cause mortality CV mortality 
eGFR≥60ml/min, p- 1 (Reference) 
 
1 (Reference) 
eGFR≥60ml/min, p+ 1.24 (1.11 – 1.39) 
 
1.29 (1.12 – 1.47) 
eGFR<60ml/min, p- 1.18 (1.08 – 1.29) 
 
1.25 (1.12 – 1.38) 
eGFR<60ml/min, p+ 1.88 (1.66 – 2.14) 
 
2.07 (1.79 – 2.40) 
 p+ - detectable proteinuria; p- - no detectable proteinuria 
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7.4 Discussion 
7.4.1 Findings of this study  
In this study we show that eGFR and dipstick proteinuria measurements at first referral to a 
specialist hypertension clinic are strong independent predictors of long-term mortality, 
independently and in combination. The patients referred to the GBPC are those who are 
difficult to treat in primary care; they have been treated and followed up in primary 
practice before referral to the blood pressure clinic for treatment escalation, extensive 
investigation and specialist follow-up. In this setting, despite specialist follow-up, eGFR 
and dipstick proteinuria at presentation are powerful predictors of long-term outcomes. 
 
There was a significant burden of kidney dysfunction in this study cohort; 23% had 
reduced excretory renal function (eGFR<60ml/min/1.73m
2
) and 22% had proteinuria 
detectable on urinary dipstick. Over one third (38.2%) had at least one of these 
manifestations of kidney disease, but only 6% had both. This is considerably higher than 
prevalence estimates of the general population, such as NHANES 1999 – 2004, when 8% 
had an eGFR<60ml/min/1.73m
2
, and 1.3% had frank proteinuria (24). However, it is in-
keeping with the prevalence of a reduced eGFR in a recent Italian study -of a primary care 
hypertensive population; proteinuria data were not available in that cohort (264).  
 
This finding highlights the importance of evaluating both eGFR and proteinuria in 
hypertensive patients as the tests identify two high risk groups and refines risk for the 
small number with both abnormalities. It is not necessarily surprising that these markers 
identify different sub-groups, as the primary underlying pathophysiological mechanisms 
may be different; loss of nephron mass secondary to glomerulosclerosis leading to reduced 
excretory capacity versus widespread endothelial dysfunction leading to proteinuria. For a 
minority with ongoing significant proteinuria, this will lead to renal interstitial fibrosis, 
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further glomerulosclerosis, progressive kidney disease and cardiovascular disease. Thus 
the highest risk group is those with both abnormal findings (reduced eGFR and 
proteinuria), as shown in this study. All cause and cardiovascular mortality increased with 
falling eGFR. This effect persisted after adjustment for other major cardiovascular risk 
factors including age, sex, blood pressure and smoking. The presence of urinary protein 
was also a strong predictor of mortality in this cohort. When reduced eGFR and proteinuria 
are combined in the survival model, the adjusted hazard ratio is significantly higher than 
for either parameter alone.  The combination of a preserved eGFR but the presence of 
proteinuria was associated with a higher risk of all-cause and cardiovascular mortality than 
the converse, a reduced eGFR but no proteinuria, though the confidence intervals overlap.  
 
7.4.2 Role of reduced eGFR and proteinuria in patients at high 
cardiovascular risk 
There is extensive evidence supporting eGFR and proteinuria as predictors of 
cardiovascular disease and death in the general population, in the elderly, in high CV risk 
cohorts (1-4, 20-22). The CKD Prognosis consortium meta-analysis of these predictors in 
the general population showed that an eGFR<60ml/min/1.73m
2
 and an ACR of 
≥1.1.mg/mmol (or a trace or more of urinary protein on dipstick) are strong independent 
predictors of cardiovascular and all-cause mortality (20). These factors are more powerful 
predictors of risk when combined in the general population (198), and stratified by age 
(265). Various high risk groups have also been studied; for instance in the HOPE (Heart 
Outcomes and Prevention Evaluation) study of participants with a history of cardiovascular 
disease or diabetes mellitus and at least one cardiovascular risk factor, but serum creatinine 
<200µmol/L, both renal insufficiency and albuminuria were predictors of subsequent 
cardiovascular events (255, 256). This relationship was confirmed in the elderly by the 
Cardiovascular Health Study, which showed microalbuminuria and elevated cystatin C to 
be predictors of cardiovascular events and mortality (266). Most recently, a meta-analysis 
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of albuminuria and reduced GFR in high risk populations, identified by diabetes, 
cardiovascular disease or hypertension, has confirmed this strong relationship (257). 
 
The combined role of eGFR and proteinuria in hypertensive cohorts is evident from a post-
hoc analysis of the Nordic Diltiazem study which showed eGFR and ACR to be predictors 
of cardiovascular disease in the trial cohort of 10 881 participants, and a small Italian study 
of 837 hypertensive patients showed the combination of reduced eGFR and proteinuria 
(measured by ACR) to be a risk factor for cardiovascular events and all-cause mortality. 
We have recapitulated and extended this relationship, in our large unselected cohort with 
long follow-up and more than 4000 deaths including a wider range of kidney function and 
using a cheaper and easier means of detecting proteinuria. Our study has shown a reduction 
in excretory renal function (eGFR<60ml/min/1.73m
2
), accompanied by dipstick 
proteinuria is associated with approximately doubling of all-cause and cardiovascular 
mortality. All the patients were managed according to the contemporaneous British 
Hypertension Society guidelines and show significant reduction in BP during follow-up at 
the clinic, but the increased risk, associated with markers of kidney disease, remained. 
 
7.4.3 Limitations 
The current study has several limitations. Firstly, it is retrospective. Urinary protein was 
measured by dipstick, which is reliant on the urine concentration and flow rate, though all 
samples were taken at the same time of day. We may have overestimated the prevalence in 
our cohort, by using single samples of blood and urine; however, even taking this into 
account, the prevalence is high. Generally prevalence estimates from single samples may 
overestimate because of intercurrent illness leading to acute renal dysfunction. As our 
cohort was attending a blood pressure clinic as asymptomatic out-patients, the impact is 
likely to be marginal. The inclusion period is long, but the data were collected consistently 
and recorded reliably and prospectively over the whole time period, and an era covariate 
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was included in the survival model to take account of secular trends. The use of renin-
angiotensin system inhibitors was not included in the multi-variate analysis, since such 
drugs were not in use at the inception of the cohort, and while these reduce proteinuria, the 
residual level of proteinuria is strongly predictive of outcome, and this is still captured in 
this analysis. Furthermore, while renin angiotensin system blockers may slow the 
progression to renal disease, there is little evidence for specific reduction in cardiovascular 
outcomes or mortality in hypertension. An index of deprivation was not included in the 
multi-variate analysis as this was not available. The strength of the study lies in its 
representative nature: a large unselected population attending a hypertension clinic. The 
use of urinary dipstick to assess proteinuria does have some strengths; dipsticks are cheap, 
easy to use and allow an assessment of proteinuria at the point of care, which is 
particularly important in resource scarce healthcare environments.  
 
7.4.4 Conclusion 
In conclusion, in this large cohort of patients with severe and difficult to treat hypertension, 
simple measures of dipstick urinary protein and eGFR at presentation are  powerful 
predictors of future risk of all-cause and cardiovascular mortality. These data illustrate the 
utility of the combined measurement of eGFR and proteinuria. They are essential to aid 
accurate risk stratification across a spectrum of patients with hypertension, in order to 
allow intensive treatment to be targeted at those at greatest risk, and should be included in 
the assessment of cardiovascular risk in primary care and specialist practice.  
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8 Chapter 8: Assessing the Impact of CKD in the 
community: the Triple A Kidney Project 
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8.1 Introduction 
Chronic kidney disease (CKD) affects 6 - 13% of the population as outlined in detail in the 
introduction (250). The vast majority of people with CKD do not develop advanced kidney 
disease requiring dialysis. However it is thought to be important to recognise patients with 
early CKD because it is associated with an increased risk of vascular disease (179), and to 
minimise risk of progression to advanced kidney disease requiring renal replacement 
therapy. The mechanisms governing the excess burden of cardiovascular disease are poorly 
understood and it is not known if traditional cardiovascular risk factors are relevant in 
patients with CKD. It is also not clear whether cardiovascular risk assessment tools used in 
the general population should also be utilised in patients with CKD. As we have shown in 
earlier chapters, there is growing evidence that other non-traditional risk factors, such as 
persistent proteinuria are associated with cardiovascular disease. 
 
In the UK, the majority of patients with CKD are looked after by their General 
Practitioner. This arrangement was formalised by the Quality and Outcomes Framework, 
as described in the introduction. However the majority of evidence available to guide the 
management of patients with CKD comes from studies of patients attending hospital 
clinics. Assuming that the patients in primary care can be treated in the same way may be 
unwise, as the patients under hospital follow-up are a selected population with more severe 
disease and a higher risk of developing complications.  
 
In this study I recruited patients with CKD stage 3 in the community in Ayrshire and Arran 
(“Triple A”), performed a detailed baseline assessment, and plan to collect subsequent data 
and outcomes, including progression of kidney disease, development of vascular disease 
and death, with the aim of identifying predictors of renal and patient outcome. 
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8.2 Methods 
8.2.1 Laboratory Assays 
All samples (except parathyroid hormone and vitamin D) were analysed at the 
biochemistry and haematology laboratories of University Hospital Crosshouse, 
Kilmarnock Ayrshire. Serum creatinine was measured using Roche Modular reagent Jaffe 
method, with a mean between batch coefficient of variation of 2.3% at a serum creatinine 
concentration of 148µmol/L and 1.7% at 326µmol/L. The adjustment factors produced by 
the UK National External Quality Assessment Service were used for the creatinine assay, 
to produce IDMS-traceable serum creatinine values and then the eGFR was calculated 
using the MDRD formula and CKD-EPI formulae (47, 215). Serum albumin was measured 
using bromocresol green, with CV of 2% between batches. Sodium, potassium and 
chloride were measured using indirect ion selective electrodes (between batch CV <1%). 
Bicarbonate and urea were measured using coupled enzyme reactions. Parathyroid 
hormone and vitamin D were measured at Glasgow Royal Infirmary on an Abbott 
Architect analyser using automated immunoassays. Total protein was measured using a 
turbidimetric method with benzethonium precipitation, with a mean between batch CV of 
3.9%. Urinary albumin was measured using an immunoturbidimetric method with a mean 
between batch CV of 4.3%. The urine creatinine was assayed by a reaction rate Jaffe 
method with a mean between batch CV is 3.6%.  
 
8.2.2 Study Population 
General Practices (GP) in Ayrshire, Scotland were invited to take part in the study, with a 
mix of urban and rural populations, and diverse geographical locations to reflect the overall 
catchment area. General practices in the United Kingdom are remunerated to maintain an 
electronic database of patients with chronic kidney disease stage 3 – 5 (known as the CKD 
register). In each participating practice a member of administrative staff interrogated the 
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database to identify potential participants with Stage 3 CKD who met the inclusion and 
exclusion criteria. All eligible patients within each practice were approached by letter 
inviting them to participate (see appendix for a sample invite letter). This was accompanied 
by a participant information sheet (see appendix). They were asked to contact their general 
practice to make an appointment to meet the study investigator. If they did not respond 
within two weeks a follow-up invite letter was sent. Thereafter no further contact was 
made.  
 
8.2.3 Determination of Sample Size 
This study was intended as a pilot study for a large cohort study. Pilot phase aimed for 500 
patients (3:2 stage 3A: stage 3B), recruited over 12 months. The pilot phase would allow 
refinement of power calculations for the main study, as there is little current data available 
regarding the primary outcome measure. The population of NHS Ayrshire & Arran is 
367,000. With an estimated prevalence of stage 3 CKD of 4.5% (low prevalence estimate), 
there are likely to be 16,500 patients with CKD stage 3. Based on other studies there is a 
1:4 split of stage 3B:3A, equating to 3,300 stage 3B and 13,200 stage 3A. There are 54 
general practices in Ayrshire. Thus we aim to recruit 2.3% of the stage 3A and 6.1% of the 
stage 3B patients. This was anticipated to be achievable from 6 - 10 practices, which 
required us to recruit 12.3% of their stage 3A and 32.7% of their stage 3B patients. 
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8.2.4 Inclusion Criteria 
• Age 18 years or older  
• Chronic Kidney Disease stage 3 as defined by the NKF-KDOQI classification (eGFR 
30 – 59ml/min/1.73m
2
 on 2 occasions at least 3 months apart) (patients are added to the 
primary care CKD Register if eGFR<60 ml/min/1.73m
2
). 
 
8.2.5 Exclusion Criteria 
• Unable or unwilling to consent to take part in a study 
• Unable to provide a spot urine sample 
• Pregnant or lactating women 
• Aged less than 18 years (the eGFR formulae are not validated in those under 18 years) 
• Renal transplant recipient  
 
8.2.6 Incorrectly enrolled participants 
It was anticipated that a number of participants would have an eGFR> 60ml/min/1.73m
2
 
on the meat fasted study sample. However the primary basis of the selection criteria for the 
study was that the participant was included in the primary care CKD register, and was not 
re-assessed by the study investigators for the presence of CKD. It was hypothesised that 
patients may have been added to the register on the basis of a single serum creatinine 
measurement, or a sample after consuming cooked meat, or taken during an intercurrent 
illness reflecting a transient low eGFR that is not found on subsequent samples. These 
participants may represent a high risk group for developing subsequent CKD. Therefore 
the study was designed pragmatically to most accurately reflect current clinical practice, 
acknowledging the fact that a proportion of those on the CKD register will not fully fit the 
criteria. A decision was made, a priori, that participants with eGFR>60 ml/min/1.73m
2
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would be retained in the study, in order to observe any renal progression.  The participant’s 
GP was informed of this.  
 
8.2.7 Ethical Permission 
Ethical approval was obtained from the West of Scotland Research Ethics Service and 
organisational approval was obtained from the Research and Development committee of 
NHS Ayrshire and Arran. 
  
8.2.8 Recruitment 
All participants were recruited and assessed by a single investigator (SM).  They were 
assessed in the local primary care practice to minimise travel and maximise participation. 
Written informed consent was obtained (see appendix for consent form). Participants were 
installed on the Scottish Electronic Renal Patient Record (SERPR) to allow automated 
collection of all blood and urine results regardless of source (using the unique Scottish 
community health index number), and via an electronic link with the Scottish Renal 
Registry subsequent outcome data were collected (including date and cause of death, 
cardiovascular events etc). Participants gave written consent for remote follow-up for ten 
years.  
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8.2.9 Primary endpoint 
• Incidence of cardiovascular disease 
 
This is defined as: 
• Myocardial infarction (Fatal or non-fatal ST elevation myocardial infarction and non 
ST elevation myocardial infarction).  
 Myocardial infarction defined as hospital discharge diagnosis code or cause of 
 death 
• Need for coronary revascularisation 
• Transient ischaemic attack 
• Fatal or non-fatal ischaemic stroke 
• Fatal or non-fatal haemorrhagic stroke 
• Need for peripheral revascularisation 
• Amputation for peripheral vascular disease 
• Death due to peripheral vascular disease 
• Sudden cardiac death 
 
8.2.10  Secondary Endpoints 
• All-cause mortality 
• Commencement of renal replacement therapy 
• Decline in renal function as measured by; 
 Doubling of serum creatinine 
 Decline in eGFR 
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8.2.11  Clinical assessment 
Participants were requested to fast for 12 hours prior to the assessment. If they were unable 
to do this (e.g. diabetic, on medication) they were asked to refrain from eating meat for 12 
hours to avoid the interference of cooked meat on the creatinine measurement (267).  
 
8.2.12  Questionnaire 
Participants completed a questionnaire regarding their medical history, current medication, 
lifestyle, family and occupational history (see appendix for a sample questionnaire). 
During the baseline assessment, this was checked by the researcher (SM) for completeness 
and cross-checked with the electronic GP records for medication and diagnoses (recorded 
on the GP electronic records using Read codes).  
 
All participants completed the International Consultation on Incontinence Questionnaire 
urinary incontinence form (ICIQ-UI). The ICIQ-UI scores urinary incontinence across 3 
domains (frequency, amount and impact on quality of life) and awards a score from zero 
(never) to 21 (frequent, large volume leakage with significant impact of lifestyle).  In 
addition male participants completed the International Prostate Symptom Score (IPSS). 
The IPSS assesses lower urinary tract symptoms in men across seven domains, awarding a 
score from zero (no symptoms) to five (severe symptoms), with a total score of 8 – 19 
reflecting moderate symptoms and ≥20 suggesting severe symptoms.  These were 
completed independently by participants (see appendix for sample questionnaires). 
 
Participants also completed a short quality of life questionnaire (the European Quality of 
Life- 5 Dimensions [EQ-5D] questionnaire) which assesses five domains of mobility, self 
care, usual activities, pain and anxiety and depression, with a choice of three possible 
answers; no problems, some problems or unable to perform for the former three domains 
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and no symptoms, moderate or severe symptoms for the latter two domains (see appendix). 
This generates a score such as 11121, where there are no problems in four of five domains, 
except the penultimate. The developers of the EQ-5D questionnaire have then created 
country specific indexes where 0.0 is death, and 1.0 is full health, to allow comparisons 
between groups and internationally (a negative score is possible where the quality of life is 
considered to be worse than death). A global assessment using a visual analogue scale is 
also included (see appendix for a sample questionnaire). The EQ-5D index was calculated 
for the cohort (268).   
 
Permission was obtained for the use of the IPSS, ICIQ and EQ5D questionnaires. 
 
8.2.13  Scottish Index of Multiple Deprivation 
The Scottish Index of Multiple Deprivation (SIMD) score was recorded. Scotland is 
divided into 6,505 small areas, known as datazones, based on postcode, and a rank is 
assigned for each datazone from 1 to 6,505 (from most to least deprived), by assessing 
deprivation across seven domains – income, employment, health, education, access to 
services, crime and housing. The overall index is a weighed sum of the seven domain 
scores and is designed to give a relative measure of deprivation. It is obtained from the 
Scottish Government website, by entering the postcode into the appropriate spreadsheet for 
each local authority (269). The commonly applied cut-point to compare groups is the most 
deprived 15%.  
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8.2.14  Physical Assessment 
The physical assessment comprised of the following: 
• anthropometric measurements: 
•  height (measured barefoot, using wall mounted measure) 
•  weight, (measured barefoot, outdoor clothing removed, pockets 
 emptied using calibrated scales) 
•  body mass index, (weight (kg)/ height (m)2) 
• waist to hip ratio, calculated as follows: 
 
 waist girth: taken at the narrowest waist level. If this is not 
apparent, at the midpoint between the lowest rib and the top 
of the hip bone (iliac crest). 
 
 hip girth: taken over minimal clothing and empty pockets at 
the widest point of the hips and greatest protrusion of the 
 gluteal muscles. Participant stands straight with 
weight evenly distributed on both legs and feet. 
 
• blood pressure, measured as follows: 
• 3 readings, using a portable automated machine (A&D Medical 
UA-767 Plus 30) measured in the seated position after 5 minutes 
rest 
• electrocardiogram (portable device) 
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8.2.15  Biochemical Assessment  
A blood sample for: 
• urea and electrolytes  
o sodium, potassium, chloride, bicarbonate, urea and creatinine 
• bone profile  
o calcium, phosphate, albumin, alkaline phosphatase, total protein, 
adjusted calcium calculated = Ca + 0.02(40 – Alb)) 
• full blood count 
o haemoglobin, platelets, total white cell count and differential count 
• lipids  
o total cholesterol, high density lipoprotein, triglycerides, and low 
density lipoprotein calculated using Friedewald equation ; 
o LDL=Total Chol – HDL – (Trig/2.2) 
• glucose 
• urate 
• Parathyroid hormone 
• 25-hydroxy vitamin D 
• serum, plasma and whole blood (for DNA analysis) for storage  
serum and plasma were centrifuged at 3500rpm for 5 minutes and supernatant 
frozen at -80°C, whole blood was frozen unchanged at -80°C  
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Participants provided 5-10mL first morning urine sample for: 
• dipstick urinalysis (Siemens 10 SG multistix) 
• laboratory quantification of: 
o total protein 
o albumin 
o creatinine 
o sodium 
o aliquot for storage at -80°C (not centrifuged) 
 
A small sub-set of participants performed a 24-hour urine collection, in addition to the spot 
sample, (if the urine dipstick ≥1+ for protein) for: 
• total protein 
• albumin 
• creatinine 
• sodium 
• aliquot for storage 
 
8.2.16  Statistical analysis 
Data were downloaded and patient identifiers removed prior to further analysis. Analysis 
was performed using SPSS version 18.0 for Windows (IBM Inc, http://www-
01.ibm.com/software/analytics/spss/). All data were assessed for normality, and 
appropriate summary statistics are presented. Significance testing was performed was 
student’s T test, Mann-Whitney U test, chi squared test and analysis of variance as 
appropriate.  
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8.3 Results 
8.3.1 Participating General Practices 
Participants were recruited from seven general practices around Ayrshire as shown in 
Figure 8-1. The number of participants, grouped according to GP and response rate are 
shown in table 8-1. 
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Figure 8-1 - Map of Ayrshire with Recruitment Locations 
 
Legend 
Beith Health Centre, Beith 
Stewarton Health Centre, Stewarton 
Kilwinning Medical Practice, Kilwinning 
Townhead Surgery, Irvine 
Old Irvine Road Surgery, Kilmarnock 
Portland Surgery, Troon 
Racecourse Road Medical Group, Ayr 
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Table 8-1 - Breakdown of Participants by General Practice 
 Number of 
participants 
Proportion of 
Total Cohort (%) 
Response Rate 
(% of invites 
sent) 
Beith 29 7.1 20 
Stewarton 48 11.7 20 
Kilwinning 107 26.0 13 
Irvine 125 30.4 11 
Kilmarnock 34 8.3 17 
Troon 36 8.8 29 
Ayr 32 7.8 7 
Total 411 100.0 13 
 
8.3.2 Baseline demographics 
The demographic information of the total cohort, and divided according to renal function is 
shown in Table 8-2. The cohort includes 17% from the most deprived 15% of datazones in 
the Scottish Index of Multiple Deprivation, which is a reflection of the overall deprivation 
of the population of Ayrshire and Arran. This is demonstrated in the histogram of SIMD 
rank of the cohort (Figure 8-2) and the corresponding histograms of East Ayrshire and 
South Ayrshire Council areas, for comparison (Figure 8-3 and 8-4). 
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Table 8-2 – Demographic information of the cohort, divided according to renal function. 
 
  Total 
Cohort 
(n=411) 
eGFR>60 
ml/min/1.73m
2 
(n=109) 
CKD  
Stage 3A 
(n=187) 
CKD Stage 
3B 
(n=94) 
Sig 
Age (yrs; ± 
SD) 
         [range] 
70.6 ±9.6 
[30 – 90] 
69.0 ± 10.3 
[31 – 90] 
70.5 ± 8.7 
[42 – 89] 
73.2 ± 9.6 
[30 – 90] 
0.014 
Female (%) 59 64 54 66 0.079 
Ethnicity     
      White 
(%) 
 
99.5 
 
99.1 
 
100 
 
100 
 
0.855 
      Mixed 
(%) 
0.5 0.9 0 0 - 
Serum 
creatinine 
(µmol/L; IQR) 
107  
(89 – 123) 
83  
(73 – 97) 
107  
(94 – 118) 
128  
(116 – 148) 
<0.005 
eGFR (MDRD) 
(ml/min/1.73m2; 
IQR) 
54  
(44 – 61) 
65  
(62 – 70) 
54  
(49 – 57) 
40  
(36 – 43) 
<0.005 
SIMD rank 
(median; 
IQR) 
2315 
(1273 – 4324) 
2351  
(926 – 3775) 
2754  
(962 – 4546) 
1954  
(769 – 3138) 
0.023 
Lowest 15% 
SIMD rank 
(%) 
 
17.0 
 
17.4 
 
17.0 
 
16.7 
 
0.999 
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Figure 8-2 - Histogram of Scottish Index of Multiple Deprivation (SIMD) rank of t-he cohort  
 
Rank 1 represents most deprived 
Figure 8-3 - SIMD deciles for the general population of East Ayrshire 
 
Figure 8-4 - SIMD deciles for the general population of South Ayrshire 
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8.3.3 Baseline renal function 
Participants were recruited on the basis that they were included in their general practice’s 
CKD register. The study samples were taken after a 12-hour meat free period. The 
estimated GFR and corresponding CKD stage of the cohort are shown in table 8-3 and 
figure 8-5, according to the MDRD formula (currently used in UK biochemistry 
laboratories,) and the CKD-EPI equation using IDMS traceable values of serum creatinine. 
The equations identify different numbers of patients as having CKD, especially Stage 3A 
CKD, and a proportion as having no kidney disease. Figure 8-6 shows the relationship 
between the eGFR derived from the formulae.  
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Table 8-3 – Prevalence of CKD Stages, according to the MDRD and CKD-EPI equations for estimating 
glomerular filtration rate 
 MDRD Formula CKD-EPI Formulae 
Median eGFR 
(ml/min/1.73m
2
; IQR) 
54 (44 – 61) 55 (44 – 63) 
No kidney disease 
(number [%]) 
83 (20.2) 104 (25.3) 
CKD Stage 1/ 2 (number 
[%]) 
26 (6.3) 35 (8.5) 
CKD Stage 3A (number 
[%])  
194 (47.2) 164 (39.9) 
CKD Stage 3B  
(number [%]) 
96 (23.4) 93 (22.6) 
CKD Stage 4 (number 
[%]) 
12 (2.9) 15 (3.6) 
CKD Stage 5 (number 
[%]) 
0 (0.0) 0 (0.0) 
CKD Stage 1/2: defined as eGFR>60ml/min/1.73m
2
 plus evidence of kidney damage such 
as TPCR>15mg/mmol or ACR>3mg/mmol. 
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Figure 8-5 - Prevalence of CKD Stages in the cohort according to the MDRD and CKD-EPI formulae 
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Figure 8-6 - Scatterplot of eGFR according to the MDRD and CKD-EPI formulae demonstrating the 
changing level of agreement between the results according to level of kidney function 
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8.3.4 Measurements of renal function prior to the study 
Over a quarter (26.5%) of the cohort have an eGFR >60ml/min/1.73m
2 
(according to the 
MDRD formula)
 
following a 12-hour meat free period. In order to investigate the impact of 
the participants being meat free at the time of sampling on the prevalence of CKD in the 
cohort, prior measurements of creatinine and eGFR (performed during routine clinical care 
and measured in the same laboratory in the preceding year) were obtained for the group of 
participants found to have an eGFR>60ml/min/1.73m
2
 (MDRD formula) at the baseline 
study measurement.  
 
63 (58%) of those had an eGFR measurement of <60ml/min/1.73m
2
 in the year preceding 
the baseline study visit, and 22 of those had 2 recorded measurements of eGFR 
<60ml/min/1.73m
2
, greater then 90 days apart. 
 
8.3.5 Characterisation of renal disease 
The cohort have predominantly early renal disease, receiving care from their general 
practice multidisciplinary team, with less than 10% under current hospital review and less 
than 5% having undergone a diagnostic percutaneous renal biopsy (table 8-4). 
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Table 8-4 - Characterisation of renal disease in the cohort 
 Total Cohort 
(n=411) 
eGFR>60ml/min/1.73m
2
  
(n=109) 
CKD Stage 3A  
(n=187) 
CKD Stage 3B  
(n=94) 
Nephrology clinic follow-up 
    Never (number [%]) 
 
341 (83) 
 
101 (92.7) 
 
163 (84) 
 
75 (78.1) 
   Current (number [%]) 32 (7.8) 3 (2.8) 8 (4.1) 12 (12.5) 
   Discharged (number [%]) 38 (9.2) 5 (4.6) 23 (11.9) 9 (9.4) 
Renal biopsy performed 
(number [%]) 
11 (2.7) 2 (1.8) 4 (2.1) 4 (4.2) 
    Primary Renal Disease (%)    
Primary glomerulonephritis 
Interstitial disease 
Multisystem diseases 
Diabetic nephropathy 
Other 
CKD; aetiology unknown 
 
2.7 
8.5 
3.6 
1.0 
0.2 
83.9 
 
2.8 
5.5 
1.8 
0.0 
0.0 
89.9 
 
2.6 
8.2 
4.1 
0.0 
0.5 
84.5 
 
2.1 
12.5 
4.2 
0.0 
0.0 
81.3 
Renal tract malignancy  
(inc prostate) (%) 
4.4 0.9 5.7 6.3 
IPSS (score; IQR) 6 (2 – 10) 5.5 (2 – 12.5) 6 (3 – 10) 3.5 (2 – 8) 
Moderate to severe LUTS 
(IPSS ≥8) (%) 
38.3 33.3 43.3 23.3 
Gynaecological malignancy (% 
of females) 
2.9 3.6 2.9 3.2 
ICIQ-UI >10 (%) 8.6 13.3 7.3 8.4 
Self-reported recurrent UTI  
(%) 
11.4 10.1 11.9 12.5 
Family history of renal disease 
(%) 
10.5 9.2 4.9 2.9 
Occupational exposure to 
nephrotoxins (%) 
8.5 5.5 11.3 7.3 
Primary renal disease; reported as recorded in the GP records 
Occupational exposure to nephrotoxins includes; lead, cadmium, mercury, silica, beryllium, uranium, chromium, ethylene glycol  
228 
   228
8.3.6 Urinary abnormalities at baseline 
The prevalence of dipstick proteinuria (≥1+) in the cohort was low (8.1%) and this was 
reflected in the median TPCR of 10mg/mmol and ACR of 0.9mg/mmol. The prevalence of 
proteinuria was significantly higher in participants with diabetes (p<0.001) (shown in table 
8-5).  
 
Overall urinary sodium excretion was high with a median of 85mmol/L in the cohort, with 
differences noted between the diabetic and non-diabetic subgroups. Diuretic usage was not 
significantly different between the groups (p=0.113), but urine sodium was significantly 
higher in the diuretic users (p<0.001) as expected. To correct for urine flow rate sodium: 
creatinine ratios were calculated and these were significantly higher in the non-diabetic 
group. 
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Table 8-5 - Urinary abnormalities of the cohort divided according to diabetic status 
 Total cohort 
(n=407 with 
dipstick) 
Non-diabetics 
(n=324) 
Diabetics 
(n=83) 
Significance 
Dipstick 
proteinuria 
Negative  
(number [%]) 
 
 
275 (66.9) 
 
 
230 (71.0) 
 
 
45 (54.2) 
Trace 
(number [%]) 
99 (24.1) 73 (22.5) 26 (31.3) 
≥1+ 
(number [%]) 
33 (8.1) 21 (6.5) 12 (14.4) 
 
 
 
 
0.03 
Median TPCR 
(mg/mmol; IQR) 
10 (7-15) 9 (7 – 15) 12 (7 – 18) 0.03 
TPCR 15 - 
50mg/mmol 
(number [%]) 
91 (22.4) 68 (21.0) 23 (28.0) 0.171 
TPCR> 50mg/mmol 
(number [%]) 
15 (3.7) 8 (2.5) 7 (8.5) 0.009 
Median ACR 
(mg/mmol; IQR) 
0.9 (0.5-1.7) 0.9 (0.6 – 1.5) 1.0 (0.6 – 5.3) 0.015 
Microalbuminuria 
(number [%]) 
62 (15.1) 45 (13.8) 17 (20.5) 0.127 
Macroalbuminuria 
(number [%]) 
9 (2.2) 3 (0.9) 6 (7.2) <0.001 
Dipstick non-visible 
haematuria ≥ 1+ 
(number [%]) 
28 (6.9) 22 (6.8) 6 (7.2) 0.524 
Urine sodium 
(mmol/L; IQR) 
85 (59 – 113) 87 (59 – 115) 76 (54 – 106) 0.038 
Urine sodium/ 
creatinine ratio 
(mmol/mmol; IQR) 
13 (8 – 18) 13 (8 – 18) 11 (7 – 18) 0.015 
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8.3.7 Relationship between TPCR and ACR in the cohort 
In earlier chapters the relationship between TPCR and ACR was explored in a cohort of 
patients attending a hospital renal clinic, with a high prevalence of proteinuria. In figure 8-
7, the relationship is shown in this low prevalence community cohort. 
Figure 8-7 - Scatterplot of the relationship between TPCR and ACR in the cohort 
 
 
Of those with significant proteinuria (TPCR>50mg/mmol, n=15) seven participants had 
discordant levels of TPCR and ACR (i.e. high levels of non-albumin proteinuria), using the 
thresholds of TPCR 50mg/mmol and ACR 30mg/mmol (as described in previous chapters). 
One participant had a TPCR>100mg/mmol, with ACR <70mg/mmol.  One participant had 
a high ACR (>30mg/mmol) and a low TPCR (<50mg/mmol). The characteristics of those 
with significant proteinuria are shown in table 8-6, divided according to the level of non-
albumin proteinuria. No one in the group had a diagnosis of multiple myeloma. 
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Table 8-6 - Characteristics of those with significant proteinuria (TPCR>50mg/mmol) divided 
according to level of non-albumin proteinuria (NAP) 
 High NAP 
ACR <30, PCR >50 
Low NAP 
ACR>30 PCR>50 
Significance 
N 7 8 - 
Age (year; ± SD s) 76.0 (± 4.6) 67.0 (±8.8) 0.031 
Female (%) 86 38 0.166 
On RAASi (%) 43 87 0.336 
SBP (mmHg;± SD) 135 (±39) 146 (± 20) 0.504 
DBP(mmHg± SD) 72 (±14) 75 (± 13) 0.673 
sCr (micromols/l; 
IQR) 
100 (75 – 142) 171 (117 - 305) 0.002 
eGFR 
(ml/min/1.73m
2
; 
IQR) 
50 (36 – 68) 31 (18  43) 0.002 
CKD; aetiology 
unknown (%) 
86 37 <0.001 
ACR (mg/mmol; 
IQR) 
11 (7 – 24) 63 (35 – 133) <0.001 
TPCR(mg/mmol; 
IQR) 
62 (50 – 99) 110 (55 – 189) <0.001 
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8.3.8 Combining proteinuria and eGFR in the classification of CKD 
It has been proposed to add proteinuria to the eGFR stage in the classification of CKD 
(11). The modified classification describes the cause, eGFR, and albuminuria using ACR; 
called the CGA classification. In order to investigate the impact of applying this 
classification to this cohort they were divided according to the level of CKD-EPI eGFR 
(using Stages 1 – 5, including 3A and 3B) and ACR (using 3 categories, ACR 
<3mg/mmol; A1, ACR 3-30mg/mmol; A2 and ACR>30mg/mmol; A3). Then prevalence 
of CKD using this approach is shown in figure 8-8. 
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Figure 8-8 - Bar chart of the prevalence of CKD using the CKD-EPI eGFR equations and ACR divided into three categories  
(A1; ACR<3mg/mmol, A2; ACR 3 - 30mg/mmol and A3; ACR>30mg/mmol) 
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8.3.9 Burden of cardiovascular disease 
Three quarters of the cohort have been given a diagnosis of hypertension (self-reported or 
according to GP records), but blood pressure is well controlled and only 7.4% of 
electrocardiograms met the criteria (by voltage) for left ventricular hypertrophy (270). In 
excess of 40% are known to suffer from vascular disease, and 20% are diabetic. Overall 
there is a large burden of cardiovascular disease in this cohort, as shown in detail in Table 
8-7 and 8-8. 
 
Participants were receiving a median of two anti-hypertensive agents, and the majority 
were receiving an ACE inhibitor or angiotensin receptor blocker, (figure 8-9). The 
prevalent use of renin angiotensin system blockade rose with severity of CKD. 
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Table 8-7 - Cardiovascular parameters of the cohort divided according to severity of renal disease 
 Total cohort  
(n=411) 
 
eGFR>60ml/min/1.73m
2
  
(n=109) 
CKD Stage 3A  
(n=187) 
CKD Stage 3B  
(n=94) 
Significance 
Mean systolic BP (mmHg; ± SD) 141 (±22) 143(±23) 142(±21) 138(±23) 0.236 
Mean diastolic BP (mmHg; ± SD) 79 (±12) 82(±11) 79(±12) 75(±12) <0.001 
Lowest systolic BP (mmHg; ± SD) 135(±22) 138(±22) 136(±21) 132(±21) 0.200 
Lowest diastolic BP (mmHg; ± SD) 76(±12) 79(±11) 76(±12) 72(±12) <0.001 
Self-reported or GP diagnosed 
hypertension (%) 
75.0 70.6 77.5 78.7 0.150 
Antihypertensive drugs (number) 2 (1 – 3) 2 (1 – 3) 2 (1 – 2) 2 (1.25 – 3) 0.002 
ECG findings: Normal 56.4 61.7 60.9 41.1 0.008 
                         Voltage criteria LVH 7.4 4.7 6.8 11.7 0.286 
                          Ischaemia 20.3 15.9 18.5 28.3 0.143 
                          Arrythmia 8.6 5.6 9.8 11.6 0.659 
Any vascular disease (%) 42.6 37.6 43.3 45.8 0.609 
Ischaemic Heart Disease (%) 31.1 28.4 29.4 38.5 0.472 
Cerebrovascular disease (%) 12.4 10.1 14.4 11.7 0.906 
Peripheral Vascular Disease (%) 12.2 11.9 15.0 8.5 0.577 
Family History of vascular disease 
(%) 
51.8 55.0 52.6 47.9 0.664 
 
Arrhythmia; paced rhythm or arrhythmia seen on ECG
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Table 8-8 – Cardiovascular parameters of the cohort (2) 
 Total cohort  
(n=411) 
 
eGFR>60ml/min/1.73m
2
  
(n=109) 
CKD Stage 3A  
(n=187) 
CKD Stage 3B  
(n=94) 
Significance 
Type 1 diabetes  
(%) 
0.24 0 0 0 - 
Type 2 diabetes  
(%) 
20.0 18.3 18.2 25.5 0.359 
    Diet controlled (% of DM) 30.5 35.0 11.8 16.7 - 
    OHA (% of DM) 48.8 55.0 70.6 58.3 - 
    Insulin requiring (% of DM) 20.7 10.0 17.6 25.0 - 
Retinopathy/ neuropathy (%) 8.5 8.3 4.8 13.8 0.004 
Impaired glucose tolerance (%) 3.2 2.7 3.7 3.2 0.648 
Cholesterol (mmol/L; ± SD) 4.9 (± 1.2) 5.0 (±1.1) 4.8 (±1.2) 4.9 (±1.3) 0.298 
HDL (mmol/L; ± SD) 1.5 (±0.5) 1.5(±0.4) 1.4 (±0.5) 1.4(±0.5) 0.110 
LDL (mmol/L; ± SD) 2.7 (±1.0) 2.8(±0.9) 2.7(±1.0) 2.7(±1.1) 0.382 
Trigs (mmol/L; ± SD) 1.7(±1.0 ) 1.6(±1.0 ) 1.6(±0.8 ) 1.9(±1.1 ) 0.060 
TC:HDL ratio 3.6 (±1.2) 3.5 (±1.1) 3.7 (±1.1) 3.7 (±1.1) 0.240 
Statin usage (%) 61.3 57.8 62.4 60.4 0.370 
Ezetimibe usage (%) 1.2 1.2 1.0 2.0 0.873 
Uric acid  
(mmol/L; mean ± SD) 
0.38 (± 0.10) 0.34 (± 0.08) 0.38(± 0.10) 0.43(± 0.10) <0.001 
Previous clinical episode of gout (%) 9.5 2.8 10.8 13.5 0.033 
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Figure 8-9 - Use of antihypertensive drugs according to severity of CKD 
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8.3.10  Complications of renal disease 
The prevalence of biochemical complications of renal disease, such as hyperkalaemia and 
metabolic acidosis, are low (table 8-9). However the prevalence of abnormalities of 
vitamin D metabolism is high in the cohort, independent of renal function, with only a 
quarter (25.8%) of the cohort having adequate levels of 25-hydroxy-vitamin D (table 8-10). 
Mild hyperparathyroidism is also common, independent  of renal function, but more severe 
hyperparathyroidism was related to severity of renal disease (p<0.001) and mean PTH 
levels were higher in the participants with CKD Stage 3B (10.9pmol/L) versus 7.7pmol/L 
in CKD Stage 3A, (p<0.001). 
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Table 8-9 - Complications of renal disease, divided according to severity of renal disease 
 Total cohort  
(n=411) 
eGFR>60ml/min/1.73m
2
 
(n=109) 
CKD Stage 3A  
(n=187) 
CKD Stage 3B  
(n=94) 
Significance 
Potassium 
(mmol/L; ± SD) 
 4.2 (±0.5)  4.0 (± 0.4) 4.2 (± 0.4) 4.3(±0.5 ) 0.025 
Hyperkalaemia  
(K>5.0mmol/L) (%) 
 4.7 0.0 2.7 7.4 <0.001 
Serum bicarbonate 
(mmol/L; ± SD) 
 26 (±3) 26(±3 ) 26(±3 ) 25(±3 ) 0.096 
Metabolic acidosis  
(serum bicarb <22mmol/L) (%) 
 5.4 0.9 4.6 9.4 0.002 
Haemoglobin 
 (g/dL; ± SD) 
13.6 (±1.5) 13.8(±1.5 ) 13.7(±1.5 ) 13.1(±1.5 ) 0.002 
Anaemia  
(Hb< 11g/dL) (%) 
4.9 2.8 4.6 5.3 0.02 
Albumin  
(g/L; ± SD) 
45 (±3) 45(±3 ) 45(±3 ) 45(±3 ) 0.321 
Hypoalbuminaemia 
(serum albumin< 35g/L) (%) 
0 - - - - 
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Table 8-10 – Features of CKD-MBD, divided according to severity of renal disease 
 Total cohort  
(n=411) 
eGFR>60ml/min/1.73m
2
 
(n=109) 
CKD Stage 3A  
(n=187) 
CKD Stage 3B  
(n=94) 
Significance 
Adjusted calcium  
(mmol/L; ± SD) 
2.2 (± 0.1) 2.3(±0.1 ) 2.2(±0.1 ) 2.3(± 0.1) 0.043 
Hypocalcaemia  
(Adj Ca <2.1mmol/L) (%) 
3.9 0.9 5.2 5.2 0.353 
Phosphate  
(mmol/L; ± SD) 
0.9 (± 0.2) 0.9(±0.2 ) 0.9(±0.2 ) 1.0(±0.2 ) 0.055 
Hyperphosphataemia  
(PO4 >1.3mmol/L) (%) 
3.2 3.7 2.1 4.3 0.002 
Alkaline Phosphatase 
(µg/L; ± SD) 
78 (±29) 75(±23 ) 77(±29 ) 80(±37 ) 0.461 
PTH  
(pmol/L; ± SD) 
8.7 (± 4.9) 7.8(±4.8 ) 7.7(±3.8 ) 10.9(±5.5 ) <0.001 
Hyperparathyroidism     
    > ULN (7.6 – 15.0pmol/L) 
    >2X ULN (15.1 – 22.5pmol/L) 
    >3X ULN (>22.5pmol/L) 
 
 
35.7 
10.3 
1.2 
 
41.7 
5.9 
1.0 
 
34.6 
5.9 
0.0 
 
42.9 
22.0 
2.2 
 
<0.332 
<0.001 
<0.001 
 
25-OH Vitamin D  
(nmol/L; ± SD) 
Insufficiency (25-49nmol/L(%) 
Deficiency (14 – 24nmol/L) (%) 
Undetectable (<14nmol/L) (%) 
38 (± 22) 
 
40.3 
20.2 
13.7 
37(±23 ) 
 
36.5 
21.9 
15.6 
40(±21 ) 
 
42.7 
17.4 
11.2 
36(±21 ) 
 
39.8 
22.0 
14.8 
0.193 
 
0.795 
0.579 
0.315 
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8.3.11  Factors related to lifestyle 
The cohort has a high prevalence of obesity with 45% having a body mass index 
>30kg/m
2
. There was no correlation between eGFR and BMI nor waist: hip ratio in this 
cohort. However less than 10% of the cohort are current smokers, with 44% reporting a 
past history of tobacco use.  Alcohol consumption is notably low (table 8-11). 
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Table 8-11 - Factors related to lifestyle in the total cohort and divided according to gender 
 Total Cohort (n=411) Males (n=169) Females (n=242) 
Weight (kg) (±SD) 
 
81 (±18) 88 (±17) 76 (±16) 
Height (cm) (±SD) 
 
164 (±11) 171 (±11) 158 (±7) 
BMI (kg/m
2
) (±SD) 
 
30 (±6) 30 (±5) 30 (±6) 
BMI 25.1 – 30kg/m
2 
(overweight)
 
(%) 
36 43 31 
BMI > 30kg/m
2
  
(obese) (%) 
45 40 48 
Waist (cm) (±SD) 
 
96 (±14) 102 (±12) 92 (±13) 
Hips (cm) (±SD) 
 
106 (±11) 103 (±9) 107 (±11) 
Waist :Hip ratio 
 
0.9 (±0.1) 1.0 (±0.1) 0.8 (±0.1) 
Central fat distribution 
(%) 
82 88 77 
Waist: Height ratio 
 
0.59 (±0.08) 0.59 (±0.007) 0.58 (±0.08) 
Current smoker (%) 
 
9.5 7.1 11.1 
Pack years 
 
25 (11 – 45) 15 (5 – 50) 25 (19 – 41) 
Ex-smoker (%) 
 
44.0 55.0 36.4 
Pack years 
 
22 (10 – 36) 25 (10 – 40) 20 (5 – 31) 
Non-smoker (%) 
 
46.5 37.9 52.5 
Alcohol (units/week) 
 
1 (0 – 8) 4 (0 – 18) 0.5 (0 - 4) 
Central fat distribution defined as waist: hip ratio >0.8 in females or >0.9 in males. 
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8.3.12  Co morbidity and Quality of Life  
The burden of co morbidity in the cohort was significant, as measured by the Charlson 
index, shown in table 8-12 and figure 8-10. Quality of life was measured using the EQ-5D 
questionnaire and the findings for each domain are shown in table 8-12. Median score was 
7 (minimum possible is 5 and maximum 15) and the median EQ-5D index for the whole 
cohort was 0.81 (0.76 – 0.85). A visual analogue scale (VAS) was used for participants’ 
global assessment of wellbeing and the median value was 75% for the whole cohort. 
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Table 8-12 – Co morbidity, as measured by the Charlson Score and Quality of Life measurements for 
the cohort, and divided according to severity of renal disease 
 Total 
cohort  
(n=411) 
 
eGFR>60 
ml/min/1.73
m
2
  
(n=109) 
CKD  
Stage 3A  
(n=187) 
CKD  
Stage 3B  
(n=94) 
P value 
Charlson Index  
(median; IQR) 
 
1 (0 – 2) 1 (0 – 2) 1 (0 – 2) 1 (0 – 2) 0.063 
Charlson Index 
>2 (%) 
 
18.0 18.3 16.6 20.2 - 
EQ-5D scores (5) 
 Mobility       (%)                               
             Level   1 
             Level   2                                 
             Level   3        
 
51.6 
48.4
0.0 
 
 
51.4 
48.6 
0.0 
 
 
57.2 
42.8 
0.0 
 
 
 
38.5 
61.5 
0.0 
 
 
 
0.018 
  Self care       (%) 
             Level    1 
             Level    2 
             Level    3                                                             
 
86.4 
13.6 
0.0
 
 
85.3 
14.7 
0.0
 
87.6 
12.4 
0.0 
 
84.4 
15.6 
0.0 
 
 
0.808 
Usual activity (%) 
            Level     1 
            Level     2 
            Level     3 
 
63.0 
33.8 
3.2 
 
 
65.1 
30.3 
4.6 
 
64.4 
34.0 
1.5 
 
57.3 
37.5 
5.2 
 
 
 
0.493 
    Pain           (%)                               
          Level      1 
          Level      2 
          Level      3 
 
35.3 
56.0 
8.8 
 
 
31.2 
58.7 
10.1 
 
38.7 
54.1 
7.2 
 
30.2 
58.3 
11.5 
 
 
 
0.316 
  Anxiety &   
 Depression    (%) 
          Level        1 
          Level        2 
          Level        3 
 
 
71.8 
26.5 
1.7 
 
 
73.4 
24.8 
1.8 
 
 
 
73.2 
25.8 
1.0 
 
 
65.6 
32.3 
2.1 
 
 
 
 
0.286 
EQ-5D Total  
(median; IQR) 
 
7 (6 – 8) 7 (6 – 8) 6 (5 – 8) 7 (6 – 9) 0.833 
 
EQ-5D Index 0.81  
(0.76–0.85) 
 
0.79  
(0.59-0.83) 
0.83  
(0.78–1.00) 
0.81  
(0.71-0.84) 
0.024 
EQ-5D VAS 
(median; IQR) 
 
75  
(55 - 90) 
80  
(60 – 90) 
75  
(60 – 90) 
70  
(50 – 84) 
0.278 
 
Level 1; no problems, Level 2; some problems, Level 3; severe problems 
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Figure 8-10 - A histogram of Charlson Index Scores in the cohort (n=411) 
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8.3.13  Co morbidity and the Quality Outcomes Framework 
The cohort was identified using the GP CKD register, maintained as part of the Quality and 
Outcomes Framework. The participants are offered regular monitoring of blood and urine 
parameters and blood pressure measurements. In addition to CKD there a number of other 
chronic conditions that are included in the QOF such as diabetes and ischaemic heart 
disease. Only 14% of the cohort (n=56) do not have another condition included in the QOF 
that would already result in regular monitoring of these parameters. Of those with an 
eGFR>60ml/min/1.73m
2
 (i.e. those who do not currently meet the criteria to be included 
on the register) only 23 (20.4% of those with eGFR>60ml/min/1.73m
2
) or 5.6% of the total 
cohort did not have another condition included in the QOF monitoring. 
 
8.3.14  The impact of age in the cohort 
The median age of the cohort was 70.6 years. Therefore the cohort was divided into 2 
groups using 70 years as the cut-point to produce two approximately equal groups. The 
comparison of key features between the groups is shown in table 8-13. 
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Table 8-13 - Demographic information divided according to age 
 Age ≤ 70 years Age >70 years Significance 
Female  
(%) 
58 59 0.851 
SIMD rank 
(median; IQR) 
2365 
(1197 – 4323) 
2306 
(1273  -4759) 
0.829 
sCr  
(micromol/L; IQR) 
103 (88 - 121) 110 (91 – 124) 0.215 
eGFR (ml/min/1.73m
2
; 
IQR) 
56 (47 - 63) 51 (43 - 59) 0.002 
eGFR<45ml/min/1.73m
2
 
(%) 
21.1 33.6 0.005 
TPCR  
(mg/mmol; IQR) 
9.4 (6.4 – 14.1) 10.6 (6.9 – 17.3) 0.077 
ACR  
(mg/mmol:IQR) 
0.84 (0.52 – 1.7) 0.9 (0.6 – 1.7) 0.106 
BMI  
(kg/m
2
; ±SD) 
31.1 (±6.0) 29.0 (±5.1) <0.001 
SBP  
(mmHg; ±SD) 
131 (±20) 139 (±23) <0.001 
DBP  
(mmHg; ±SD) 
80 (±11) 73 (±12) <0.001 
Pulse pressure  
(mmHg; ±SD) 
52 (±17) 66 (±20) <0.001 
Hypertension  
(%) 
72.4 77.0 0.289 
Diabetes  
(%) 
21.1 19.5 0.685 
Vascular disease  
(%) 
33.0 50.4 <0.001 
ACEi usage  
(%) 
66.5 73.9 0.101 
Charlson score 
(median; IQR) 
1 (0 – 2) 1 (0 – 2) 0.082 
EQ5D score 
(median;IQR)  
7 (5 – 8) 7 (6 – 8) 0.384 
Haemoglobin  
(g/dL; ±SD) 
13.8 (±1.5) 13.3 (±1.6) 0.001 
Adjusted calcium  
(mmol/L; ±SD) 
2.2 (±0.1) 2.2 (±0.1) 0.095 
PO4  
(mmol/L; SD) 
0.9 (±0.2) 0.9 (±0.2) 0.654 
PTH  
(pmol/L; ±SD) 
8.1 (±4.6) 9.1 (±5.1) 0.039 
Vitamin D  
(nmol/L; ±SD)  
39 (±21) 37 (±22) 0.295 
Urate  
(mmol/L; ±SD) 
0.38 (±0.10) 0.38 (±0.1) 0.742 
Total cholesterol  
(mmol/L; ±SD) 
5.0 (±1.2) 4.7 (±1.2) 0.006 
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8.3.15  Outcomes 
The cohort has been followed for a median of 13.2 months (11.1 – 15.7) to date. During 
this time 8 participants (1.9%) died, one has commenced renal replacement therapy, and no 
participant sustained a doubling of serum creatinine.  
 
Three hundred and fifty eight participants (87%) have had subsequent serum creatinine and 
eGFR measurements. Of those with baseline eGFR >60ml/min/1.73m
2 
(n=109), 88 have 
had follow-up measurements recorded and 51% of those now have eGFR 
<60ml/min/1.73m
2
. The median change in eGFR from baseline measurement is  
-0.2ml/min/1.73m
2
 (-0.73 – 0.20). 
 
Data regarding cardiovascular events is not yet available.
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8.4 Discussion 
8.4.1 Findings of the Study 
In this chapter we have presented the baseline results of an observational longitudinal 
cohort study of patients with a diagnosis of chronic kidney disease in primary care, 
recruited from varied rural and urban settings and differing levels of deprivation in order to 
obtain a representative sample of the Ayrshire population. The participants are 
predominantly female, white and elderly with a mean age of 70.6 years. The 
socioeconomic and ethnic make-up of the cohort is representative of Ayrshire (217, 269). 
Overall the cohort has early CKD with a median eGFR of 54ml/min/1.73m
2
. A significant 
proportion of the cohort had an eGFR >60ml/min/1.73m
2
 (26.5% using the MDRD 
formula) which rose to 23.8% when eGFR was calculated using the CKD-EPI formulae. 
The design of the study was pragmatic; all patients with a coded diagnosis of CKD were 
invited to participate, rather than those who we identified as having CKD stages 3-5 using 
the KDIGO definition (6). There are strengths and weaknesses to this approach. The 
strength is to obtain a truly representative sample of those patients who are being treated as 
having CKD by their GPs rather than those who strictly fit the criteria, and allows 
comparison over time with those with consistent eGFR<60ml/min/1.73m
2
. The weakness 
is that the absolute number of those with eGFR< 60ml/min/1.73m
2
 in the study is lower 
and therefore some statistical power is lost. However the natural history of the group with 
eGFR> 60ml/min/1.73m
2
 will be of interest during the follow-up period. Some of this 
group may have borderline function and eGFR dips below the threshold on random 
samples, but is >60ml/min/1.73m
2
 when a meat fasted sample is taken (as the baseline 
study sample was). Alternatively they may have highly variable renal function as a result 
of altered haemodynamics and renal perfusion and therefore still represent a high risk 
group. Or some patients may have simply been misclassified; perhaps as a result of 
creatinine being checked during an intercurrent illness (over 60% are taking renin 
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angiotensin system blockade which puts them at increased risk of AKI (134)). This will 
become clear during follow-up. Reviewing the previous results gave some insight into this 
with 58% of the eGFR> 60 ml/min/1.73m
2
 group having had a single low eGFR result in 
the preceding year, and 20% having had 2 low results greater than 90 days apart (the NKF-
KDIGO definition of CKD stage 3 - 5). The vast majority have never seen a nephrologist 
and 84% did not have a cause of their renal disease recorded in their GP records. The 
prevalence of proteinuria in the cohort was notably low with 67% having no urine protein 
detectable on dipstick and 74% having a normal TCPR (<15mg/mmol) and 83% having a 
normal ACR (<3mg/mmol). The prevalence of macroalbuminuria was higher in the group 
with diabetes, but overall prevalence was still low. Only 15 participants had a TPCR 
>50mg/mmol, and 7 of those had discordant results with a high proportion of non-albumin 
proteinuria (high TPCR but low ACR). The discordant group were older, with better renal 
function and significantly more CKD of unknown aetiology. The urine sodium levels of 
the participants were high in keeping with a high salt diet (as measured by urine sodium in 
mmol/ L and the sodium: creatinine ratio [mmol/mmol]). The long term significance of 
sodium: creatinine ratios derived from spot samples is not known currently, and this will 
be of interest in the future. There is a large burden of pre-existent cardiovascular disease 
and cardiovascular risk factors in the cohort. Seventy five per cent have been diagnosed 
with hypertension, which is generally well controlled with a median of two 
antihypertensive agents. Forty three per cent have a history of vascular disease (ischaemic 
heart disease, peripheral vascular disease or cerebrovascular disease). Over 60% are 
currently receiving a statin, though very few are receiving combination therapy with 
ezetimibe as the recent SHARP study would suggest they should (161), over 50% have a 
family history of vascular disease and over 50% are either current or former smokers. 
There is also a very high prevalence of obesity with 45% of the overall cohort having a 
BMI of >30kg/m
2
 (approximately 30% of age matched men and women have BMI 
30kg/m
2
 in the Scottish Health Survey) (271). Alcohol consumption was generally very 
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low. The participants have a number of co-morbid conditions (as measured by the Charlson 
score) with 18% having a score >2. Quality of life was measured using the EQ-5D 
questionnaire and the median value for global health state using a visual analogous scale 
was 75%, comparable to that of patients with many cancers (272) and much lower than the 
UK mean of 83% (273). The median calculated EQ-5D index was 0.81 (0.76 – 0.85) which 
is very similar to other studies of patients with conditions such as type 2 diabetes (274) but 
lower than a Japanese CKD cohort (275). 
 
Comparison was made between those over 70 years of age and those 70 years or less. 
Kidney function was significantly worse in the older group as measured by eGFR 
(p=0.002). Systolic blood pressure and pulse pressure were significantly higher in the older 
group, as was the prevalence of vascular disease.  
 
Overall the cohort has an apparently low risk of progressive renal decline and the need for 
renal replacement therapy, with low prevalence of proteinuria, older age and relatively 
preserved excretory renal function. However the risk of future cardiovascular events is 
high with a significant proportion having pre-existing vascular disease and a large burden 
of cardiovascular risk factors. These outcomes will be followed over the next 10 years.  
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8.4.2 Comparison with Other Cohorts 
The demographics of this cohort are similar to those of the patients with equivalent 
severity of CKD in the overall population, as presented in the laboratory database analysis 
in chapter 6, demonstrating that we have recruited a broadly representative sample of the 
Ayrshire population. Compared to the general population of Ayrshire (and Scotland as a 
whole), the cohort is older, with a higher proportion of women. The proportion of study 
participants from minority ethnic groups is very low compared to the general population of 
Scotland, but is more representative of Ayrshire which is not an ethnically diverse area 
(217). The demographics are strikingly similar to those of the CKD cohort from the Renal 
Research in Derby (RRID) study and a longer term comparison of the outcomes in these 
similar CKD cohorts from different parts of the UK should be informative (276). It is 
notable that the demographics of the UK studies are quite different to those of the large 
American Chronic Renal Insufficiency Cohort (CRIC) which has a younger cohort with 
more severe renal disease and a large proportion of black and hispanic participants (277). 
The selection criteria for this cohort and RRID were very similar and designed to reflect 
real life practice in the UK, while CRIC purposefully limited the number of older 
individuals recruited by using age-based eGFR entry criteria and an upper age limit of 74 
years.  
 
We can also compare the community cohort to that of the patients under follow-up in the 
Glasgow nephrology clinic, the cohort described in chapters 2 – 5, with the community 
cohort being older, with a higher proportion of women, better renal function and less 
proteinuria. A table comparing the key demographics of these cohorts is shown below 
(table 8-12). Patients receiving RRT in Scotland are also younger with a higher proportion 
of men (12). These important differences should be taken into account when providing 
advice to primary care, and cohorts such as this one will provide evidence to guide such 
recommendations in the future. 
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Table 8-14 - Comparison of key demographics of the study cohort with other CKD cohorts 
 
 Triple A RRID Glasgow 
Nephrology 
Clinic 
CRIC 
Age  
(years; ±SD ) 
71 ± 10 73 ±9 59 ± 16 58 ±11 
Sex  
(% female) 
59 60 50 46 
Ethnicity  
(% white) 
99.5 97.5 - 45 
Serum 
creatinine 
(adjusted) 
(µmol/L; IQR) 
103 (86 – 119) - 140 (100 – 190) 153 ±50 
MDRD eGFR 
(ml/min/1.73m
2
) 
54 (44 – 61) 52±10 42 (28 – 63) 43±13 
24-hour urine 
protein (g/day) 
- - 0.34  
(0.15 – 0.92) 
0.17  
(0.07 – 0.81) 
ACR 
(mg/mmol; 
IQR)) 
0.9 (0.5 – 1.7) 0.33 (0 – 1.5) 10 (2 – 48) - 
TPCR 
(mg/mmol; 
IQR)) 
10 (7 – 15)  35 (17 – 106) - 
Blood pressure 
(mmHg; ±SD) 
141/79 ± 22/12 134/73 ±18/11 144/78 ±27/14 128/71 ± 22/13 
ACEi/ARB 
therapy (%) 
69 65 22 68 
 
8.4.3 The added value of the Primary Care CKD Register? 
This cohort was recruited by identifying potential participants from primary care CKD 
registers. These registers allow automatic recall notices to be sent to patients to facilitate 
regular monitoring of kidney function (blood and urine) and blood pressure control. 
However the observation that only 14% of the cohort do not have another condition that 
would lead to regular monitoring calls in to question the value of the CKD register, in 
addition to those for conditions such as diabetes and ischaemic heart disease.  
 
 Additionally over 26% of the cohort had an eGFR>60ml/min/1.73m
2
 and may not require 
specific renal monitoring. Twenty per cent of those did not have another condition that 
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would lead to regular monitoring and therefore may be receiving this monitoring 
spuriously as they do not meet the criteria for CKD in the first instance. Potentially this 
may lead to anxiety and definitely adds to costs with little current evidence of benefit. 
According to the QOF data, the prevalence of CKD in Ayrshire is around 4.3%. The 
prevalence in the laboratory database study in chapter 6 was 5.63% using the MDRD 
formula, though this was based on single creatinine measurements which can lead to a 
degree of overestimation. The QOF prevalence in Ayrshire is the highest in Scotland. 
However this study would suggest that a significant proportion (26%) of those on the CKD 
registers do not have an eGFR<60ml/min/1.73m
2
, and if we extrapolate these findings to 
the whole Scottish and UK population it may be that thousands of patients are included in 
registers of CKD who are ineligible, and thousands of patients who do meet the criteria 
have not yet been registered, five years after the introduction of CKD to the QOF. 
 
8.4.4 Limitations 
Over one fifth of the cohort had eGFR>60ml/min/1.73m
2
 on the meat fast sample and the 
implications of this are discussed in section 8.4.1. Further detailed assessment of vascular 
function would have been beneficial but this could not be performed in the primary care 
setting. A number of the primary care premises where participants were recruited were a 
significant distance from hospital. The requirement of an additional compulsory hospital 
visit may have deterred frail participants or resulted in selection bias. The primary care 
setting was one of the key aspects of the study design to maximise the recruitment of a 
representative cohort. The data regarding outcomes will be gathered via remote follow-up, 
using the Scottish electronic renal patient record and data from the information and 
statistics division of NHS Scotland. This limits the availability of further clinical 
parameters such as blood pressure measurements. However it is an extremely robust 
method, as by using the unique community health index identifier, all laboratory blood and 
urine parameters will be electronically downloaded and this will limit the number of 
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participants who are lost to follow-up. Likewise, the data on cardiovascular events and date 
and cause of death will be electronically downloaded from a central source allowing more 
complete data collection.  
 
The strengths of this study are the detailed baseline assessment, performed by a single 
investigator (SM) which eliminates inter-observer variation, and the representative nature 
of the cohort.  
 
8.4.5 Conclusion 
This study presents a representative cohort of patients with CKD in primary care in 
Ayrshire, who are predominantly female, elderly, overweight or obese, with early CKD. 
The prevalence of proteinuria is notably low and the prevalence of pre-existent 
cardiovascular disease and cardiovascular risk factors is high. They represent a cohort at 
high risk of subsequent cardiovascular events and death and low risk of requiring renal 
replacement therapy. They have a different risk profile from those attending hospital 
nephrology clinics and the outcomes of this cohort will provide evidence for appropriate 
guidance on the investigation, monitoring and management of patients with CKD in 
primary care in the future.  
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9 Chapter 9: Discussion 
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9.1 Summary of findings 
The aim of this thesis was to explore the optimal measurements of renal function and the 
optimal predictors of renal and patient outcome in those with chronic kidney disease in a 
variety of settings including a hospital nephrology clinic, a laboratory database of the 
general population, a specialist hypertension clinic and a primary care setting.  
 
The main findings were: 
• TPCR is a more sensitive predictor of 24-hour total proteinuria than ACR in a cohort of 
patients with CKD attending a hospital nephrology clinic, though the performance of 
both varies significantly with age and gender. 
 
• TPCR and ACR are both strong independent predictors of renal and patient outcome in 
a cohort of patients with CKD attending a hospital nephrology clinic. They were as 
powerful as 24-hour total proteinuria and albuminuria to predict outcomes. TPCR 
performed well at low levels (15-50 mg/mmol), where albuminuria has traditionally 
been considered to be the superior marker. 
 
• Using TPCR as a screening test identifies a group of patients with a high proportion of 
non-albumin proteinuria, who are not identified using ACR alone. This group is at 
higher risk of adverse outcomes than those with equivalent levels of albuminuria. 
 
• TPCR and ACR vary between individuals as a result of differences in creatinine 
excretion in addition to changes in protein excretion. Adjusting TPCR and ACR for 
creatinine excretion (measured or estimated) improves the performance of TCPR/ACR 
to predict 24-hour proteinuria.  However, this adjustment does not improve the 
prediction of renal and patient outcomes. 
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• The prevalence of CKD stages 3 – 5 falls when MDRD eGFR is replaced by the CKD-
EPI formula in a laboratory database of all creatinine samples measured during two 12-
month periods in Ayrshire. The population prevalence of CKD stages 3 – 5 remained 
stable over a 5-year period, when the CKD-EPI equation was used to calculate eGFR, 
despite a rise in the number of patients having their creatinine measured. 
 
• Baseline reduced eGFR and dipstick proteinuria independently predict poor outcome in 
patients attending a specialist hypertension clinic, despite subsequent intensive 
management of blood pressure. 
 
• Patients in the community with CKD are predominantly overweight or obese, elderly 
white women with early CKD. They have a large burden of pre-existent cardiovascular 
disease and cardiovascular risk factors and a low risk of requiring renal replacement 
therapy as a result of an extremely low prevalence of proteinuria and relatively 
preserved excretory renal function.  
 
• The community cohort was recruited by interrogating the primary care CKD registers 
for those identified as having a diagnosis of CKD stages 3-5. However, over one 
quarter of the community CKD cohort did not meet the diagnostic criteria for CKD 
stage 3-5 when creatinine analysis was performed on a fasted sample.  
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9.2 Strengths of the studies 
The nephrology clinic cohort (chapters 2-5) is large and unique in the fact that both TPCR 
and ACR were measured prospectively in all those attending the clinic, allowing the 
comparisons presented here. The geography of Ayrshire means that virtually all blood 
samples taken within the health board area are analysed at a single laboratory, meaning 
that the prevalence estimates in chapter 6 are reliable (allowing for the inherent 
weaknesses of any laboratory database analysis). The community cohort was extremely 
well phenotyped by a single investigator (SM) and robust arrangements are in place for 
follow-up for the next 10 years. The hypertension database is also relatively unique as a 
result of its size, completeness, length of follow-up and large number of events.  
 
9.3 Prediction of 24-hour Total Proteinuria 
Given that proteinuria is the single strongest predictor of renal progression, the accurate 
quantification of urine protein is paramount. Total proteinuria was traditionally measured 
until relatively recently when albumin came to the fore. The theory was that albuminuria is 
pathological, in contrast to physiological non-albumin proteins such as uromodulin. 
Therefore measuring only the single entity of albumin would improve the signal: noise 
ratio (with albumin the signal and NAP the noise) and subsequently improve the diagnosis 
of renal disease. However the evidence for clinical interventions in non-diabetic CKD such 
as target blood pressure and renin-angiotensin system blockade is based on the 
measurement of 24-hour total proteinuria (138) and there have been few studies comparing 
the performance of total proteinuria and albuminuria as diagnostic tests.  
 
Twenty-four-hour urine collections have traditionally been considered the gold standard, 
however there is increasing evidence of the utility of spot samples and they are in 
widespread use. Therefore the spot measurement (whether that be total protein or albumin) 
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needs to have a good overall correlation with 24-hour total proteinuria. Additionally, it 
should correctly identify patients excreting >0.5 g/day or >1 g/day of proteinuria as these 
are important diagnostic thresholds. In chapter 2 we studied a secondary care cohort of 
6842 patients with CKD who had undergone simultaneous measurements of total protein, 
albumin and creatinine on spot urine samples.  TPCR had a superior test performance to 
ACR to predict 24-hour proteinuria. {{}} ACR had a sensitivity of only 79.0%, compared 
to TPCR’s sensitivity of 93.9% to predict 1 g/day of total proteinuria. To improve the 
sensitivity of ACR to a comparable level with TPCR, the cut point fell to an ACR of 17.5 
mg/mmol, with resultant fall in specificity to 69.8% (cf. TPCR 88.5%). Given that spot 
urine tests are primarily used by non-nephrologists to identify high risk patients for onward 
referral, investigation and treatment, sensitivity is of prime importance. 
 
9.4 Prediction of Outcomes Relevant to Patients 
It is perhaps unsurprising that TPCR is superior to ACR at predicting 24-hour urine total 
protein. Far more important than the ability to predict 24-hour total proteinuria, is the 
prediction of patient-relevant outcomes in CKD. There is increasingly strong evidence 
demonstrating the importance of proteinuria as a predictor of patient outcomes, whether 
measured by dipstick, ACR or TPCR (20, 69, 197). In chapter 3, we demonstrated that 
TPCR and ACR had comparable performance to predict doubling of serum creatinine, 
commencing RRT and all-cause mortality in a retrospective study of 5586 patients with 
CKD attending hospital renal clinics. This has not been shown previously. We also showed 
that the performance of TPCR and ACR was comparable to that of 24-hour collections to 
predict outcomes in this cohort.   
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9.5 The Issue of Non-Albumin Proteinuria 
TPCR takes account of non-albumin proteins while ACR only measures albumin. 
In chapter 4 using the same retrospective secondary care cohort, we examined the 
outcomes of patients with high levels of non-albumin proteinuria who would not have been 
identified as having significant proteinuria using ACR alone. Those with high levels of 
NAP were older, with poorer kidney function and had worse outcomes than those with 
heavy albuminuria (in terms of all-cause mortality and progressive renal decline measured 
by doubling of serum creatinine and commencement of RRT). When these factors were 
entered into a multi-variate model some of the excess risk was truncated, but they still 
remained a high risk group that would be identified using TPCR, but not ACR which failed 
to identify 16% of patients with proteinuria >1 g/day. The AusDIAB study in a general 
population sample, and using a lower threshold for proteinuria (≤0.2 mg/mg equating to 
0.2 g/day) also found that ACR failed to detect 8% of patients with proteinuria (95). Non-
albumin proteinuria covers a diverse spectrum from small proteins such as beta-2-
microglobulin, representing tubular dysfunction, to large proteins such as transferrin, 
whose presence in the urine suggests loss of glomerular size selectivity. Despite this 
diversity the presence of a high proportion of non-albumin proteins in the urine would 
appear to offer additional prognostic information.  
 
9.6 The Issue of Microalbuminuria 
One of the arguments often given in favour of ACR is that it has superior sensitivity at low 
levels (around 3 – 30 mg/mmol, known as microalbuminuria) because of the signal: noise 
ratio described above. This assumes that the quantity of non-albumin proteinuria adds no 
additional information to albumin, and that the quantity of physiological proteinuria is 
irrelevant to risk.  
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However, our study showed that TPCR had comparable performance to ACR at 
microalbuminuria levels. Risk associated with albuminuria is raised even at levels lower 
than microalbuminuria (20). However, even when our reference group was divided in two, 
and the lower half used as the reference group in survival modelling, the utility of TPCR 
persisted showing that low levels of TPCR are clinically useful. These unexpected findings 
need to be confirmed by others, but challenge the paradigm. 
 
9.7 The Issue of Muscle Mass 
In chapter 2 the sensitivity and specificity of TPCR and ACR were found to vary according 
to age and sex, with a three-fold difference in the diagnostic threshold for an elderly 
woman versus a young man. We hypothesised that this was as a result of differing muscle 
mass, and therefore differing urine creatinine excretion (used as the denominator in TPCR 
and ACR). This has been acknowledged in some guidelines in the past where a different 
ACR reference range was recommended for males versus females (usually <2.5mg/mmol 
for males and <3.5mg/mmol for females) however a differential threshold has not 
previously been recommended for higher thresholds (such as 30 or 70mg/mmol) nor for 
TPCR.  Therefore in chapter 5 we adjusted TPCR and ACR for predicted creatinine 
excretion and found that this approach was successful in improving the prediction of 24-
hour proteinuria, especially in those with low muscle mass such as the elderly and females, 
with the result that differences in performance between sub-groups were eliminated. 
However the adjustment led to an inferior test performance for the prediction of renal and 
patient outcomes. This may reflect that urine creatinine was acting as an independent 
predictor of outcome. Therefore, whether TPCR and ACR should be adjusted for creatinine 
excretion depends on the intended purpose of the test: if TPCR is being measured to 
accurately quantify urine protein excretion (for instance to guide the decision to perform a 
renal biopsy) then adjusting for urine creatinine will afford an advantage in certain groups 
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of patients. However if the TPCR or ACR is being measured as a prognostic marker (i.e. to 
identify those at risk from subsequent adverse outcomes such as cardiovascular disease) 
then the unadjusted value, including the influence of urine creatinine, will provide more 
information that the proteinuria quantification alone. This issue is of particular importance 
given the ongoing development of renal and cardiovascular risk scores: the TPCR or ACR 
consist of 2 distinct biomarkers.  
 
9.8 eGFR estimation 
In chapter 6 we assessed the impact on CKD prevalence of changing from the MDRD 
formula to the CKD-EPI formulae for the routine estimation of eGFR in the Ayrshire 
population. The prevalence fell using the CKD-EPI formula predominantly as a result of 
reclassification from Stage 3A CKD to eGFR >60ml/min/1.73m
2
 in middle aged women. 
The formulae were applied longitudinally in a 12 month period in 2006 and then in 2010-
11; prevalence rose slightly between the study periods using the MDRD formulae but 
remained stable when the CKD-EPI formulae were used. The group that were re-classified 
as having better renal function have been shown to be low risk in other cohorts(254), 
however there is also a group (of predominantly elderly women) who were re-classified 
downwards to a more advanced stage of CKD and their outcomes remain unclear at 
present. Therefore, it may be premature to replace the MDRD formula with the CKD-EPI 
formulae in the UK at present.  
 
9.9 Have 24-hour urine collections had their day? 
In the studies described in this thesis we have shown that 24-hour urine collections are not 
needed to identify significant proteinuria, nor are they necessary as a prognostic indicator. 
Formulae to calculate eGFR are becoming ever more precise and accurate and so the role 
of the 24-hour collection to measure creatinine clearance is becoming more limited. Based 
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on these findings some might conclude that the 24-hour urine collection for total protein, 
albumin and creatinine(92) is no longer indicated except for very specific circumstances 
(such as cytotoxic drug dosing), though there are still some who disagree (92). 
 
9.10  CKD in a community cohort 
In chapter 7 the baseline characteristics of a prospective community cohort of patients with 
CKD are described. They differ markedly from the demographics of those attending 
hospital clinics, and those receiving RRT. They are predominantly elderly women with a 
large burden of hypertension and cardiovascular disease. Proteinuria is of notably low 
prevalence, however the use of renin angiotensin system blockade is high. Primary vitamin 
D deficiency is extremely common, but renal bone disease is not. The incidence of other 
complications of kidney disease such as anaemia, metabolic acidosis and 
hypoalbuminaemia is low. They represent a cohort at high risk of cardiovascular death, and 
a low risk of progressive renal decline. The cohort will be followed-up for 10 years and 
should provide valuable insights to guide recommendations for the management of CKD in 
the community. 
 
9.11 The issue of overdiagnosis 
The community cohort was recruited from 7 general practices by inviting all patients 
included in the CKD register. Over one quarter did not have an eGFR<60ml/min/1.73m
2
 
according to the meat fasted sample taken at the study visit (the criterion by which patients 
should be added to the register) and over one fifth did not have any sign of kidney disease 
at all. Estimates of CKD prevalence differ around the world, but are generally high. There 
has been considerable debate in the nephrology community regarding the possible 
overdiagnosis of CKD (278). Areas of disagreement include issues such as medicalisation 
of old age, over ascertainment of CKD because of the imprecision of eGFR formulae or 
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incorrect measurement of non meat-fasted samples (239, 267). The inclusion of samples 
taken during intercurrent illness which are not repeated during the convalescent phase to 
confirm CKD (rather than AKI) may exacerbate the problem. These issues are not confined 
to nephrology with other conditions including prostate cancer and gestational diabetes 
being the subject of similar debate (279). 
 
9.12  CKD in a hypertension cohort 
In chapter 8 baseline measurements of eGFR and dipstick proteinuria are shown to be 
independent predictors of cardiovascular and all-cause mortality in a cohort of patients 
attending a specialist hypertension clinic. A reduced eGFR and dipstick proteinuria 
identify almost mutually exclusive high risk groups, and in the minority with both 
abnormalities the risk is even greater.  It is notable that these simple baseline measures 
remain such powerful predictors despite subsequent aggressive modification of 
hypertension and could be utilised as powerful risk markers at baseline.  
 
9.13  Limitations of these studies 
Chapters 2 – 5 are based on retrospective data gathered in the course of routine clinical 
care and therefore have limitations of some missing data and potential bias. For instance, 
everyone attending the clinics had their urine sent for spot quantification but 24-hour 
collections were requested at the discretion of the individual clinician. 
 
The study of CKD prevalence in chapter 6 was a laboratory database study which has 
inherent limitations; only those individuals with a serum creatinine measurement in the 
course of their clinical care were included, and no clinical data were available to correlate 
with biochemical parameters. However, reassuringly, between 2006 and 2011 (the first and 
second study periods) the number of individuals undergoing creatinine measurement rose 
Chapter 9  266 
 266 
dramatically but the prevalence of CKD did not, implying that ascertainment is already 
high. 
 
In the community cohort study a significant number of the participants had an eGFR 
>60ml/min/1.73m
2
 on the meat fasted study sample. This was anticipated (though the scale 
was not expected) but gives an extremely useful insight into the limitations of the CKD 
classification, and the realities of the identification of CKD in primary care. Interestingly 
the proportion with eGFR >60ml/min/1.73m
2 
in the cohort on the follow up measurements 
(after median 13 months follow-up) was much lower.  
 
In the hypertension cohort the urine protein was measured by dipstick which is less 
sensitive and specific than laboratory quantification, however the prognostic importance of 
proteinuria was still demonstrated.  
 
In both chapters 6 and 7 eGFR was based on a single creatinine measurement, which has 
limitations as described above, though measures were taken to minimise the impact of this. 
The samples were not fasted.  
 
9.14  Future studies 
A prospective study comparing TPCR and ACR as predictors of outcome is needed. 
Comparison with other cohorts would be valuable. Both total protein and albumin have 
been measured in our community cohort study but this population has a low prevalence of 
proteinuria and therefore may not be able to answer the question. The importance of 
specific non-albumin proteins in the urine should be examined, both for prognostication 
and to shed light on underlying pathophysiology. The expanding field of urine proteomics 
may allow the identification of novel prognostic urine markers.  Clinical assessment of 
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muscle mass (for instance using bio-impedance techniques) would be worthwhile in any 
future study of urine creatinine excretion. An evaluation of outcomes in a large cohort of 
people who are re-classified from CKD Stage 3A to eGFR>60ml/min/1.73m
2
 and those re-
classified to a more advanced stage of kidney disease is necessary before the new CKD-
EPI formulae are adopted into clinical practice in the UK.  
 
Samples from the community cohort have been stored to allow future study of novel 
biomarkers in the urine and blood, and the 10-year follow-up data will provide data on 
renal and patient outcomes. These data, when combined with other cohorts, will hopefully 
provide further insights into the predictors of outcome in early CKD and allow the 
development of robust renal risk scores. This is essential for the future, given the high and 
possibly rising prevalence of CKD, in order to allow the limited healthcare resources to be 
targeted at those at highest risk of adverse renal and cardiovascular outcomes in the future. 
Whole blood has also been stored from the cohort to allow DNA analysis in the future, 
perhaps to look for genetic promoters or inhibitors of renal progression.  
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9.15  Conclusions 
This thesis investigated optimal measurements of renal function and the optimal predictors 
of renal and patient outcome in patients with CKD. Firstly, the role of TPCR and ACR in 
the risk stratification of patients with CKD was examined. TPCR is the superior predictor 
of 24-hour total proteinuria on which the evidence for our current interventions is based. It 
performs equally well as ACR to predict clinically relevant outcomes including renal and 
patient survival and performs well at low levels where albumin has traditionally been seen 
to be the superior marker. Only TPCR takes account of non-albumin proteins that may play 
an important pathological role in the progression of renal disease. Furthermore, adjusting 
TPCR and ACR for creatinine excretion improves the accuracy of urine protein 
quantification, but does not improve prediction of patient relevant outcomes. More 
research is needed to compare these tests prospectively before a definitive answer can be 
found but in the meantime TPCR remains a cheap, powerful test to identify patients at high 
risk of adverse outcomes.  
 
Secondly the role of eGFR was examined. The prevalence of CKD Stages 3 – 5 falls if the 
CKD-EPI formulae are used in place of the MDRD formula for the estimation of eGFR in 
the Ayrshire population.  The predictive role of eGFR was also examined. Baseline eGFR 
is a powerful independent predictor of adverse outcomes in a specialist hypertension cohort 
despite subsequent specialist intervention. Dipstick proteinuria also identifies a high risk 
group in this cohort and the two combine to provide important prognostic information and 
should be used for risk stratification in patients with hypertension. 
 
Lastly in order to examine the prognostic role of eGFR and proteinuria prospectively, 
along with other predictors of outcome, a community cohort of patients with CKD was 
recruited. They differ significantly from those under hospital follow-up with a low risk of 
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renal progression versus a large burden of cardiovascular disease. A considerable 
proportion of the cohort did not meet the eGFR criteria for CKD stages 3-5 on the serum 
creatinine measurement of the meat fasted study sample, suggesting that overdiagnosis of 
CKD may be an issue in the community in the UK.  
 
Proteinuria and eGFR are two of the key aspects of the diagnosis and monitoring of 
chronic kidney disease. Identification of the optimal measures of both is therefore 
essential, and the findings presented in this thesis contribute to that. There is an urgent 
need to refine our risk stratification abilities in CKD, in order to identify those who require 
intensive intervention, and to reassure the others. The findings of this thesis also contribute 
to that. Further study is required to refine these core aspects of the diagnosis, investigation 
and management of CKD.  
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GP Headed Notepaper 
Date as postmark 
 
 
Dear  
 
A study of the factors influencing outcomes in patients with chronic 
kidney disease  
 
We would like to invite you to take part in the above research study that is happening in 
your GP practice. The study aims to look into factors that cause worsening kidney disease 
and to look at factors that may contribute to heart disease in patients with kidney disease. 
Our records indicate that you have a mild to moderate reduction in your kidney function 
and therefore qualify to be included in the study. Please take a few moments to read the 
following information regarding the term Chronic Kidney Disease. 
 
• Chronic Kidney Disease is the international term used to describe deterioration in 
kidney function over a long period of time. However, it may not necessarily mean 
there is a disease as such, but more that the kidneys aren’t functioning at the level 
they once were. 
• The level of kidney function that you may have affects about 5% (1 in 20) of the 
UK population.  
• For the vast majority of people nothing else will happen. However there will be a 
small minority of people who will develop more advanced kidney problem, and 
will need specialist kidney care.  
• This research is to try to work out who will and who won’t develop more severe 
kidney disease and to identify what it is that makes most people stable, but for 
some makes their condition progress.  
 
The researchers are kidney doctors based in Crosshouse Hospital Renal Unit and your GP 
practice is helping them with the study. In the envelope, along with this letter you will find 
a participant information sheet, which explains in some detail what the study will involve. 
Please read this carefully. You will not be paid to take part in the study, but we can refund 
the cost of your travel (bus fare, petrol etc) so please keep your ticket. 
 
If you would like to discuss the study further or have questions, please contact the 
researchers (contact details on the Information sheet) or me. Once you have decided 
whether or not to participate please telephone 01563 825132 to arrange the first study visit 
(at the GP practice) or to inform the researchers that you do not wish to participate. If there 
is no answer, please leave your name and telephone number and somebody will get back to 
you to make arrangements. Due to the high volume of calls, please do not worry if your 
call is not returned on the same day.  
 
 
 
You can also contact us by post or email: 
 
By post:  Dr Shona Methven, Renal Office, Level 2 East, Crosshouse Hospital,            
Kilmarnock KA2 0BE 
By email:  shona.methven@nhs.net 
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If we do not hear from you in the next 2 weeks, we will write again to ask you to take part. 
If we still do not hear from you, we will not get back in touch. 
 
We look forward to hearing from you. 
 
Yours sincerely 
 
 
 
 
General Practitioner    
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Participant Information Sheet                  
A study of the factors influencing outcomes in patients with chronic kidney disease 
 
You are being invited to take part in a research study.  Before you decide if you wish to take part, it 
is important for you to understand why the research is being done and what it involves.  Please take 
time to read the following information carefully and discuss it with others if you wish.  Ask us if 
there is anything that is not clear or if you would like more information.  Take time to decide 
whether or not you wish to take part. Thank you for reading this. 
 
What is the purpose of the study? 
Chronic kidney disease (CKD) is common. It affects 8 - 13% of the population. It is important 
because it is associated with an increased risk of disease of the blood vessels (vascular disease). 
Most of the research on this condition has been performed with people who were attending hospital 
clinics. We do not know if people with CKD, who are looked after by their General Practitioner 
(GP) should be looked after the same way. The aim of this project is to study people with CKD in 
the community for the next 10 years, to find out what happens to them.  
 
Why have I been chosen? 
You have been invited to take part because you have chronic kidney disease, and your GP looks 
after you. We plan to study 500 people with chronic kidney disease. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you will be asked 
to sign a consent form. You will be given this information sheet and a copy of the signed consent 
form, to keep. If you decide to take part, you are free to withdraw at any time and without giving a 
reason. Your usual treatment will not be affected in any way if you do not wish to take part or if 
you withdraw. 
  
What will happen to me if I take part? 
Most people will be asked to come for one visit to their GP practice. Some people may be asked to 
come back for a second visit to their GP practice or the hospital. There will be no further visits for 
the study. We will contact you by letter after a year to ask you to fill in a questionnaire.  
 
The doctors who are running the research project will look at the computer records that your GP 
practice keep about you (not the paper records). We will enter your personal details onto a 
confidential NHS database called the Scottish Electronic Renal Patient Record. This is linked to 
other NHS computers, which contain records of laboratory results, hospital admissions, diagnoses, 
and operations. This will allow us to see what happens to your health over the next 10 years, 
without having to contact you regularly.  
 
If something happens to you, and you are no longer able to make decisions about being in the 
study, we will not ask for any more blood or urine samples. If you have consented to be in the 
study, we will assume that we can continue to gather information about your health as described 
above. If you change your mind, and ask us to stop collecting information, we will of course, stop 
immediately. You would not have to explain why. 
 
You will not be given any specific treatment as part of the study, you will receive all the usual 
treatments from you own doctor, and we will keep a record of those.   
 
If you take part in the study, you will be asked to visit your GP practice to meet the research doctor. 
You will be able to ask questions about the study and discuss anything you are not sure about, or 
do not understand. If you are happy to take part in the study you will be asked to sign the consent 
form. You will be given a copy of the form to keep (along with this information sheet). Before the 
visit you will be sent a questionnaire to fill out, with questions about your health and treatment. 
You will be asked to bring the completed questionnaire to the GP practice when you come. On the 
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morning of the visit, you should not have anything to eat or drink, except water. When you arrive, 
you will have your height, weight, waist and hips measured and have your blood pressure checked. 
You will be asked some questions about how you feel, and how your health affects your life. You 
will be asked to provide a urine sample (around 30mls or 6 teaspoons). An electrocardiogram 
(ECG) will be performed. This is a trace of the electrical activity of the heart, and is measured by 
applying sticky pads to the chest, and attaching wires to the pads which are connected to the ECG 
machine. You lie on the examination couch for this test, and stay still while this is done. You do 
not feel anything when the recording is being taken. You will also have a blood sample taken, of 
around 30mls (6 teaspoons) of blood. If you would like to lie down while the sample is taken, 
please let the researcher know. This visit will last approximately 50 minutes.   
 
Some people may also be asked to perform a 24-hour urine collection. This involves collecting all 
the urine that you pass for 24 hours, and storing it in a plastic container (that we will provide). This 
can be performed when it suits you, and handed in. On the first day of the test, when you get up in 
the morning and pass urine, discard it in the toilet, then collect all the urine you pass that day, and 
overnight, and the first time you pass the following morning, then stop the collection.  
 
Small amounts of blood and urine from the samples you give will be stored in a freezer. Your 
details will be removed from the samples. If this study gives new information about kidney disease, 
we may do extra tests on the frozen samples, and may analyse the samples for DNA to look for 
which inherited traits are associated with kidney disease. If your samples were analysed for DNA 
in the future, this would be done anonymously and you would not be identified. We would also ask 
permission from the West of Scotland Research Ethics Service before doing any further tests, but 
we would not get in touch with you again to ask further permission. We will not give or sell your 
samples to insurance companies or other similar organisations.  
 
What do I have to do? 
You should not eat or drink anything apart from water on the morning of your study visit. You may 
be asked to perform a 24-hour urine collection (described above) or attend the hospital for a scan. 
There are no other restrictions during the study, you can eat and drink normally, and go about your 
usual business.  
 
What are the possible disadvantages and risks of taking part? 
The visit to the GP practice or hospital or performing a 24-hour urine collection may be 
inconvenient. Giving a blood sample is uncomfortable, and can leave a bruise at the site of the 
needle. Some people feel faint when having blood taken. It can be uncomfortable when the sticky 
pads are removed from the chest, after the ECG recording, particularly if you have hairs on your 
chest. The ultrasound of the neck, kidneys or heart can be slightly uncomfortable when the probe is 
pressed on the skin.  
 
What are the possible benefits of taking part? 
If we find any health problem that has not been noted before, for instance protein in the urine, we 
will inform your GP, and recommend the best treatment for this. Otherwise you will receive no 
direct benefit from taking part in this study. The information that is collected during this study will 
give us a better understanding of chronic kidney disease and how that affects people’s lives in the 
community. 
 
Will my taking part in this study be kept confidential? 
All information, which is collected, about you during the course of the research will be kept strictly 
confidential. You will be identified by an ID number and any information about you will have your 
name and address removed so that you cannot be recognised. 
 
What will happen to the results of the research study? 
The results will be presented at conferences, and published in medical journals. The first set of 
results is likely to be published around 12 – 18 months after your study visit. You can contact us, if 
you would like a copy of the published results. The results will be anonymous and no individual 
person will be identified in the publications. 
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Who is organising and funding the research? 
The research is funded by NHS Ayrshire and Arran, and an unrestricted educational grant from 
Bristol Myers Squibb. 
Who has reviewed the study? 
This study has been reviewed by the West of Scotland Research Ethics Service. 
 
Will my General Practitioner (GP) know? 
Yes. We will tell your GP that you are taking part in the study. 
 
Contact for Further Information 
1. Dr Shona Methven, Renal Office, Level 2 East, Crosshouse Hospital, Kilmarnock, KA2 0BE 
Telephone: 01563 825177 Email: shona.methven@nhs.net 
2. Your General Practitioner  
 
If you wish to make a complaint 
A leaflet called “Information for Patients and Carers – Complaints Procedure” is available from 
your GP practice with details of how to make a complaint. 
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Study Identification Number: 
CONSENT FORM 
 
A study of the factors influencing outcomes in patients 
with chronic kidney disease 
 
Name of Researcher: Dr Shona Methven 
         Please initial box 
1. I confirm that I have read and understand the information sheet  
 dated 19/4/2010 (version 2 ) for the above study and  
 have had the opportunity to ask questions and have had these  
 answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free 
      to withdraw at any time, without giving any reason, without my 
      medical care or legal rights being affected. 
 
3.  I agree to my GP being informed of my participation in this study 
 
4.  I understand that my details will be added to the Scottish  
      Electronic Renal Patient Record, and these records will be used  
      to follow up my health status for the next 10 years 
 
5.  I agree that a small sample of my blood and urine can be stored  
     for possible further testing in the future, including DNA testing 
 
6.  I agree to take part in the above study.       
 
 
           
Name of participant Date Signature 
 
Dr Shona Methven   
Researcher Date Signature 
 
 
1 for participant; 1 for researcher; 1 (original) to be kept in medical notes 
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Background Information Questionnaire   
 
Please complete this questionnaire and bring it with you to your study visit 
        
Date completed …………… 
Study ID Number ……….. (the researcher will fill this in) 
 
1. PERSONAL MEDICAL HISTORY 
 
1. Have you ever attended a hospital kidney clinic?  
 
Yes currently  Yes previously  No  (Please circle)  
 
2. Have you ever had a kidney biopsy?  
(a small sample of the kidney is taken to be examined in detail) 
   
Yes       No   (Please circle) 
 
3. If yes to either question 1 or 2, what is the cause of your kidney problem (if known)?  
 
………………………………….................................................................................... 
 
4. Do you suffer from or are you receiving treatment for any of the following conditions? 
 
If yes, please circle all that apply: 
 
High Blood Pressure     Heart attack   
Angina      Heart Failure   
Stroke       Diabetes   
Emphysema/chronic bronchitis (COPD)  Kidney Stones   
Frequent urine infections    Enlarged prostate  
Rheumatoid arthritis    Asthma  
Narrowed blood vessels in your legs   Liver disease  
5. Have you had an operation performed on your kidneys or bladder? 
 
Yes      No    (Please circle) 
 
If yes please give details……………………………………………………………. 
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6. Do you have any problems passing urine? Yes  No (Please circle) 
 
If yes please circle all that apply: 
 
Passing urine more than once during the night Pain passing urine  
Difficulty starting to urinate    Poor flow  
Difficulty stopping urination    Blood in the urine  
2.  MEDICAL SUMMARY 
 
Please list any serious illnesses, hospital admissions or operations. Continue overleaf if 
necessary. 
DATE PROBLEM 
  
  
  
  
  
  
  
  
  
 
3. ALCOHOL INTAKE 
  
Do you drink alcohol?  Yes    No (please circle) 
 
If yes how many of the following do you have a week? 
Pints of beer/ cider  ……….. 
Glasses of wine  ……….. 
Measures of spirits   ……….. 
Cocktails or other drinks ……….. 
 
4. SMOKING STATUS 
 
Do you smoke? Yes           Ex-Smoker         Never (please circle) 
 
If Yes or Ex-smoker – how many per day? ………............for how long?……………….. 
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5.MEDICATION 
Please include any medicine or supplement you take regularly or as needed, not just 
prescribed medication. Continue overleaf if needed. 
 
Name of medication Dose Number per day What is it for? 
    
    
    
    
    
    
    
    
 
Please list any allergies to medication: ……………………………………...………… 
 
 Do you regularly take any of the following painkillers? (please circle) 
 
 Paracetamol     Co-codamol   
Ibuprofen (Brufen/ Nurofen)   Diclofenac (Voltarol) 
If yes, for how long have you taken them? …………………….. 
 
6. FAMILY HISTORY 
 
Have your parents, brothers or sisters had any of the following conditions?  
(please circle) 
 
Kidney Disease    Diabetes    
Heart Disease      Stroke    
High blood pressure 
Any other important family illness ……………………………… 
   
7. OCCUPATION 
Have you ever worked with any of the following?  Please circle 
 
Lead      Cadmium   
Mercury     Silica 
Beryllium     Uranium   
Chromium     Ethylene glycol  
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8. ETHNICITY 
What is your ethnic group?  Choose ONE section A to E, and then circle to indicate your 
ethnic group. 
 
A: White 
  Scottish 
English 
Welsh 
Northern Irish 
British 
  Irish 
 Gypsy/ Traveller 
Any other White ethnic group, please state ……………………………………... 
 
B: Mixed or multiple ethnic groups 
   Please state  ……………………………………….. 
C: Asian, Asian Scottish or Asian British 
  Indian 
  Pakistani 
  Bangladeshi 
Sikh 
 Chinese 
  Any other Asian background, please state  ……………………………………….. 
D: Black, Black Scottish or Black British 
  Caribbean 
  African 
  Any other Black background, please state  ……………………………………….. 
E: Other ethnic group 
  Arab 
Jewish 
  Any other, please state  ……………………………………………………………. 
 
Not stated      
 
 
Thank you very much for answering these questions, please turn over to 
answer a few more questions. 
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International prostate symptom score (IPSS)  
Name:       Date: 
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Incomplete emptying 
Over the past month, how often have you had a 
sensation of not emptying your bladder 
completely after you finish urinating? 
0 1 2 3 4 5 
 
11.1.8 Frequency 
Over the past month, how often have you had to 
urinate again less than two hours after you 
finished urinating? 
0 1 2 3 4 5 
 
11.1.9 Intermittency 
Over the past month, how often have you found 
you stopped and started again several times when 
you urinated? 
0 1 2 3 4 5 
 
11.1.10 Urgency 
Over the last month, how difficult have you found 
it to postpone urination? 
0 1 2 3 4 5 
 
11.1.11 Weak stream 
Over the past month, how often have you had a 
weak urinary stream? 
0 1 2 3 4 5 
 
11.1.12 Straining 
Over the past month, how often have you had to 
push or strain to begin urination? 
0 1 2 3 4 5 
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Nocturia 
Over the past month, many times did you most 
typically get up to urinate from the time you went 
to bed until the time you got up in the morning? 
0 1 2 3 4 5 
 
11.1.13 Total IPSS score 
 
 
 
Quality of life due to urinary symptoms 
 
 
 
 D
el
ig
h
te
d
 
P
le
as
ed
 
M
o
st
ly
 
sa
ti
sf
ie
d
 
M
ix
ed
 –
 
ab
o
u
t 
eq
u
al
ly
 
sa
ti
sf
ie
d
 
M
o
st
ly
 
d
is
sa
ti
sf
ie
d
 
U
n
h
ap
p
y
 
T
er
ri
b
le
 
If you were to spend the rest of your life with your 
urinary condition the way it is now, how would 
you feel about that? 
0 1 2 3 4 5 6 
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By placing a tick in one box in each group below, please indicate which 
statements best describe your own health state today. 
 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
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To help people say how good or bad a health 
state is, we have drawn a scale (rather like a 
thermometer) on which the best state you can 
imagine is marked 100 and the worst state you 
can imagine is marked 0. 
 
We would like you to indicate on this scale 
how good or bad your own health is today, in 
your opinion. Please do this by drawing a line 
from the box below to whichever point on the 
scale indicates how good or bad your health 
state is today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
   Worst 
    imaginable 
     health 
state 
0 
Best  
imaginable 
health state 
